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During cardiac ischemia, intracellular calcium (Ca2+) overload occurs, which can 
result in cell death. MRI T1 shortening contrast agent manganese (Mn
2+) acts as a 
surrogate marker for Ca2+. Cardiac T1-mapping manganese-enhanced MRI (MEMRI) 
techniques were applied to study the efflux of Mn2+ from both healthy mice and mice 
post-myocardial infarction (MI) surgery. Post-MnCl2 infusion temporal changes in the 
myocardial relaxation rate, ∆R1, were shown to be linearly correlated to the absolute Mn 
content. The relative importance of individual efflux mechanisms in healthy mice were 
investigated by inhibiting the sodium-calcium exchanger (NCX) with SEA0400, 
following infusion of MnCl2, with SEA0400 reducing the rate of Mn
2+ efflux. Regional 
alterations in Mn2+ uptake and efflux were also studied post-MI, allowing for the 
identification of potentially salvageable myocardium in the peri-infarcted zone 
surrounding the necrosed tissue. Application of pharmacokinetic models to in vivo and 
elemental analysis data from both the healthy and MI mice groups suggested that the 
NCX was more active in Mn2+ efflux than for Ca2+ and that there was an increase in Mn2+ 
uptake due to the disease condition, consistent with Ca2+ overloading. Studying Mn2+ 
efflux using these protocols could provide a pre-clinical model for examining alterations 
in relative Ca2+ fluxes and to potentially monitor disease progression. 
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Coronary heart disease remains the leading cause of death in the United States 
despite encouraging trends over the past three decades. Recent data from the American 
Heart Association reveals that 80 million American adults have one or more types of 
cardiovascular disease, of which 16.8 million have coronary heart disease (CHD) (1). 
Myocardial infarction (MI; heart attack) accounts for approximately 7.9 million of the 
total CHD cases. Despite being seen predominantly in developed countries, myocardial 
infarction is also becoming increasingly more common in developing countries. Recent 
advances in diagnostic techniques and therapeutic patient care have seen the number of 
deaths from heart disease in the US drop by approximately 36% between 1991 and 2006 
(1). However, in 2006 at total of 631,636 US deaths (26% of the total number of US 
deaths) were still caused by heart disease, the largest cause of death ahead of cancer (with 
559,888 deaths, 23.1% of the total US deaths) (1). 
It has been demonstrated that the principle cause of diminished cardiac 
performance following a MI is due to abnormal intracellular Ca2+ handling impairing 
cardiomyocyte contractility (2). During ischemia the sodium-hydrogen exchange 
mechanism can lead to intracellular sodium overload. This in turn leads to reduced 
calcium efflux and increased calcium influx via the sodium-calcium exchanger (NCX) 
mechanism, resulting in intracellular calcium overload (2). The mitochondria act as a 
buffer to uptake this excess calcium from the cytosol, resulting in the expenditure of 
considerable energy (3). Energy starvation impairs calcium removal from the cytosol by 
inhibiting the sodium pump and the calcium pumps of the sarcoplasmic reticulum (SR) 
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and plasma membrane. All of these processes result in the increase of intracellular 
calcium that can inhibit actomyosin dissociation, impairing relaxation and therefore 
further increasing energy expenditure (4). These vicious cycles amplify the calcium 
overload, and cell death can result from one of several mechanisms following elevations 
in intracellular calcium concentration. Examples of these mechanisms include protease 
activation, membrane rupture, cell contracture, and gap junction dysfunction (2,5). 
In spite of this established importance of calcium regulation in the heart both prior 
to, and following, myocardial injury, monitoring strategies to assess intracellular Ca2+ 
fluctuations across the plasma membrane in affected cardiac tissue are limited. In order to 
address the alterations in Ca2+ handling following MI, it is first necessary to consider 
calcium transport in the healthy heart. Section 1.1 introduces the calcium fluxes involved 
in cardiac myocyte contraction, looking at the excitation-contraction coupling process 
involving both intracellular and extracellular Ca2+ cycles. Alterations in calcium handling 
following MI are discussed in §1.2, along with a discussion into cellular viability and 
different techniques and modalities used to detect viable myocytes. One imaging 
modality used to detect myocardial viability in post-MI patients is magnetic resonance 
imaging (MRI). An introduction to the physics and principles of MRI is provided in §1.3. 
A number of MRI contrast agents are routinely used in the clinic to increase image 
contrast between different tissue types, or to act as a molecular marker. By altering the 
relaxation properties of tissue, the contrast agents can increase image contrast, allowing 
for enhanced tissue discrimination that can be used for a number of purposes including 
tumor delineation and viability studies. The general properties of MRI contrast agents are 
introduced in §1.4. Gadolinium (Gd3+) is the most commonly used contrast agent and has 
3 
many applications, including the ability to diagnose hibernating myocardium. However, 
Gd3+ is limited as a viability agent, providing only perfusion information due to its 
extracellular properties. Manganese (Mn2+), another MRI contrast agent, is an 
intracellular agent and has been shown to act analogously to Ca2+. Section 1.5 therefore 
introduces the technique of manganese-enhanced MRI (MEMRI). MEMRI has many 
biological applications including studying brain neuroarchitecture (6), tracing neuronal 
connections (7), visualizing cerebral function and dysfunction (8), cell labeling (9) and 
cardiac viability (10). MEMRI has the potential to be used as a clinical viability agent in 
cardiovascular studies (11), offering molecular information not achievable with other 
modalities. The specific application of MEMRI to cardiac imaging is discussed in §1.6. 
Positive paramagnetic contrast agent Mn2+ is known to reduce the longitudinal relaxation 
time, T1. Application of quantitative imaging techniques, such as T1-mapping, with 
MEMRI can be used in viability studies (§1.7), and can be used to infer indirect changes 
in Ca2+ handling following MI. Mn2+ based contrast agent MnDPDP is clinically 
approved for liver imaging, and is discussed in (§1.8). Finally, in order to study the effect 
of altered Ca2+ handling on Mn2+ transport within the heart, different pharmaceutical 
agents such as dobutamine (an inotropic agent) and SEA0400 (a NCX inhibitor, NCXi) 
can be administered. These pharmaceuticals have also demonstrated therapeutic 
properties and are described in §1.9. This introduction provides a framework for 
understanding how in vivo cardiac MEMRI T1-mapping techniques can be applied to a 




1.1 Calcium and Excitation Contraction Coupling 
 
Intracellular calcium (Ca2+) is the central regulator of cardiac contractility (12). 
Action potentials, traveling from the sinus node to the ventricular cells, travel along the 
transverse tubules (T-tubules) and induce the opening of L-type calcium channels within 
contractible myocytes (3). A majority of the calcium entering the cells initiate calcium-
induced calcium release from the SR, with a smaller contribution leading to direct 
myofilament activation. The resultant increase in intracellular free calcium, [Ca2+]i, 
causes Ca2+ binding to multiple cytosolic Ca2+ buffers. The most important of these for 
contraction is the thin-filament protein troponin C. Binding of Ca2+ to troponin C induces 
a conformal change in the thin-filaments, resulting in contraction. More specifically, 
troponin C is activated by Ca2+ released from the SR, and binds to the inhibitory 
molecule troponin I. This enables interaction between the actin and myosin heads and 
induces contraction. A reduction in [Ca2+]i leads to dissociation of Ca
2+ from the troponin 
C, as well as the binding of troponin I to actin with a resultant loss in the binding between 
actin and myosin and ultimately relaxation (3). The third protein in the troponin complex, 
troponin T, binds the troponin complex to tropomyosin (4). Following relaxation Ca2+ is 
removed from the cytosol via one of four transporters (13): [1] SR Ca2+-ATPase, [2] 
sarcolemmal sodium-calcium exchanger (NCX), [3] plasma membrane Ca2+-ATPase 
(PMCA), and [4] mitochondrial Ca2+ uniporter. All of these processes, along with 
contributions from numerous other cellular structures, combine to form the excitation-
contraction coupling process in cardiac muscle cells (14). 
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1.1.1 Calcium Influx Across the Plasma Membrane 
There are three types of Ca channels; L, T and N type. Cardiac muscle contains 
both L and T type, with N channels being found in nervous tissue. L-type Ca channels are 
characterized with four properties; large conductance (~25 pS in 110 mM Ba), long 
lasting openings, sensitivity to 1,4-dihydropyridines (DHPs) and activation at larger 
depolarizations. In contrast, T type Ca channels are characterized by a small conductance 
(~8 pS), transient openings, insensitivity to DHPs and activation at smaller 
depolarizations (14). The L-type Ca channels are responsible for the vast majority of Ca 
entry in ventricular muscle, and are therefore of primary interest in the discussion of 
myocyte Ca influx. 
L-type voltage-gated ion channels can be found in excitable cells (e.g., myocytes, 
glial cells, neurons, etc.) with a permeability to the Ca2+ ion (15,16). At physiological or 
resting membrane potential, voltage-gated calcium channels are normally closed. They 
are activated (i.e., opened) at depolarized membrane potentials, providing the name 
"voltage-dependent". Activation of particular voltage-gated calcium channels allows Ca2+ 
entry into the cell which, dependent on the cell type, can result in muscular contraction 
(17), excitation of neurons, up-regulation of gene expression, or release of hormones or 
neurotransmitters. 
Voltage-gated calcium channels are formed as a complex of several different 
subunits: α1, α2δ, β1-4, and γ. The α1 subunit forms the ion conducting pore, and the 
associated subunits have several functions, including modulation of gating (18). At 
approximately 190 kDa the α1 subunit pore is necessary for the Ca
2+ channel functioning. 
The α1 subunit consists of the characteristic four homologous I-IV domains containing 
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six transmembrane α-helices each. The α1 subunit forms the Ca
2+ selective pore, which 
contains voltage-sensing machinery and the drug/toxin-binding sites. 
Calcium ions can also enter the cytosol by the reversal of the exchange 
mechanisms used for calcium efflux (13). In particular, the sodium-calcium exchanger 
(NCX), described in the following subsection as a mode for Ca2+ efflux, can reverse 
during depolarizing voltages to allow Ca2+ entry into the cell. Ca2+ entry via this 
mechanism can also act as an activator for the release of Ca2+ from the SR, thus 
enhancing the contractile process (3). 
 
1.1.2 Calcium Efflux Across the Plasma Membrane 
Calcium entry through L-type Ca2+ channels into cardiac myocytes is known to be 
the initiating event of the excitation-contraction coupling process (19,20). Calcium that 
enters cells via the L-type Ca2+ channels during each action potential must be pumped out 
of the cell to maintain composition of the cytosol at a steady state. There are two known 
mechanisms to remove Ca2+ from cardiac cells (21), either via the NCX, or via the 
PMCA (22). Attempts to estimate the relative contributions to Ca2+ efflux have shown 
that the NCX is the dominant efflux mechanism, with only between 9 and 32% (23,24) of 
the efflux occurring from non-NCX mechanisms (including the PMCA) in rats and 19% 
in mice (25). 
First discovered in cardiac muscle in 1968, the NCX is a transmembrane protein 
expressed in the membrane of almost every cell (26). Even from this early date the 
quantitative importance of sodium-calcium exchange was known: approximately 80% of 
myocardial calcium efflux is known to occur via this mechanism. The NCX is an antiport 
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that carries Na+ ions against Ca2+ ion (4). The stoichiometry was originally established at 
3 Na+ : 1 Ca2+ (27), but more recently it has been reported to be closer to a mean ration of 
4 Na+ : 1 Ca2+ with significant variation in this ratio (28). This discrepancy comes from 
the NCX having two modes, a Na+-only mode and the major Na+/Ca2+ co-transport mode 
at 3 Na+ : 1 Ca2+. This gives the overall stoichiometry as 3.2 Na+ : 1 Ca2+ (29). The 
direction of the antiport is determined by electrochemical energies from the membrane 
potential and from the Na+ and Ca2+ concentration gradients. The NCX Ca2+ flux during 
an action potential is an initial Ca2+ influx with outward current due to the strong 
depolarization at initially low intracellular Ca2+ concentrations (30). In the ‘forward 
mode’, the NCX extrudes Ca2+ from the cell in exchange for Na+ entry into the cell, 
generating an inward current (31). This small current can be clinically important, 
especially in calcium-overloaded hearts, where the change in depolarizing current 
associated with increased calcium efflux can cause transient depolarizations and lethal 
arrhythmias. 
Due to the dominance of the NCX mechanism in cellular Ca2+ efflux, the NCX 
has a large effect not only on the cytoplasmic Ca2+ concentration, but also indirectly on 
the amount of Ca2+ stored in the SR. The voltage dependence of the NCX may produce 
net Ca2+ entry into the cell at the start of the action potential and contribute a small 
amount to triggering Ca2+-induced Ca2+ release from the SR (32). In steady state, the Ca2+ 
influx, largely occurring via the L-type voltage gated Ca2+ channel, must equal the efflux. 
Changes to either the influx or efflux, which results in increased cytoplasmic Ca2+ 
concentration, will require the SR to uptake more Ca2+ (33). In addition, the direction of 
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the NCX current is also influenced by transient increases in intracellular Na+ 
concentrations due to Na+ influx with the upstroke of the action potential (34,35). 
The primary competing mechanism for intracellular Ca2+ efflux is the PMCA, 
which uses energy from the hydrolysis of ATP to expel Ca2+ ions from the cell. Unlike 
the NCX, the PMCA is an electroneutral pathway transporting 2 H+ ions per Ca2+ ion 
(36). Energy in the form of ATP is required to transport the calcium ions against the large 
concentration gradients that exist between the relatively low cytosolic Ca2+ 
concentrations and the much higher concentrations in the extracellular space. With no 
specific inhibitor to study the PMCA, attempts have been made to study its function by 
inhibiting other Ca2+ removal processes. 
 
1.1.3 Intracellular Calcium Cycles 
The primary cytosolic Ca2+ store is the SR. Ca2+ ions entering the cell from the 
extracellular fluid alone are not sufficient to initiate cardiac contraction. Therefore Ca2+ 
needs to be released from the intracellular stores in order for contraction to occur. 
Following the influx of a relatively small concentration of Ca2+ from the extracellular 
space, the Ca2+ binds to ryanodine receptors (RyR, intracellular calcium release 
channels), initiating the release of larger amounts of Ca2+ from the SR. This process is 
called calcium-induced calcium release. Release of Ca2+ from the SR occurs via a passive 
flux due to SR Ca2+ concentrations several orders of magnitude greater that the 
corresponding intracellular concentrations. Within cardiac myocytes, Ca2+ released from 
the SR is insufficient to fully saturate the troponin C, allowing for the contractile 
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response to be controlled. This is in contrast to skeletal muscle where Ca2+ released from 
the SR binds to a majority of the troponin C resulting in maximum contractions. 
Stores of Ca2+ within the SR are repopulated following release of Ca2+ from the 
contractile proteins. Uptake of Ca2+ into the SR requires the expenditure of energy and 
occurs via the sarco(endo)plasmic reticulum calcium pump ATPase (SERCA), a P-type 
ion pump. Ca2+ is then transported across the concentration gradient using energy derived 
from ATP, a similar process to that involved with Ca2+ efflux via the PMCA. 
 
 
1.2 Myocardial Infarction 
 
The existence of myocardial ischemia is owed to the severe reduction of coronary 
flow, leading to a supply of oxygen to the myocardium that is insufficient to meet the 
demands of the tissue (3). The major myocardial adaptation to the decrease in blood flow 
is reduced contraction. Following reperfusion, if the myocardium eventually undergoes a 
full recovery the tissue is defined to be stunned during the period of time required to 
achieve the fully recovered state of the myocardium. The negative inotropic effect of 
stunning is completely reversible as is does not result in cell death. This process can last 
many weeks. Hibernation, in contrast, is the return to function of myocardial tissue 




Table 1.1 Clinical classification of different types of myocardial infarction (37) 
Type 1 
Spontaneous myocardial infarction related to ischemia due to a primary coronary 
event such as plaque erosion and/or rupture, fissuring, or dissection 
Type 2 
Myocardial infarction secondary to ischemia due to either increased oxygen demand 
or decreased supply, e.g. coronary artery spasm, coronary embolism, anemia, 
arrhythmias, hypertension, or hypotension 
Type 3 
Sudden unexpected cardiac death, including cardiac arrest, often with symptoms 
suggestive of myocardial ischemia, accompanied by presumably new ST elevation, or 
new left bundle branch block, or evidence of fresh thrombus in a coronary artery by 
angiography and/or autopsy, but death occurring before samples could be obtained, or 
at a time before the appearance of cardiac biomarkers in the blood 
Type 4a 
Myocardial infarction associated with percutaneous coronary interventions 
Type 4b 
Myocardial infarction associated with stent thrombosis as documented by 
angiography or at autopsy 
Type 5 
Myocardial infarction associated with coronary artery bypass grafting 
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Myocardial viability can be defined as the presence of living myocytes, with non-
viability defined as the presence of necrotic myocytes, or the replacement of myocytes by 
fibrosis or scar tissue (38). Ischemic cell death, called myocardial infarction (MI), is a 
major cause of mortality and morbidity worldwide (39). More that 3 million people each 
year are estimated to have an acute ST-elevation MI (STEMI), with more than 4 million 
having a non-ST-elevation MI (NSTEMI). 
Myocardial infarction (MI) is defined as the presence of necrosis (cell death of 
cardiac myocytes) resulting from prolonged ischemia due to a coronary perfusion 
imbalance between blood supply and demand (40). Along with the rise and fall of cardiac 
serum biomarkers (41), the clinical criteria for diagnosing a MI includes images showing 
new loss of viable myocardium. Clinically, the various types of MI can be classified as 
shown in Table 1.1 (37). 
Acute MI occurs when coronary flow is reduced to levels so low as to cause 
myocardial cell death (4). During MI blood flow is reduced in occluded coronary arteries 
to such a low level that myocardial cell death occurs as a result of oxygen deprevation. 
The endocardial myocytes, which are especially vulnerable to decreased oxygen and 
perfusion pressure, die off quicker than those in the epicardium causing a thinning of the 
muscular cardiac wall. Myocardial cell death begins approximately 15 to 40 minutes after 
the heart’s blood supply is cut off completely, with few viable cells remaining in the 
ischemic region approximately 6 hours later. The timescale is dependent on collateral 
flow in humans, but does not exist in a murine model. If irreversibly damaged ischemic 
tissue is reperfused, an infarct ensues that leads to contraction band necrosis. In these 
regions the cells literally tear themselves apart (4). Death of ischemic myocardial cells 
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can occur via either necrosis (a process leading to fibrosis following remodeling) or 
apoptosis (a regulated process not associated with inflammation, occurring after 
reperfusion of severely ischemic myocardium).  
Necrosis is associated with the leaking into the bloodstream of intracellular 
proteins following plasma membrane damage. Myocardial cell death can therefore be 
recognized by the appearance in the blood of different proteins released into the 
circulation from the damaged myocytes: myoglobin, cardiac troponin T and I, creatine 
kinase (CK), lactate dehydrogenase (LDH), and many others (42,43). The preferred 
clinical biomarker for myocardial necrosis is cardiac troponin (I or T), which has nearly 
absolute myocardial tissue specificity as well as high clinical sensitivity, therefore 
allowing for even microscopic zones of myocardial necrosis to be identified. Apoptosis 
can also occur after reperfusion of severely ischemic myocardium (44). The release of 
cytochrome C from the mitochondria appears to be the apoptosis inducing mechanism 
(45). 
Alterations in myocyte Ca2+ handling appear to be centrally involved in the 
dysfunctional characteristics of the failing heart (46). Abnormal intracellular Ca2+ 
handling leading to impaired cardiomyocyte contractility is the primary cause of 
diminished cardiac performance in the diseased heart (47,48). During ischemia the 
sodium-hydrogen exchange mechanism can lead to intracellular sodium overload. This in 
turn leads to reduced calcium efflux and/or increased calcium influx via the sodium-
calcium exchanger mechanism, resulting in intracellular calcium overload (2). Cell death 
can result from one of several mechanisms following elevations in intracellular calcium 
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concentration. Examples of these mechanisms include protease activation, membrane 
rupture, cell contracture, and gap junction dysfunction (2,5). 
Following MI there is progressive myocardial remodeling in the murine model, 
characterized by left ventricular dilation, contractile dysfunction and myocyte 
hypertrophy. There are also altered expressions of contractile, calcium-handling, and 
extracellular matrix proteins (49). Similarly, myocardial ischemia appears to have 
significant negative effects both on acute and chronic cardiac remodeling and on damage 
to other organs, likely due to decreased cardiac output, including the vascular 
endothelium (50,51), kidney (52), skeletal muscle (53,54), and brain (55). 
Many clinical infarctions involve the left ventricle, specifically by way of 
occlusion of the left anterior descending coronary artery (LAD); however, the infarction 
may not affect the entire left ventricle. Successful treatment for injured myocardial tissue, 
both by pharmacological intervention and physical revascularization procedures, is 
heavily dependent on being able to salvage viable tissue in the peri-infarcted region 
bordering the ischemic area (56,57). 
 
1.2.1 Detecting Myocardial Viability 
In theory, all ischemic events that occur before cell death are reversible, and the 
further a diagnostic technique deviates from directly assessing whether myocytes are 
present or absent, the more imprecise the technique becomes in determining myocardial 
viability. Several imaging methods such as nuclear medicine (58), computerized 
tomography (59) and magnetic resonance imaging (MRI) (60,61) are clinically useful for 
detecting the location and size of newly infarcted tissue. However, current imaging 
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techniques primarily utilize extracellular techniques to study myocardial perfusion or 
metabolism, leading to an inadequate assessment of the peri-infarcted zone adjacent to 
the necrosed tissue, and no direct viability information. Kim et al. (62) demonstrated that 
MRI delayed enhancement methods using gadolinium (Gd) contrast could delineate 
regions of irreversible injury and viable tissue after a myocardial injury. Mechanisms 
underlying Gd concentration in the necrotic myocardium are most likely due to abnormal 
coronary perfusion and increased tissue edema (63). However, use of an intracellular 
viability tracer would allow for improved identification, quantification and evaluation of 
the potentially salvageable peri-infarcted tissue. Such an improved imaging technique 
and the more accurate determination of the peri-infarcted tissue may assist in developing 
new therapies for treating damaged tissue in the heart. These therapies could be directly 
or indirectly applied to the affected myocardium to ultimately enhance clinical outcomes 
for the post-MI patient (56). 
Assessment of myocardial viability in patients with coronary artery disease and 
left ventricle dysfunction has been known to be of major importance for prognosis for 
over two decades (64-66). Dysfunctional but viable myocardium have the potential to 
recover after restoration of myocardial blood flow by either coronary artery bypass 
grafting or percutaneous transluminal coronary angioplasty (58). The extent of these peri-
infarcted zones in patients with prior MI has been shown to provide a good noninvasive 
predictor of post-MI mortality (56). Left ventricular ejection fraction is currently the most 
robust clinical parameter for post-MI risk assessment, but the need for other accurate 




Electrocardiographic (ECG) techniques are routinely used in the diagnostic work-
up of patients with suspected MI (69-72). The extent of myocardium at risk can be 
estimated by evaluating the acute or evolving changes in the ST-T waveforms and the Q-
waves. During an MI, the ECG goes through a series of abnormalities. The initial 
abnormality, a hyperacute T wave, is a T wave with greater amplitude and reduced width 
relative to the normal T wave. This abnormality lasts for a very short time, and then 
elevation of the ST segment may occur, reflecting epicardial ischemia. During this 
period, ion pumps in the ischemic tissue fail, resulting in cells that are depolarized 
throughout the cardiac cycle. Due to differences in the charge of the positively charged 
normal tissue and the negatively charged depolarized tissue, during diastole a current will 
flow between the normal and ischemic tissue zones (3). Ultimately this leads to elevated 
ST segments, and is the hallmark abnormality of an acute MI. This elevation occurs when 
the heart muscle is being injured due to a lack of blood flow. An ECG can be used not 
only to indicate the presence of MI but can also show the approximate location of the 
heart attack, and often which artery is involved. Although ECG provides an indication for 
MI, the observed changes in ST or Q-waves can be caused by other conditions. 
 
Nuclear Imaging 
Nuclear imaging techniques play a major role in the assessment of myocardial 
viability and perfusion (66,73-75). Positron emission tomography (PET) imaging was 
first used clinically to identify myocardial viability in the mid 1980’s (66), and has since 
been recognized as an accurate technique for the quantification of metabolism and 
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perfusion of the myocardium. Positron emitting radionuclides provide versatility for PET 
with their ability to be incorporated into important biochemical molecules. Uptake of 
these radionuclides can be imaged and quantified leading to assessment of myocardial 
perfusion, glucose utilization, fatty acid uptake and oxidation, oxygen consumption and 
contractile function (76). For metabolic FDG imaging, the preserved or increased glucose 
utilization, and subsequent FDG uptake in hypoperfused and dysfunctional myocardium, 
is regarded as a metabolic marker of cell viability. This can be differentiated from scar 
tissue where reductions in both blood flow and FDG uptake are detected. FDG (a glucose 
analogue) and ammonia (a perfusion tracer) studies are commonly combined to 
differentiate between different types of myocardium in the post-MI heart. Infarcted 
myocardium exhibit reduced uptake of both FDG and ammonia dependent on the extent 
of infarction, while stunned myocardium have normal uptake of both tracers and 
hibernating myocardium only have a reduction in uptake of ammonia (66,77). 
Flow tracer radiopharmaceuticals such as 201Thallium, 99mTc-sestamibi and 99mTc-
tetrofosmin are all used for diagnosis of myocardium viability, with their active uptake by 
myocardial cells dependent on myocardial blood flow and active transport (78). 
Thallium, in association with single photon emission computed tomography (SPECT), 
has been extensively used for identifying myocardial viability and hibernation, and was 
the first tracer used for this purpose (79). 201Thalium acts as a potassium analogue, with 
myocardial uptake dependent on both regional flow and intact sarcolemmal membranes 
(79). This technique therefore provides information regarding both cell perfusion and 
viability. However, simple stress-redistribution protocols using 201Thalium can 
underestimate the amount of viable myocardium. Technetium-99m labeled tracers offer 
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lower radiation doses and a shorter half-life versus thallium. However, uptake of 99mTc is 
dependent on both perfusion and viability, leading to underestimates of viable tissue in 
areas of reduced perfusion. In addition to viability studies, another nuclear imaging 
technique, myocardial perfusion scintigraphy (MPS) SPECT, is well established as a 
diagnostic technique for detection of coronary artery disease (80-82).  
Despite the application of nuclear medicine techniques to determine myocardial 
viability, in addition to the above mentioned shortcomings the modalities are limited by 
the achievable spatial resolution: an ultimate spatial resolution of approximately 2 mm 
for PET and a spatial resolution in the order of 4 to 6 mm for SPECT. This clearly limits 
the precise determination of necrotic of peri-infarcted tissue in the post-MI myocardium. 
 
Computed Tomography 
In recent years, cardiac computed tomography (CT) has also been shown to be 
able to accurately diagnose coronary artery disease, as well as having the potential to 
provide information on myocardial function, perfusion, structure and viability (59). Until 
recently CT was not commonly used to evaluate the myocardium; however 
improvements in whole-heart CT imaging from clinical multi-slice spiral CT (for 
example improved scan speed, gantry rotation times and spatial resolution along with 
improved post-processing facilitated single breath-hold) now permits assessment of 
cardiac function as well as myocardial viability using contrast-enhanced CT. Iodated 
contrast agents have similar kinetics as gadolinium-DTPA in infarcted and noninfarcted 
myocardium (83). Therefore, contrast-enhanced chest CT is able to detect initial acute MI 
as a focal area of decreased left ventricular myocardial enhancement in a specific coronal 
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artery distribution (83,84). Contrast-enhanced multidetector CT is able to determine and 
characterize acute and chronic MI via perfusion deficits but determination of cellular 
viability if only made indirectly. 
 
Magnetic Resonance Imaging 
Recent advances in cardiac MRI technology and availability have lead to 
increased use of the technique for identifying myocardial viability, with its role in 
cardiovascular imaging also providing information regarding anatomy, function and 
blood flow. Increased image resolution and the ability to measure sub-cellular 
metabolites of the myocardium using MR spectroscopy make MRI an attractive imaging 
modality for the detection and classification of myocardium viability in vivo (85).  
One application of MRI is to use an extracellular paramagnetic contrast agent, 
such as gadolinium-DTPA. Gd-DTPA exchanges rapidly between the intravascular and 
extracellular interstitial space. However, Gd-DTPA does not pass through the membranes 
of cardiac myocytes so this technique cannot be used as a direct marker of viability. The 
value of delayed contrast hyper-enhancement imaging is an accurate identification of 
infarcted myocardium with resolution that allows the transmural extent of myocardial 
injury to be examined. In 2001, Saeed et al. attempted to use extracellular MRI contrast 
agent Gd-DTPA to identify the peri-infarcted zones of the reperfused MI rat heart (86). 
Their results indicated that Gd-DTPA-enhanced regions encompassed both the peri-
infarcted and necrosed (non-viable) tissue collectively. This non-specific extracellular 
uptake was shown to overestimate the infarct zone. However, by subsequent 
administration of mesoporphyrin (a tumor seeking agent converted into necrotic 
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myocardium markers (87)), and Gd-DTPA, differences in the tissue enhancement 
allowed for more accurate estimations of the peri-infarcted tissue to be made. Other 
studies have suggested that delayed gadolinium-enhanced MRI under-predicts the extent 
of the necrosed tissue (88). As discussed previously, however, Kim et al. (62) have 
demonstrated that MRI delayed enhancement methods using Gd could delineate regions 
of irreversible injury and viable tissue after a myocardial injury. Hyper-enhancement 
during Gd-DTPA-enhanced cardiac MRI occurs due to the chelated gadolinium diffusing 
into the interstitial space between cells. However, as mentioned above, Gd-DTPA does 
not penetrate the cell membrane and can therefore only be used to indirectly infer 
viability. 
Myocardial tagging is a well developed method for the evaluation of regional 
myocardial contraction (89), and, via indirect methods, viability. In MRI tagging studies, 
a set of saturation pulses placed in the tissue provide a spatially varying signal intensity 
pattern that is an intrinsic part of the tissue. The change in shape of this intensity pattern 
reflects changes in the shape of the underlying tissue (90). In coronary artery disease, 
regional heterogeneity of myocardial function is common under conditions of ischemia 
and infarction. The assessment of this heterogeneity can be used to determine the 
underlying myocardial viability. In acute infarction, normal systolic deformation may be 
diminished, abolished or reversed to systolic stretching (91). However, in tissue that has 
either been reperfused or not, the extent of the post-infarction dysfunction far exceeds the 
extent of necrosis, and even extends beyond the peri-infarct ischemic zone to affect the 
remote normally perfused myocardium (91,92). Additionally, tagging has demonstrated 
some residual active myocardial deformation in the center of the infarct regions, 
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presumably reflecting islands of viable myocardium and/or effects of cross-fiber 
shortening due to remote contraction (89). Regions of viable but stunned and 
dysfunctional myocardium adjacent to the necrotic infarct region that return to normal 
function a few months after infarction can be shown to have some residual contraction 
early after infarction (93). 
 
Manganese-Enhanced MRI 
Despite the number of techniques available for determining myocardial viability, 
a majority of the contrast agents and technique currently under clinical use and are only 
able to provide indirect viability estimates via extracellular perfusion, metabolism or 
contraction measurements. A number of cellular ionic changes, such as Ca2+ overload, 
occur in the ischemic heart that can lead to cellular necrosis (§1.2). The ability to monitor 
changes in the intracellular handling of these ions could provide a more direct assessment 
of viability that is not available to perfusion agents. One such example is the MRI 
molecular contrast agent manganese (Mn2+), an intracellular agent known to act as a Ca2+ 
analogue. Manganese acts to shorten the T1 relaxation time of tissue in which it is uptake, 
allowing it to serve as an MR contrast agent (94,95). Mn2+ has the potential to enter 
viable myocardium via voltage gated calcium channels (96-98), accumulating in the 
myocytes in an additive fashion (99,100). This accumulation in excitable cells, along 
with its T1 shortening effect, makes Mn
2+ a useful molecular contrast agent in the study 
of calcium flux and viability. 
While Mn2+ has the potential to be used as a truly intracellular contrast agent, as 
well as taking advantage of the excellent soft-tissue contrast and high spatial resolution of 
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MRI, Mn2+ is known to be cardiotoxic. Care must therefore be taken in to minimize these 
toxicity concerns in both preclinical studies and in the clinic to realize the full potential of 
the technique of manganese-enhanced MRI (MEMRI). The properties and applications of 
Mn2+, including the use of MEMRI in post-MI studies, are described in more detail in 




1.3 Magnetic Resonance Imaging (MRI) 
 
Magnetic resonance imaging (MRI) is a noninvasive, nonionizing, high 
resolution, high contrast cross-sectional (tomographic) imaging modality which provides 
excellent soft-tissue contrast. These properties have contributed to making MRI the 
fastest growing modality in recent years (101). MRI is made possible by the physical 
phenomenon of nuclear magnetic resonance (NMR). Nuclei are comprised of neutrons 
and protons, so therefore have positive charges. In addition, nuclei with either an odd 
atomic number or odd mass number have an associated angular momentum. MRI is based 
on the interaction of this nuclear spin with an external magnetic field,   . 
The dominant nucleus in a majority of MRI applications is the proton in 
hydrogen, 1H (102). These protons are primarily found in water, with contributions also 
from lipids. Each nucleus with an intrinsic spin also possesses a microscopic magnetic 
field. This fact can be derived both quantum mechanically and using a classical approach, 
and has been demonstrated in many texts (102). Below is a description of how protons 
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interact within the large  field (typically 1.5 or 3T clinically, and 7T or 9.4T for small 
bore magnets) in order to create the MRI signal. The description provides a basic 
introduction to the topics of MRI, relevant to this dissertation, following the text of Webb 
(103), as well as texts by Haacke at al. (102), and Prince et al. (101). 
 
1.3.1 Quantum Mechanical Description 
Protons have an intrinsic angular momentum,  , referred to as “spin”, named as 
such because it can be conceptualized as the proton spinning around an internal axis of 
rotation (although this is not rigorously accurate). The positively charged proton therefore 
has a magnetic moment, , which produces an associated magnetic field, similar to a bar 




1 ⁄  Equation 1.1
where h is Planck’s constant (6.63 × 10-34 J·s) 2⁄ . For protons 1 2⁄ , so the 




The magnetic moment is related to the angular momentum of the proton by 
  | |  Equation 1.3
where γ is the gyromagnetic ratio. The hydrogen nucleus, 1H, has a gyromagnetic ratio, 
2⁄  of 42.58 MHz T−1, with other common nuclei for MRI 13C, 19F and 31P 
having  values of 10.71, 40.05 and 11.26 MHz T−1 respectively. Because  is quantized, 
so too is the value of | |: 
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  | | 1 ⁄  Equation 1.4
When placed in a strong external magnetic field , defined to lie along the z axis, the z 
component of the magnetic moment is restricted to values given by 
   Equation 1.5
where mI is the nuclear magnetic quantum number, defined to take values of I, I-1, …, −I. 
There are therefore two values of mI for the proton, 1 2⁄  and 1 2⁄ , leading to partial 
alignment with (parallel) or against (anti-parallel)  respectively. 
Because the magnetic moment is discretized, the energy values are also quantized: 
  ·  Equation 1.6
There are therefore two possible interaction energies for the proton. The 
magnitude of energy absorbed or released by the proton spin system due to transitions 













This energy difference can be inserted into the Boltzmann equation to calculate 
the relative number of nuclei in each configuration:  
  ∆
 Equation 1.8
Here k is the Boltzmann coefficient (= 1.38 × 10-23 J K−1) and T is the temperature in 
kelvins. Using a first order approximation:  
  
1  Equation 1.9
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The magnitude of the MRI signal is proportional to the differences in populations 




Ns is the total number of protons in the region of MRI signal generation. For typical 
clinical field strengths of 1.5 T, the excess of parallel versus anti-parallel oriented protons 
is approximately five per million. 
 
1.3.2 Classical Description 
Due to the fact that the magnetic moment  does not align itself along the z-axis 
(in fact it can be shown to align at an angle of 54.7°), the external magnetic field creates a 
torque, , while attempting to align  along ̂.  
  | || | sin  Equation 1.11
Here iN is a unit vector normal to both  and . The torque leads to precession of the 
proton around the magnetic field, which can be shown to have an angular precessional 
frequency, ω, of:  
   Equation 1.12
ω is known as the Larmor frequency. 
Following the previous quantum mechanical description, the amount of energy 
absorbed or released from the proton spin system following energy state transition can be 
written as: 
  ∆  Equation 1.13
The frequency associated with the emission or absorption of the quantum of 
energy (the photon) is exactly the Larmor precessional frequency. In order for transitions 
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to occur between parallel and antiparallel energy levels, electromagnetic energy of a 
given frequency ( Δ ⁄ ) needs to be delivered to the system. Due to range of 
required frequencies within the electromagnetic spectrum (~63.9 MHz for a 1.5-T 
scanner), the applied electromagnetic energy is commonly referred to as radiofrequency 
(RF) pulses. 
Considering the net effect of all the protons in the body, the net magnetization of 






When placed in an external magnetic field, the random distributions of the magnetic 
moments as they rotate around ̂ give zero contributions of the net magnetization to the x 
and y components of . The net magnetization therefore only has a z component, 
. Application of a second magnetic field, B1, oscillating at the Larmor 
frequency, creates non-zero components Mx and My. The resultant effect is that the net 
magnetization precesses around both the applied B1 field ( ) and around the B0 
field ( ). The tip angle, α, is defined as the nutation angle through which M0 is 
rotated by the action of the B1 field:  
   Equation 1.15
α is therefore dependent on the strength of the field, and the duration of the field, . 
Signal detection is achieved by placing an RF coil close to the excited tissue. The 
time-varying magnetic field produced by the precessing magnetization vectors cause a 
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current to flow in the coil, following Faraday’s law. The current induces a voltage, E, 
across the ends of the loop that is proportional to change of magnetic flux;  
  
 Equation 1.16
Since the magnetization only precesses in the xy plane, it is only this plane of 
magnetization that contributes to the signal, and not the z component. 
 
1.3.3 Imaging 
MRI utilizes spatially varying gradients to create position dependent magnetic 
fields. This in turn leads to position dependent resonant frequencies of the proton. For 
example, for a linear gradient, Gz, applied along ̂: 
   Equation 1.17
A system of three separate gradient coils is required to encode the three spatial 
dimensions:  
  
; ;  Equation 1.18
A slice select gradient, Gslice, is used simultaneously with a frequency-selective 
RF pulse to select the required imaging slice. Slice select orientations are defined as 
coronal (y), axial (z) or sagittal (x), with oblique slices being achieved by the application 
of two gradients. For an RF pulse applied at a frequency of ωs and with an excitation 
bandwidth of ±∆ωs, only protons with precessional frequencies in the range ∆  are 




Because the frequency response of an RF pulse can be reasonably approximated 
by its Fourier transform, a sinc-shaped RF pulse is often used to produce a square-shaped 
frequency excitation profile. The phase, φsl, accumulated by nuclei during the application 




where τ is the duration of the pulse, and z is the proton position within the slice. A 
rephasing gradient can be used to overcome this undesired loss of phase coherence. 
A two-dimensional image requires encoding of the two dimensions following 
slice selection. This is achieved using phase- (Gphase) and frequency-encoding (Gfreq) 
gradients. The former imposes a spatially dependent phase on the protons, while the latter 
creates a spatially dependent precessional frequency during signal acquisition. After the 
slice selection pulse, Gphase is applied for a period τpe. When applied in the direction y, 
Gphase introduces a spatially dependent phase shift;  
  ,  Equation 1.21
During data acquisition, Gfreq is applied (assumed for this discussion to be applied 
along the x direction) in order to encode the frequency-encoding direction. The combined 
effects of the phase- and frequency-encoding gradients give a signal:  
  
, , , ,  Equation 1.22
where , , the proton density, is the number of protons at position , . 
To form a two dimensional dataset, the phase-encode gradient is repeated with 
different values Np times, with Nr data points acquired during readout. k-space can be 
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used to model how the acquired    matrix can be transformed into the final image. 






for the frequency- (x) and phase- (y) encoding direction respectively, the signal can be 
rewritten as:  
  
,  Equation 1.24
A two-dimensional inverse Fourier transform of the k-space data above provides 
an estimate of , , and therefore an image of proton density. The image FOV can 













Following excitation of the protons with an RF pulse, the z component of the net 
magnetization, Mz, is reduced from its equilibrium value of M0. Additionally, Mx and My 
become non-zero. With time post-excitation these components return to their equilibrium 







The above equations contain characteristic relaxation times T1 and T2, the spin-
lattice and spin-spin relaxation times respectively. The rate of return of Mz to the 
equilibrium M0 is governed by T1, while the return of Mx and My to their thermal 
equilibrium values of zero depend on T2. 
Following an excitation pulse α, the longitudinal magnetization, Mz, at time t is 
given by: 
  cos cos 1 ⁄  Equation 1.27
The spin-lattice relaxation occurs as protons lose their energy to the surrounding 
lattice. In contrast, spin-spin relaxation involves the loss of phase coherence between 
protons in the transverse plane. These two components of magnetization, Mx and My, relax 
back to the thermal equilibrium value of zero with a characteristic time T2: 
  
,  Equation 1.28
For example, following an RF pulse, α, along the x axis, the value of My is given 
by: 
  sin ⁄  Equation 1.29
The loss of phase coherence is caused by two different mechanisms. The first, 
pure T2, is caused by variations in proton precessional frequencies due to changing 
magnetic moments as protons interact with their neighboring nuclei. This effect occurs 
even in a perfectly homogeneous external magnetic field B0. The second mechanism, 
termed T2
+, is caused by variations in the local magnetic field strength at a given location 
in the body. This can be caused by imperfections in the magnet, or by differences in 
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tissue susceptibility. Combined, these processes lead to an overall relaxation time T2
*, 
given by 
  1 1 1
 Equation 1.30
Different tissues types have inherently different T1 and T2 relaxation properties so 
pulse sequences designed to provide either T1 or T2 contrast can be used to gain 
anatomical of physiological information. 
 
 
1.4 Magnetic Resonance Imaging Contrast Agents 
 
The bulk of modern clinical radiological imaging relies on the existence of image 
contrast between tissue types. Before the field of MRI was realized, early experiments 
were conducted to assess alterations in the spin-lattice (T1) and spin-spin (T2) relaxation 
times in solutions containing paramagnetic ions. The significance of the alterations 
caused by the ions for the development of MRI was that differences in the local magnetic 
properties of substances could be probed according to their access to water. In particular, 
Damadian observed that the relaxation times for tumors in rats presented differently than 
normal tissue as a function of the decrease in water constrained in tumor tissue (104). 
Lauterbur shortly thereafter demonstrated the utility of relaxometry in imaging. His 
classic paper on “zeugmatography” in 1973, which laid the foundation for the frequency-
domain MR techniques employed in the modern clinic, used two capillary tubes of water. 
One of the capillaries was doped with a solution of MnSO4 in order to induce T1-
shortening (105). By varying the power of the RF transmission, two different images 
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(“zeugmatograms”) were acquired, which showed variation in the image intensity for the 
Mn-doped capillary and demonstrated the feasibility of using T1 variation as an image 
contrast. 
As illustrated in the example above, intrinsic relaxometric differences in tissue 
can serve as image contrast, and furthermore contrast can be enhanced by agents with 
different affinities for pathological and healthy tissue. Useful qualities of a contrast agent 
include: (a) physical properties that affect the local magnetic environment sensitively; 
and (b) chemical properties that allow the contrast agent to travel to the appropriate 
region of interest for imaging. 
 
1.4.1 Magnetic Properties of Paramagnetic Agents 
In ionic form, elements such as Mn and the lanthanide series exact a dramatic 
effect on the relaxation properties of water; this results from unpaired electrons in the d 
or f atomic shells, which give rise to a strong magnetic moment. Other elemental 
examples include: Cr3+ (3 unpaired electrons), Fe3+ (5 unpaired), Ni2+ (2 unpaired), Cu2+ 
(1 unpaired, with dipole contributions from the d shell), Eu3+ (6 unpaired), Gd3+ (7 
unpaired) and Dy3+ (5 unpaired, with contributions from the f shell). Although the 
properties of each ion govern its utility in imaging, the strength of an ions effect on 
contrast will depend upon the strength of the magnetic moment. 
The effect of these ions on the excited 1H nuclei (which comprise the MRI signal) 
depends on multiple components. First, the dipoles of the ions may interact with nuclear 
1H dipole, which in turn stimulates spin-flip transitions and accelerates T1 relaxation of 
1H. The strength of this interaction depends on the approach distance between 1H and the 
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ion. If the ion is part of a larger molecule (e.g., deoxyHb), large distance leads to a small 
interaction. The effect magnitude of the dipole-dipole interaction is also modulated by the 
correlation time which determines the duration of the coupling between 1H and ionic 
dipole. To increase coupling, the rotational rate of the ion or chelating molecule should 
be similar to the excitation frequency of 1H. If the ion is not chelated, it will have a wide 
range of rotational velocities compared to the excitation frequency of 1H. In this case, the 
dipole-dipole interaction is weaker. For suitable rotational rates, the correlation time will 
depend on the electron spin relaxation time of the agent, where slower electronic 
relaxation results in greater coupling of the dipoles. Ultimately, relaxation rates should be 
comparable to the 1H Larmor frequency for an agent to be effective at increasing T1 
relaxation. Electron spin relaxation times for ionic Mn, and Gd are ~10-8 – 10-10 seconds 
(106) and appropriate for the range of Larmor precessional frequencies in clinical 
scanners. Larmor precession, as described in the previous subsection, refers to the 
precession of the magnetic moments of electrons, atomic nuclei, and atoms about an 
external magnetic field. Those effects which lead to spin-flip transitions also result in 
randomization of 1H phase after de-excitation and result in increased local T2 relaxation. 
Finally, the presence of the paramagnetic dipoles around less mobile 1H nuclei (e.g., 
tissue containing macromolecules) alters the local precessional frequency, which further 
increases T2 relaxation. 
Consideration of these effects determine the ratio of T1 and T2 relaxation rates for 
a given contrast agent concentration. Relaxation describes several processes where 
nuclear magnetization prepared in a non-equilibrium state return to the equilibrium 
distribution in the external magnetic field (107). Ions with longer spin relaxation time 
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(e.g., Mn2+, Gd3+) tend to stimulate spin-flip transitions effectively and are useful for 
enhancing contrast positively on T1-weighted images. At higher concentrations, they are 
also useful for increasing T2 relaxation. Typically, paramagnetic agents, such as chelated 
Gd, increase T1 and T2 relaxation at the same rate per mM (108). Since this rate is the 
same, the change of T1 relaxation per mM is larger by proportion than the change in T2 
relaxation. On the other hand, ions with shorter spin relaxation times, such as dysprosium 
(Dy3+), do not stimulate spin-flip transitions readily (108). These ions function primarily 
to vary the local Larmor frequency and to decrease the intensity on T2-weighted images. 
While Mn2+ may not have as strong of a magnetic moment as other agents such as Gd3+, 
the T2 relaxation rate 1⁄  of water containing Mn2+ ions at 1.5T grows at 10 
times the rate per mM as compared to the T1 relaxation rate 1⁄ . This makes 
Mn2+ a valuable agent for both T2 and T1 imaging. 
Another avenue to increase T1 relaxation is to chelate the paramagnetic ions to 
decrease their rotational velocity and increase the correlation time. An added benefit of 
using a chelate is that for less chemically-reactive but toxic metals, such as Gd and Mn, 
the chelated complex is excreted from the body within a short timescale (~ a few hours). 
This greatly decreases potential toxic side effects. Examples of chelates that have been 
used include: Gd-DTPA, Gd-DPDT, Gd-DOTA, and other macromolecules such as Mn-
DPDP, Cr-EDTA, Dy-EDTA. Nonionic molecules have also been utilized to prevent the 
release of the ion and to decrease the rotational velocity. 
Quantitatively, alterations in the relaxation rates (R1 and R2), can be described in 
terms of the relaxivities (r1 and r2) and the concentration C of the contrast agent within 







Here, T1,C is the longitudinal relaxation time of the tissue containing a concentration C of 
contrast agent, and T1,0 is the corresponding value without the contrast agent. 
 
1.4.2 FDA Approved Clinical MRI Contrast Agents 
A list of clinically approved contrast agents are listed in Table 1.2, along with 
some of their characteristics. At the time of writing there are 5 clinically approved Gd-
based contrast agents, MultiHance® (110), Magnevist® (111), OmniscanTM (112), 
ProHance® (113) and OptiMARKTM (114). Additionally, there is one Mn-based contrast 
agent, TESLASCAN® (115), and one Fe-based contrast agent, Feridex I.V. ® (116). 
 
 
1.5 Manganese-Enhanced MRI (MEMRI) 
 
Ionic manganese in divalent form (Mn2+) is a particularly useful contrast agent for 
its sensitivity, as well as its function as a calcium (Ca2+) analogue. Consequently, the use 
of Mn2+ in imaging studies has increased dramatically as molecular medicine 
incorporates clinical imaging techniques (117). As a paramagnetic MRI contrast agent, 
manganese (Mn2+) has been found to be particularly useful for cardiac research and 
research in the brain (117,118). The ability to monitor changes in the intracellular 
handling of Ca2+ ions in the heart could provide a more direct assessment of cardiac 
viability that is not available to other imaging modalities or MRI contrast agents (§1.2.1). 
Manganese-enhanced MRI (MEMRI), an intracellular molecular imaging technique, is 
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able to fill the gap left by the other imaging techniques, and has the potential to be used a 
true viability agent. Section 1.6 discusses the use of MEMRI in cardiac studies in detail. 
Within the central nervous system (CNS), Mn2+ enters excitable cells via major 
routes of transport for Ca2+ and Na+, such as voltage-gated Ca2+ channels, the NCX, the 
Na+/Mg2+ antiporter, and the active Ca2+ uniporter in mitochondria (119,120). Once 
inside the cells, Mn2+ can bind with high affinity to Ca2+ and Mg2+ binding sites in 
proteins and nucleic acids, or it can be transported anterogradely in axonal tracts 
(121,122) and released into the synaptic cleft along with the neurotransmitter glutamate 
(123). Based on such properties, three major applications of neuronal MEMRI have been 
defined: (1) to enhance the cerebral neuroarchitecture; (2) to trace neuronal tracts in the 
living brain; and (3) to demarcate active regions of the brain. Mn2+ has also been used as 
a cell labeling MRI contrast agent (9). 
Both the physical and chemical characteristics of Mn2+ are reviewed in the 
following subsections, with a thorough introduction to the use of MEMRI in cardiac 
studies presented in §1.6. 
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1.5.1 Biochemical Properties of Mn2+ 
Unlike the typically toxic heavy metals in the lanthanide series, transition elements 
such as Mn, Fe, and Cr are utilized to some degree by the human body. This property 
makes them useful as a contrast agent for labeling metabolic processes. Considering the 
normal human intake, 20 µg of Mn is retained in the body per day. The U.S. Federal Drug 
Administration currently recommends a daily intake of 5 mg day−1, and the American 
Medical Association Nutrition Advisory Group recommends a dosage of 0.15-0.8 mg 
day−1. A healthy human body is capable of tolerating a wide range of variation, and normal 
whole blood ranges have been listed as 0.4-1.4 ng mL−1 (124). One case study described a 
patient with a blood Mn2+ value of 3.7 ng mL−1 (125). 
Manganese is normally eliminated via the biliary tract. Overload of manganese in 
the body may result from high intake of supplements (126), pathological conditions such as 
hepatobiliary disease, or environmental exposure in occupations such as welding (127). 
Manganese poisoning may present neurotoxic symptoms such as Parkinsonian-like 
behavior, psychological change, anxiety, or seizures (125,127). Cardiovascular effects 
include tachycardia or hypotension. The biological role of Mn in the body is for regulation 
of enzymes. Chemically, Mn2+ is similar to Ca2+ and Mg2+ and has a high affinity for 
protein sites where these elements may be present. The ionic radius of Mn2+ (0.08 nm) is 






1.6 Cardiac MEMRI 
 
A majority of calcium enters myocytes through voltage-gated calcium channels, 
initiating contraction. Calcium exits through the sarcolemma sodium calcium exchanger 
(NCX) and plasma membrane calcium pump ATPase (PMCA) for relaxation (§1.1). 
Inflowing calcium triggers the release of additional calcium from the sarcoplasmic 
reticulum (SR) by activation of the ryanodine receptors (RyR) in the SR membrane. 
Although intracellular calcium is a key regulator of myocardial contraction, there are only a 
few ways to assess this important factor. Fluorescent techniques have been widely used in 
isolated cardiac myocytes, but these techniques cannot be extended to in vivo studies. MRI 
calcium probes, such as fluoroBapta and DOPTA-Gd, have also not found widespread use. 
 
1.6.1 Mn2+ Uptake by Myocardial L-Type Ca2+ Channels 
One possible technique for assessing intracellular calcium is to use a paramagnetic 
agent that has physical properties similar to calcium, such as manganese ions (Mn2+). Mn2+ 
has an ionic radius similar to that of Ca2+, and is handled similarly in many biological 
systems. For example, Mn2+ is known to enter cardiac myocytes through voltage-gated 
calcium channels (99,128). Mn2+ is also an excellent T1 contrast agent (94). These 
properties of Mn2+ were recently used to detect and visualize cell activity using MRI. The 
results of those studies indicate that Mn2+ might be a useful MRI agent for quantifying 
relative rates of calcium influx in the heart. 
Infusion of Mn2+ via the mouse tail vein leads to significant signal enhancement in 
T1-weighted images (99); an increase of approximately 40–50% in healthy hearts. 
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Dobutamine (increased inotropy) or diltiazem (decreased inotropy) have been used with 
MEMRI experiments to examine whether alterations in cardiac inotropy affect the MRI 
signal enhancements detected with Mn2+ infusion. Dobutamine has been shown to increase 
the steady-state signal enhancement in the left ventricular free wall (LV Wall) of mice, and 
diltiazem decreased the steady-state signal enhancement significantly when compared to 
control conditions (99). Both results lend themselves to the conclusion that Mn2+ is 
transported via the L-Type Ca2+ channel, and that the rate of Mn2+ enhancement is 
proportional to changes in Ca2+ influx. 
At 14.0 nmoles min−1 g−1 BW infused Mn2+, dobutamine increased the steady-state 
signal enhancement by 102% for both the interventricular septum and LV Wall compared 
to Mn2+ infusion alone. Similar increases in signal enhancements were detected following 
dobutamine administration in mice infused with 3.3 nmoles min−1 g−1 BW MnCl2, relative 
to MnCl2 infusion alone. Signal intensity decreases of 69% and 59% for diltiazem plus 
Mn2+ compared to Mn2+ infusion alone have been observed in the interventricular septum 
and LV wall respectively (99). 
Unfortunately Mn2+ is known to be cardiotoxic at high doses (129). Indeed, it is the 
toxic properties of Mn2+ that have limited its development as an MRI contrast agent. 
However, Mn2+ is also an essential element for maintaining cell viability. With the increase 
in stability and sensitivity of MRI scanners it should be possible to use much lower doses 
of Mn2+ than have been used in early studies to determine the suitability of Mn2+ as an MRI 
contrast agent. Thus far, data in mice have indicated that subtoxic Mn2+ doses can cause 
significant enhancement of the heart without affecting left ventricular ejection fraction or 
heart rate after the MRI experiments (99). These mice then survived for at least one month 
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after the MRI experiments. However, the reliance of T1 weighted images on short TRs 
rather than the inversion recovery pulse sequence means these protocols will not be 
optimally designed for MEMRI studies. For the same Mn2+ dose the dynamic enhancement 
range using an optimal pulse sequence may be increased by a factor of 2 over more 
traditional T1 weighted protocols. Furthermore, signal enhancements detected in 
experiments to data have been relatively large, indicating that still lower doses of Mn2+ 
could be used. 
 
1.6.2 Assessment of Myocardial Viability 
Alterations in myocyte Ca2+ regulation may be critical for both the mechanical 
dysfunction and the arrhythmogenesis associated with congestive heart failure (12,130). 
Recent advances have improved the feasibility of studying ischemic heart disease with MRI 
(131). MR contrast agents can be applied in a variety of ways to improve MRI sensitivity 
for detecting and assessing ischemically injured myocardium. Contrast-enhanced perfusion 
MRI has been used to explore disturbances in large (angiography) (132) and small coronary 
arteries (myocardial perfusion) (133). It is known that the size of the abnormal signal area 
on Gd-enhanced T1-weighted MRI correlates relatively well with infarct area (62). 
However, the size of the nonperfused area on first-pass perfusion images is often smaller 
than the final infarct area. Therefore, there is a need to obtain intracellular measures of cell 
viability not achievable with perfusion agents. 
The application of Mn2+ contrast enhancement to cardiac MRI, either in the form of 
paramagnetic free manganese (MnCl2) or in a chelated form (manganese dipyridoxyl 
diphosphate, MnDPDP), allows for the potential monitoring of calcium dynamics. This is 
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of particular importance in studies of the infarcted heart. MEMRI has previously been used 
to detect cell viability in the ischemic heart (134,135). A study to assess whether viable 
myocardium can be distinguished from necrosed tissue using MnDPDP-enhanced MRI has 
been conducted in rats (136). Infusion of various doses of the chelated Mn contrast agent 
demonstrated that Mn was retained in the viable myocardium, but was shown to have rapid 
clearance from the infarcted region. This demonstrated the ability of the contrast agent to 
differentiate infarcted tissue from viable tissue. In its free paramagnetic form, MnCl2 has 
similarly been shown to demarcate infarcted zones in mice (137) and dogs (10).  
To date there is some inconsistency between in vitro and in vivo results. In vivo 
manganese-enhanced MRI has observed signal attenuations in the affected myocardium of 
mice (137), rats (138) and larger mammalian species (139). However, in vitro studies have 
shown enhanced Ca2+ influx as a compensatory process (140). Camelliti, et al. (141) have 
presented ex vivo results demonstrating small islands of viable myocytes in ischemic 
regions, with potentially reduced perfusion. These islands could potentially be used to 
explain the non-zero Mn2+ uptake in the ischemic regions. Additionally, limited perfusion 
in the affected tissue could also explain the disparity. Clearly, there is a need for ongoing 





Divalent manganese (Mn2+) has been used as a molecular MR contrast agent in 
many biological applications due to it T1 shortening effect. Indeed, T1 weighted images 
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have been shown to provide contrast following uptake of Mn2+. In many MEMRI 
experiments there are a large range of T1 values, such as those experienced in the mouse 
brain following systemic administration of MnCl2 (142). T1 weighted images need to be 
optimized in order to detect a specific range of T1 values. However, it is not typically 
possible to detect the complete range of T1 values using just one protocol, and acquisition 
of multiple images is required. Similarly, small changes in T1 values can provide important 
information that might not be detectable with T1 weighted protocols. Utilization of a 
quantitative technique would provide a greater sensitivity to a wide range of T1 changes, 
and would also allow for reduced doses of Mn2+ to be administered. By reducing the dose, 
potential cardiotoxic and neurotoxic effects caused by high levels of Mn2+ can be 
minimized. 
The use of Mn2+ to produce shortening of the spin-lattice relaxation time, T1, was 
proposed soon after the conception of using NMR for radiological imaging. In 1973 
Lauterbur used Mn2+ to shorten T1 in a pure water sample. As T1-mapping techniques were 
developed, the field of MEMRI started to take advantages of their quantitative nature. 
Experiments to measure tissue T1 and T2 relaxation times were conducted as early as 1971, 
where discriminations between normal tissue and malignant tumor specimens were 
discerned from their relaxation times (104). Mansfield et al. extended these techniques to 
imaging biological structures. In 1970, a commonly used method to calculate T1 values was 
conceived by Look and Locker (143,144). Using this technique, T1 relaxation times can be 
estimated using a periodic train of excitation pulses following an inversion pulse, sampling 
multiple time points during signal recovery. This method can significantly reduce the 
scanning time without sacrificing accuracy, and has been shown to have almost the same 
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efficiency as spin-echo IR methods in terms of the SNR per unit time (145,146). The first 
published biological T1-maps were by Pykett et al. (147) in 1978. These images provided 
anatomical insight into a tumerous rat leg. 
Quantitative MEMRI T1-mapping has been applied to numerous fields. The 
quantitatively derived results using such techniques provide an insight into altered Ca2+ 
handling dynamics, and may prove useful in determining potentially salvageable tissue in 
the diseased heart. Elemental analysis, a process where a sample of the blood or tissue 
material is analyzed for the elemental and sometimes isotopic composition, can be used to 
obtain the ex vivo Mn2+ content for a given tissue sample. The analysis can be qualitative 
(determining what elements are present), and it can be quantitative (determining how much 
of each are present). By correlating regional T1 values to elemental analysis sample data, 
estimates of the absolute regional Mn content can be made in vivo using Equation 1.31, 
which can be of particular importance under diseased conditions where alterations in Mn2+ 
and Ca2+ handling are expected.  
One application of MEMRI T1-mapping has been to improve neuronal tract tracing 
techniques (145). In neuronal tract tracing, Mn2+ causes a wide range of T1 changes, 
varying from short T1 values at the injection site to longer values in more distant regions. 
This particular study used a Look Locker T1 mapping protocol enabling sufficient 
sensitivity to detect the full range of T1 values with full brain coverage in a reasonable time. 
It was concluded that the use of quantitative techniques in MEMRI should allow for the 
study of more extensive pathways and should also allow for lower Mn2+ doses 
administrations. 
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T1-mapping has also been applied to studying the common neuropsychiatric 
condition hepatic encephalopathy (HE) (148). Within clinically relevant acquisition times 
significant correlations between the change in T1 and HE severity have been shown in the 
globus pallidus, the caudate nucleus, and the posterior limb of the internal capsule. 
MRI has been used as a modality to track cellular migration. A majority of this 
work to date has been performed using ultra-small iron oxide particle. However, recently 
MnCl2 has been shown to be a potential alternative to iron oxide in cell labeling studies 
(149). One of the limitations of cell labeling with iron oxide particles is that a decrease in 
signal is observed for the T2
* effects which requires homogeneous images. In an ideal 
experimental system, all nuclei in a given chemical environment within a magnetic field 
possess the same spin frequency. However, in a real system, there are minor differences in 
chemical environment which can lead to a distribution of resonance frequencies around the 
ideal system. Over time, this distribution can lead to a dispersion of the tight distribution of 
magnetic spin vectors, and loss of signal coherence leading to the corresponding transverse 
relaxation time constant, T2
*, which is usually much smaller than T2. Mn
2+ enhancement 
causes signal enhancement and alleviates some of these drawbacks. In addition, only a 
relatively short amount of time is required to achieve labeling of cells with MnCl2. Within 
this study by Aoki et al., T1-maps were calculated following a 1 hour period of human 
lymphocytes incubation with 0.05-1.0 mM MnCl2. Significant signal enhancement was 
observed. This suggests that MnCl2 might be an alternative to iron oxide cell labeling for 




1.7.1 Look Locker T1-Mapping 
One potential goal of using a quantitative technique for cardiac MEMRI studies is 
to estimate the delivery of Mn2+ to viable myocardium in vivo, with applications to assess 
regional Mn2+ handling alterations in a myocardial infarction model. One such technique 
used to quantify T1 values, developed by Look and Locker, was previously introduced. 
Following the description of Look-Locker (LL) T1-mapping presented by Chuang et al. 
(145), multiple time points are sampled during the relaxation following an inversion pulse 
separated by the interexcitation interval τ. This sampling is achieved using RFN  pulses 
of the same flip angle (FA), α. Both Look and Locker (144) and Brix et. al (150) derive an 
expression for the signal evolution in the above LL T1-mapping protocol. The partially 
relaxed longitudinal magnetization, )(nM , before each excitation pulse, can be described 
by an exponential recovery with time constant *1T . 






















 . eqM  is the equilibrium longitudinal magnetization and the 









 Equation 1.33 
The T1 value for each pixel can be calculated by obtaining 
*
1T  from a three-
parameter fit to Equation 1.32, and substituting this value into Equation 1.33. However, this 
assumes that the exact FA is known for each pixel, which is a poor assumption. Due to 
inhomogeneities in the B1 field caused by imperfect excitation pulses and the RF coil 
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profile, the FA differs from the intended value. This can be overcome by taking the 
relationship between )(M  and )0(M , with T1 being simplified to )(/)0(*1 MMT  when 
*
1T , as shown by Steinhoff et. al (151). Chuang et al. (145) demonstrate how 
)0(/)( MM  , *1T , and therefore T1, can be obtained independent of knowing the precise 
FA, and without the requirement that   and Td, the delay time between the inversion and 
the first excitation pulse of a slice, are short. This is achieved under the assumption that the 
longitudinal magnetization before each inversion pulse has reached steady state. 
Estimates of T1 acquired by the imaging techniques both prior to and following 
Mn2+ administration can be applied to Equation 1.31 to obtain in vivo estimates of the 




1.8 Clinical Manganese Based Contrast Agents 
 
1.8.1 Development of MnDPDP 
Manganese dipyridoxyl diphosphate (MnDPDP) is approved as an i.v. contrast 
agent for MR imaging of the liver. MnDPDP is a chelate consisting of the organic ligand 
dipyridoxyl diphosphate (DPDP) and Mn2+. Following i.v. injection, MnDPDP is 
metabolized by a process involving dephosphorylation of MnDPDP to MnPLED 
(manganese dipyridoxyl ethyliamine), and exchange of Mn2+ for Zn2+ (152) with the 
consequent release of manganese ions. In humans the rate of total manganese plasma 
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clearance is multiphasic (152). The initial clearance half-life lasts for less than 20 minutes, 
with the longer terminal elimination phase occurring between 5 and 11 hours. Following 
i.v. injection of MnDPDP, the released manganese accumulates in the liver, bile, pancreas, 
kidneys and cardiac muscle (153). Following oral intake the manganese accumulation 
occurs only in the liver and bile (154). Due to its T1 relaxation effect, the released Mn
2+ 
ions act as an MR contrast agent (94,95), which allows MnDPDP to be used as an MR 
contrast agent. 
With a wide range of application in both humans and animals, MnDPDP has been 
shown as a gradual or slow-release complex for Mn2+ uptake in hepatocytes (153,155,156). 
Similarly, animal studies have shown that Mn2+ release from MnDPDP can be used to 
demarcate infarcted (136,157) and stunned (158) myocardium. 
One clinical concern over the use of MnDPDP is the potential neurotoxic effects 
caused by manganese overexposure. The brain is a major target organ for Mn toxicity and 
retains Mn much longer that other tissues. Mn neurotoxicity results in progressive 
neurodegenerative disorders of the extrapyrimidal system, similar to Parkinson’s disease 
(119,126). Such a disorder is the result of chronic overexposure to Mn, with limited 
treatment options and no cure. However, no cases of Mn intoxication have been reported 
following singular low doses of MnDPDP, even after several years of clinical use (119). It 
is unlikely that a single dose of MnDPDP would lead to any neurological consequences, but 
care should be taken to avoid repeated exposure to Mn. Studies in rodents and dogs (159) 
have indicated that a single i.v. injection of MnDPDP is tolerated at doses of approximately 
400 times the clinical dose, up to 2000 μmol kg−1. Combinations of clinical and non-
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clinical studies demonstrate that MnDPDP has a good safety profile for clinical use as an 
i.v. hepatobiliary MR contrast agent. 
 
1.8.2 MnDPDP in the Liver 
MnDPDP is clinically approved for MR imaging of the liver, and is available in two 
preparations; one for a 1-2 min injection (USA) at a concentration of 0.05 mol L−1, and one 
for 10-15 min infusion (Europe) with a concentration of 0.01 mol L−1 (160). Primarily 
developed for imaging of the hetatobiliary system (161), MnDPDP causes homogeneous 
liver enhancement following injection in healthy patients (156). The liver signal 
enhancement begins within 1-2 minutes following injection, with the maximum 
enhancement seen within 5-10 minutes after infusion. The enhancement then persists for 
several hours. 
Hepatocellular carcinoma (HCC) is curable by liver transplantation if the tumor is 
small (<3 cm) and solitary (162). Therefore the accurate and timely diagnosis and 
characterization of liver tumors is important for a successful prognosis. In 1997, Kane et al. 
conducted a study comparing the lesion detection and characteristic predicted by MnDPDP-
enhanced MR imaging to surgical excision and pathological examination (163). As part of a 
phase III clinical trial, 90 patients under consideration for surgical treatment of the 
neoplastic hepatic disease were infused with 5 μmol kg−1 MnDPDP. Comparisons were 
made between both spin-echo and gradient-echo T1-weighted MR images pre- and post-
contrast. These pre-operative findings were compared to intra-operative ultrasonography 
and histology of the resected liver specimens. Eleven out of 14 patients with liver 
metastases showed a good correlation between the MR images and the hepatic disease. For 
49 
patients with primary liver tumors, 5 out of 6 MR findings correlated to the hepatic disease. 
The authors concluded that it is possible to characterize liver lesions using MnDPDP-
enhanced MRI. MnDPDP is considered important to the assessment of patients with liver 
disease where accurate decisions for surgical planning are imperative. 
More recent research has been into the detection of colorectal hepatic metastases 
using MnDPDP (164). Colorectal hepatic metastases show high signal restricted diffusion 
on diffusion-weighted MRI (DWI), as compared to the healthy liver tissue. The diagnostic 
accuracy of three different MR imaging protocols were compared: MnDPDP, DWI and 
combined MnDPDP and DWI. It was found that the combination of DWI and MnDPDP-
enhanced MR imaging resulted in the highest diagnostic accuracy and increased the 
sensitivity without loss in specificity. 
In a European phase III clinical trial, MnDPDP was shown to be a safe contrast 
agent at the approved dose of 5 μmol kg−1, and at a slow infusion rate of 2-3 ml min−1 
(165). This study showed MnDPDP to be effective and safe in enhanced MR imaging of 
the liver, with adverse effects reported in only 7% of the 624 patients involved. A majority 
of the reported adverse effects were nausea, headache and pruritus. 
 
1.8.3 MnDPDP in Cardiac Research 
Manganese-enhanced MRI (MEMRI) has a number of applications to cardiac 
studies. As discussed previously, Mn2+ is an excellent cardiac contrast agent candidate due 
to its similarity to Ca2+. Initial studies using manganese contrast demonstrated the ability to 
demarcate infarcted regions in animal hearts, both ex vivo (166,167) and in vivo 
(136,157,168). The effect of MnDPDP-enhanced MRI on different animal models has been 
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studied, with myocardial R1 1⁄  increasing steadily with i.v. doses of MnDPDP up to 
20 μmol kg−1 in pigs (169) and up to 100 μmol kg−1 in rats (136,157). 
The latter two studies looked at the effect of MnDPDP in rat MI models. The 
necrosed myocardium showed a higher rise in R1 than the viable myocardium over the first 
5-10 minutes. However, while the viable myocardial R1 values continued to rise with time, 
the necrosed tissue R1 values decreased. This trend continued over several hours, with the 
necrosed regions being clearly discernable, even at low doses of MnDPDP.  
More recently the relaxation enhancing properties of MnDPDP in the human 
myocardium has been studied (170). In this particular investigation, R1 measurements were 
calculated for the myocardium of fifteen healthy patients using an inversion recovery (IR) 
turbo fast low-angle shot (FLASH) sequence, both before and at various time points post 
i.v. MnDPDP injection. Left ventricular (LV) wall R1 values increased on average 37% one 
hour following a MnDPDP dose of 5 μmol kg−1, the clinical liver dose. This elevation 
remained for approximately two hours, before a gradual decline lasting over 24 hours. 
Varying the dose of MnDPDP injections did not cause the R1 values to increase linearly. 
Following this work, Skjold et al. performed a study on patients with recent 
myocardial infarction (11). The aim was to see if regions of the affected LV wall would 
show signs of reduced R1 compared to healthy, viable myocardial tissue after a low dose of 
MnDPDP. The results showed that reduced wall thickening at the infarction site was 
associated with reduced contrast enhancement. On the other hand, the remote regions 
showed larger increases in R1. This is most likely due to the selective and slow Mn 
accumulation in viable myocytes. Conclusions drawn from this work suggest that the 
demarcation of infarcted myocardial regions is possible with manganese-based MRI 
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contrast. The combination of low doses of MnDPDP with R1 mapping techniques can 
reliably identify infarcted regions. 
Studies using clinical MnDPDP have demonstrated that Mn2+ is released slowly 
from DPDP (171,172). These findings helped to more fully evaluate those mechanisms 
which enhance myocardial signal intensity due to MnDPDP (173-176). MnDPDP has also 
been found to be retained in non-ischemic myocardial tissue (136). Encouragingly, 
MnDPDP (170) and EVP-1001 (a newer developed Mn2+ -based contrast agent in Phase II 
trial) have both been used to image human myocardium. 
One concern with the administration of MnDPDP is the potential cardiac side effect 
caused by the reaction of the released Mn2+ with the myocardial processing of Ca2+. 
However, it has been shown that MnDPDP is well tolerated in the rat heart up to 
concentrations of 250 μmol L−1 and is approximately 10 times less cardiotoxic than MnCl2 
(129). 
 
1.8.4 Further MnDPDP Applications 
In addition to liver and heart studies, pancreatic and neuronal manganese 
accumulation has opened avenues for MEMRI research. MEMRI has been used to develop 
techniques for improving anatomical and functional imaging of the rat brain (142,145). As 
discussed previously, toxicity is a concern that needs to be addressed when applying 
MEMRI to the CNS. Use of a Mn2+ releasing contrast agent, such as MnDPDP, could avoid 
the high initial Mn2+ concentrations following local injections into the CNS. Olsen et al. 
establish that MnDPDP gives sufficient Mn enhancement compared to MnCl2 in the CNS 
(177). The group injected both MnDPDP and MnCl2 intravenously into a rat model to 
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produce functional visual pathway images. Significant contrast enhancement of the retina 
and optic nerve on T1-weighted FLASH MR images were produced 12-24 hours post-
MnDPDP injection. The signal enhancement was similar to that of the MnCl2 injection. The 
conclusion drawn from this study was that Mn2+ was released from MnDPDP in sufficient 
amounts to obtain functional tracing of the adult rat primary visual pathway. 
There are a wealth of studies, both completed and ongoing, into the use of 
MnDPDP as a pancreas-specific contrast agent (178). A 20 min infusion of 10 μmol kg−1 
BW MnDPDP in healthy volunteers resulted in an increase in gradient-echo T1-weighted 
image signal-to-noise of 98±13% in the pancreatic parenchyma (179). The use of 
MnDPDP-enhanced imaging of pancreatic ductal adenocarcinoma was assessed in a phase 
II trial (180). The tumor contrast-to-noise was increased 209% in gradient-echo T1-
weighted images after MnDPDP injection. In contrast, the tumors showed no significant 
increase in signal intensity following injection. The fact that MnDPDP is only taken up by 
the normal pancreatic parenchyma gives this contrast agent a theoretical advantage over 
Gd. Further work on MnDPDP pancreatic mass detection has shown that MnDPDP 
facilitates staging of pancreatic tumors by detection of metastatic lesions in the liver. Here 
it was suggested that MnDPDP could be useful in the differential diagnosis of patients with 
pancreatitis. The degree of uptake homogeneity could help diagnoses between focal 






1.9 Pharmaceutical Alterations of Ca2+ Handling 
 
1.9.1 Positive Inotropic Agents 
Heart failure is primarily caused by a defect in cardiac contractility, and as such 
drugs that increase the inotropy and contractility (positive inotropes) have long been used a 
pharmacologic agents (181). Classical inotropes, such as beta-agonists (dobutamine, 
dopamine) and phosphodiesterase inhibitors (milrinone) have been shown to improve 
clinical symptoms and hemodynamics of acutely decompensated chronic heart failure 
(ADHF) patients (182). However, these classical inotropes can promote and accelerate 
some pathophysiologic mechanisms causing further myocardial injury leading to increased 
short- and long-term mortality (183,184). This has lead to the introduction of more 
clinically cardioprotective inotropes, such as levosimedan (185,186). 
Classical inotropic agent dobutamine, one of the most potent inotropes currently 
available in the clinic (187), exists as a racemic mixture of dextroisomers and levoisomers, 
which are potent β- and α-adrenergic agonists, respectively (188). Dobutamine increases 
contractility by inducing an increase in calcium released from the SR by increasing the 
intracellular cyclic adenylate monophosphate (cAMP) levels (181). Dobutamine is known 
to increase intracellular Ca2+ while also increasing the stroke volume. However, increased 
contractility is achieved at the expense of increased myocardial oxygen demand, potentially 
exacerbating the myocardial ischemia and leading to increased myocardial apoptosis in the 
presence of hibernating myocardium (189). 
As discussed in §1.6, dobutamine has been used concurrently with MEMRI studies 
in mice to demonstrate the effect of altering Ca2+ influx on Mn2+ handling. Increases in the 
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steady-state signal enhancement in the left ventricular free wall (LV Wall) of mice 
following dobutamine administration were observed, relative to mice receiving no 
dobutamine (99). This is in agreement with the fact that Mn2+ is transported via the L-Type 
Ca2+ channel, and that the rate of Mn2+ enhancement is proportional to changes in Ca2+ 
influx. 
 
1.9.2 Sodium-Calcium Exchange Inhibitors 
Protocols that selectively inhibit the NCX are useful for investigating the roles of 
the NCX and PMCA, and have been shown to have potential therapeutic effects during 
myocardial ischemic-reperfusion injuries (190). During Ca-dependent arrhythmias NCX 
inhibitors will change the degree of cellular Ca2+ overloading and will also change the 
membrane current. When the NCX is functioning to pump Ca2+ from the cell, the NCX 
inhibitor is expected to increase the intracellular Ca2+ concentration, inducing cardiotonic 
and hypertensive effects in the circulatory system (191). When the NCX works as a 
pathway for Ca2+ entry - as it does during ischemia/reperfusion injury and digitalism - the 
NCX inhibitor is expected to guard against Ca2+ overloading. 
In 1984 the first NCX inhibitor drug, an amiloride analogue 3’,4’-dichlorobenzamil 
(DCB) (192), was reported. The first potent and relatively selective inhibitor of the NCX 
(193) was KB-R7943 (194). New benzyloxyphenyl analogues have more recently been 
developed and are both selective and potent NCX inhibitors. These include SEA0400 (195), 
SN-6 (196) and YM244769 (197). These newer inhibitors are trypsin-insensitive drugs that 
act from extracallular or intramembrane sites. Amongst the three, SEA0400 is the most 
potent and selective inhibitor (190). 
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Given the potential clinical benefits of inhibiting the NCX during states of 
myocardial ischemia reperfusion, studies have been conducted to clarify the importance of 
this efflux mechanism. SEA0400, 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-
ethoxyaniline, has been shown to provide protection from cardiac ischemia/reperfusion 
injury and digitalis induced arrhythmia (190,198,199) and from myocardial stunning (200). 
The drug inhibits salt-dependent hypertension induced in transgenic mice with vascular 
expression of NCX1.3, commonly referred to as the kidney variant. SEA0400 also prevents 
hypertension associated secondary organ injury in the kidney and heart (201). 
 
Despite the number of techniques available for determining myocardial viability, a 
majority of the contrast agents and techniques currently under clinical use only provide 
indirect viability estimates via extracellular perfusion, metabolism or contraction 
measurements. This dissertation applies the technique of cardiac MEMRI to indirectly 
study cellular ionic Ca2+ changes that are known to exhibit changes under ischemic 
conditions. The ability to monitor changes in the intracellular handling of these ions could 
provide a more direct assessment of viability that is not available to perfusion agents. 
Cardiac MEMRI studies have previously been used to assess myocardial viability, 
however the true quantitative potential of this technique is yet to be realized. This 
dissertation also attempts to address this current gap by performing quantitative MEMRI 
studies in order to better understand Mn2+ handling in the myocardium and its relationship 
to Ca2+ handling, and to study alterations in handling post-MI. This information could 
allow for more accurate diagnosis and therapeutic treatment monitoring in the diseased 
myocardium.
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Intracellular calcium is a central regulator of cardiac contractility and viability 
(202); despite its importance, methods to assess calcium dynamics during myocardial 
infarction are currently limited. In recent years MEMRI has emerged as a non-invasive 
technique to monitor Ca2+ in cardiovascular disease, both diagnostically and prognostically. 
However, the full potential of this technique, and the interpretability of its results, are 
limited by the lack of a thorough understanding of the Mn2+ transport mechanisms 
involved. For example, reduced perfusion in the diseased heart may lead to a reduction in 
the accumulation of Mn2+ due to the relatively small extracellular Mn2+ concentration, 
[Mn2+]e, irrespective of Ca
2+ transport kinetics (203). In addition to the perfusion required 
to deliver Mn2+ ions to the viable myocytes, Mn2+ accumulation also depends on the Gibbs 
free energy and the sarcolemmal Ca2+-transporters. 
The work contained within this dissertation attempts to investigate the feasibility of 
using an in vivo T1-mapping MEMRI technique to assess and model Mn
2+ dynamics in the 
mouse myocardium for both healthy mice and mice following myocardial infarction. Due 
to the biochemical similarities between Ca2+ and Mn2+, the results of this study could 
provide an innovative and effective technique to monitor the progression of calcium 
dependent heart disease. Such knowledge could be applied to the development of 
preclinical and clinical protocols, such as in the detection of potentially salvageable 
myocardium in vivo for future treatment or evaluation of disease progression. 
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2.1 Background – Quantitative Cardiac Manganese-Enhanced MRI 
 
2.1.1 Introduction 
In spite of the established importance of calcium regulation in the heart both prior 
to, and following, myocardial injury, monitoring strategies to assess calcium homeostasis in 
affected cardiac tissue are limited. Mn2+ infusion in mice has been shown to lead to 
significant signal enhancement in T1-weighted cardiac MRI (99). It has also been 
demonstrated that MEMRI is sensitive to changes in inotropy (99), consistent with the 
model that Mn2+-induced enhancement of cardiac signal is indicative of the rate of calcium 
influx into the heart. In order to more accurately assess manganese fluxes in vivo and to 
assess changes in Mn2+ uptake due to myocardial infarction, a quantitative imaging 
technique is required. The goal of using a quantitative technique is to be able to estimate 
absolute regional Mn2+ content in vivo, with applications to assess regional Mn2+ handling 
alterations in a myocardial infarction model. 
The following background studies were conducted in order to assess the feasibility 
of combining quantitative imaging protocols to the field of cardiac MEMRI. Results from 
these background studies could then lay the foundations for a more thorough investigation 
into the Mn2+ handling properties of myocytes, the goal of this dissertation. 
 
2.1.2 Myocardial Manganese Influx 
As a background study (204), a T1-mapping protocol was implemented to determine 
the relationship between the Mn2+ infusion dose and the calculated absolute tissue 
relaxation times due to Mn2+ uptake in murine cardiac myocytes. T1-mapping MEMRI 
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experiments were performed in adult male C57Bl/6 mice anesthetized with a mixture of 
medical air, oxygen (1:1), and 2.5% isoflurane, and maintained at a heart rate of 460±30 
bpm with 1.25±0.32% isoflurane throughout the MRI session. MnCl2 doses ranging from 
25 to 297 nmoles g−1 total body weight (BW) (prepared from a 60mM stock solution) were 
infused into healthy mice via the tail vein at a rate of 0.6 ml h−1. This dose range had 
previously been shown not to cause cardiac depressive effects (99). 
Short-axis T1-weighted images and T1-maps were acquired both prior to and 
following MnCl2 infusion on a 7.0-T 20-cm horizontal bore BioSpec MRI spectrometer 
(Bruker Instruments, Billerica, MA, USA), as described by Waghorn et al. (204). Sample 
ECG gated short-axis cardiac MRI images are shown in Figure 2.1. Figures 2.1a and 2.1b 
show the T1-weighted signal intensity enhancements pre- and post-Mn
2+ infusion, 
respectively, while Figures 2.1c and 2.1d show the corresponding T1-maps pre- and post-
Mn2+ infusion, respectively. At this manganese dose of 280 nmoles g−1 BW there is 
significant signal intensity enhancement in the myocardium following Mn2+ infusion. 
Region-of-interest (ROI) analysis was performed on the 2D T1-maps using AMIDE (205) 
to calculate the average regional T1 value. A ROI was created within the left ventricular 
free wall (LV Wall), Figure 2.1b. T1 values were obtained from both pre-Mn
2+ infusion T1-
map ROIs and post-Mn2+ infusion T1-map ROIs. In vivo ∆R1 [s
−1] values were calculated as 
(post-MnCl2 infusion R1) – (pre-MnCl2 infusion R1), Equation 1.31, where the relaxation 
rate, R1, is defined as 1/T1. 
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Figure 2.1 Example short-axis heart images for a control mouse. (a) T1-weighted pre- 
MnCl2 infusion image; (b)T1-weighted post- MnCl2 infusion image; (c) pre- MnCl2 infusion 
T1-map; (d) post-MnCl2 infusion T1-map. (b) shows the locations of the interventricular 




In order to acquire in vivo Mn content data, two pieces of information are needed. 
One is the dependence of MnCl2 infusion dose on LV Wall relaxivity, and the other is the 
absolute tissue Mn content following MnCl2 infusion. Absolute manganese content data for 
heart and blood samples acquired from mice sacrificed immediately after imaging were 
measured by inductively coupled plasma-mass spectrometry (ICP-MS) analysis 
(CANTEST Ltd., North Vancouver, BC, Canada). These ex vivo absolute manganese 
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content values were then correlated to in vivo ∆R1 values, allowing for an estimate of the 
absolute Mn content in the heart. 
The effect of altering the infusion dose on LV Wall ∆R1 is shown Figure 2.2, with 
the data summarized in Table 2.1. Here, the post-MnCl2 infusion T1-map sequence was 
initiated approximately 5 minutes post-infusion. The summarized T1-map data points are 
shown as triangles in Figure 2.2, with the sample size and uncertainty (±1 SD) shown. The 
first two columns in Table 2.1 display the grouped Mn2+ infusion doses and corresponding 
LV Wall ∆R1 values. The sample sizes are displayed in parentheses. ∆R1 values ranged 
from 0.16 s−1 for the lowest dose regime, up to an average of 4.61 s−1 for doses above 197 
nmoles g−1 BW. 
Also shown in Figure 2.2 and Table 2.1 are the elemental analysis results for the 
heart tissue and blood sample absolute manganese content. These absolute manganese 
content values were quantified using ICP-MS, and are shown in columns 3-5 of Table 2.1. 
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Figure 2.2 Effect of altering the dose of infused Mn2+ on left ventricular free wall 
relaxivity (triangles). The x-axis shows the total dose of infused MnCl2, normalized to the 
mouse BW. The y-axis shows the change in relaxation rate, ∆R1, pre- vs. post- MnCl2 
infusion. As a function of dose, two linear dose uptake regions were noted, along with a 
plateau region above 197 nmoles g−1 BW. The least square fits are shown with total Mn2+ 
infusion dose, X [nmoles g−1 BW]. Comparison of this data to the total heart manganese 
content [μg g−1 dry], as determined by ICP-MS (squares) is also shown. This plot can be 
used to estimate the Mn content in vivo. 
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Table 2.1 Dose dependent T1-map ∆R1 values for the LV Wall are shown in columns 1 and 2. ICP-MS absolute blood and heart 
Mn values from mouse samples are displayed in columns 3-5. LV Wall ROI absolute Mn content from the calculated content 
maps are given in the final column. 
Mn2+ Infusion Dose 
(nmoles g−1 BW) 
LV Wall ∆R1 
(s−1) 
Mn2+ Infusion 
Dose for Elemental 
Analysis 
(nmoles g−1 BW) 
Heart Absolute 
Mn Concentration 






LV Wall ROI Data 
(nmoles g−1) 
38.34±11.98 (n=3) 0.16±0.17 37.55±16.82 (n=2) 8.15±6.04 0.22±0.04 6.48±7.78 
65.46±8.16 (n=2) 0.33±0.29 - - - 12.22±8.87 
86.21±4.37 (n=5) 1.23±0.84 83.85 23.78 0.41 36.05±23.91 
108.33±8.09 (n=3) 1.96±0.34 108.87±11.36 (n=2) 53.87±3.31 0.41±0.03 63.16±10.65 
132.98±5.92 (n=4) 2.23±0.87 130.38 52.32 0.53 80.04±35.68 
156.17±7.01 (n=2) 3.67±0.15 156.17±7.01 (n=2) 72.72±1.03 0.55±0.09 114.52±13.04 
189.89±13.59 (n=2) 4.26±1.24 199.50 132.74 0.61 139.74±77.11 
230.40±15.10 (n=3) 4.83±2.02 243.17 151.35 0.69 166.41±77.11 
283.13±9.73 (n=6) 4.49±1.63 - - - 221.97±131.13 
Values are expressed as mean ± SD, with sample size in parentheses 
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Three regions are shown in Figure 2.2. At MnCl2 infusion doses, X [nmoles g
−1 
BW], below 197 nmoles g−1 BW two linear uptake regimes can potentially be fit to the 
data, intercepting at 61 nmoles g−1 BW. Above 197 nmoles g−1 BW, the relaxivity 
enhancement reaches a plateau. Within this physiological steady state any further 
increase in Mn2+ dose does not result in an increase of ∆R1. The plateau occurs at ∆R1 = 
4.61±1.64 s−1. The best fit for the two phases below 197 nmoles g−1 BW have the form 
∆R1,low = 0.007X-0.107 (r
2 = 0.99) and ∆R1,high = 0.032X-1.613 (r
2 = 0.97) for the doses 
below and above 61 nmoles g−1 BW, respectively. The lower curve is fit under the 
assumption that ∆R1 = 0 below 16.3 nmoles g
−1 BW. This is deduced visually from 
Figure 2.2 and is consistent with the fact that there is initially a non-zero volume of saline 
infused into the tail vein prior to Mn2+ entering the mice, inherent in the infusion line 
setup. For the average mouse weight of 22.6±2.2 g, the average dose of saline present in 
the infusion line is 16.3±0.7 nmoles g−1.  
This dose dependent relationship can be used to optimize current manganese 
infusion protocols by minimizing the potential toxic effects of Mn2+ while still achieving 
adequate signal enhancement. Also, fitting this dose dependent data to ex vivo absolute 
Mn content values provides the ability to produce Mn concentration maps and to quantify 
the in vivo manganese content. 
The correlation between the infused Mn2+ dose, X [nmoles g−1 BW], and absolute 
heart Mn content, Y [μg g−1 dry weight], can be fit linearly with Y = 0.70X-25.9 (r2 = 
0.94, Figure 2.3a). Similarly, the effect of altering the dose of infused Mn2+ on absolute 
blood sample Mn content, Z [μg ml−1], yields a linear relationship of Z = 0.002X+0.16 (r2 




Figure 2.3 Effect of MnCl2 infusion dose on the total Mn content determined by ICP-MS 
for (a) the heart and (b) blood. The x-axis shows the total dose of MnCl2 infused. The y-
axis shows the absolute Mn content in μg g−1 dry weight for the heart and μg ml−1 for the 




One of the primary goals for this background study was to apply quantitative 
techniques to cardiac MEMRI studies in order to quantitatively estimate the absolute 
manganese map for the heart, in vivo. The data presented in Figure 2.2 shows the 
relationship between ∆R1 and the absolute heart manganese concentration, where the 
elemental analysis data points (square data point) are overlaid onto the dose dependent 
plot (triangular data points). Using the data obtained from this dose dependent study a 
myocardial relaxivity of 5.17 mM-1s-1 was estimated, based on the measured R1 values in 
the myocardium and from the elemental analysis measurements. Using this relaxivity, in 
 
65 
vivo absolute Mn concentration maps [nmoles g−1] were produced. The LV Wall ROI 
data for these maps are shown in the final column of Table 2.1. 
 
T1-mapping of cardiac MEMRI has proved sensitive enough to provide 
quantitative information over a range of Mn2+ doses. By demonstrating the dynamic 
range of relaxation rate changes over a range of Mn2+ infusion doses this method can 
provide a means of optimizing Mn2+ infusion protocols. Mn2+ is known to be cardiotoxic 
at high doses (129). However, this study has demonstrated a large range of signal 
enhancement at subtoxic levels. Due to this fact, lower doses of Mn2+ can be used while 
still producing significant relaxivity changes.  
Results of the dose dependent study (Figure 2.2) not only allow for the design of 
contrast agent optimal doses to minimize toxicity concerns, but also allow for in vivo 
estimates of absolute Mn content to be made following LV Wall ∆R1 calculations. This 
technique can therefore be used to monitor the in vivo Mn levels non-invasively. One 
interesting observation is the non-linear relationship between the total MnCl2 infusion 
dose and the LV Wall ∆R1. Instead of a purely linear increase in signal intensity 
enhancement a plateau region occurs at a dose above 197 nmoles g−1 BW, likely due to 
physiological effects. This is in good agreement with previously reported results (99). 
Following the same non-linear form as the total infusion dose, it is seen that above 
approximately 100 μg g−1 dry heart weight, the absolute Mn content also reaches a 
plateau. Within this plateau there is no increase in ∆R1 following an increase in absolute 
heart Mn content. As the infusion of MnCl2 increases, the absolute Mn content of the 




The plateau effect can be potentially explained in a number of ways, either due to 
the limitations of Ca2+ uptake, or due to limited compartmentalization. The cellular 
binding sites could become saturated at a certain dose, limiting the uptake of Mn2+. 
Another explanation for the plateau phenomena could be due to a gradient effect whereby 
the cells become saturated and are unable to uptake more Mn2+. Similarly, Mn2+ could 
have an inhibitory effect on the Ca2+ channels, limiting the scope for Mn2+ uptake. 
The non-zero intercept in Figure 2.2 is in part due to the finite length of infusion 
tubing attached to the tail vein needle. A short, 9.9±0.4 cm, length of PE10 tubing 
containing saline solution connects the infusion needle to the MnCl2 infusion line. This 
length of tubing corresponds to an equivalent infusion dose of 16.3±0.7 nmoles g−1 BW 
MnCl2. This helps to validate our assumption for the low dose linear fit, where at doses 
below 16.3 nmoles g−1 BW there is assumed to be no manganese infusion and ∆R1 = 0. 
 
2.1.3 Preliminary Myocardial Manganese Efflux Studies 
A second preliminary study was performed to test the feasibility of using the T1-
mapping MEMRI technique to study the Mn2+ efflux phenomena temporally. This is 
important because it could provide a quantitative means of measuring the rate of 
manganese efflux from the myocardium, and could also potentially provide information 
regarding the Mn2+ efflux rates from individual compartments. Within this study 
temporal signal washout curves were produced from T1-maps acquired at multiple time 
points post-infusion. The form of this curve could provide interesting information about 
the manganese efflux mechanisms, and could allow for useful in vivo examinations of the 
sodium-calcium exchanger (NCX) as a potential efflux pathway. 
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For this Mn2+ efflux study, a single dose of 282.57±5.96 nmoles g−1 BW was 
infused into the healthy mice at a constant rate of 0.6 ml h−1. A temporal ∆R1 washout 
curve was produced from T1-maps acquired both prior to and at multiple time points post-
infusion. The washout period was examined from 0.2 – 99.2 h. Values of ∆R1 were 
calculated by subtracting the average baseline ROI R1 (R1,baseline,LVWall = 0.78±0.04 s
−1 
from 33 control mice) from the post-Mn2+ infusion ROI R1 value. Figure 2.4 shows the 
temporal relationship of the Mn2+ washout curve in the LV Wall, while Table 2.2 
summarizes the washout data for the LV Wall. The LV Wall ∆R1 signal had been 
attenuated by 50% in the first 2.5 hours post-infusion. In comparison, it has been shown 
in a rat model that manganese is cleared from all the major organs within 24 hours (206). 
Despite this initially rapid attenuation of the ∆R1 signal, there is a non-zero ∆R1 value 
remaining until a few days post-infusion suggesting retention of the remaining Mn2+. 
During the first 9 hours post-infusion the washout data for this infusion dose can be fit 
exponentially with LV Wall ∆R1 = (5.24 s
−1)e-0.40·t (r2 = 0.93, with t given in units of 
hours). This information provides a better imaging timeframe for the cardiovascular 
disease model in the current study, while containing information on the potential 




Table 2.2 Temporal ∆R1 signal attenuation post-MnCl2 infusion in the LV Wall. 
Time Post-Mn2+ Infusion (h) LV Wall ∆R1 (s
−1) 
0.31±0.11 (n=7) 4.44±1.48 
1.35±0.30 (n=3) 3.65±1.08 
2.41±0.37 (n=5) 2.23±0.75 
3.33±0.04 (n=2) 1.04±0.29 
4.25±0.41 (n=3) 0.70±0.16 
6.33±0.08 (n=2) 0.63±0.36 
7.34±0.37 (n=5) 0.45±0.35 
9.22±1.11 (n=2) 0.59±0.39 
11.40±0.54 (n=5) 0.64±0.16 
13.19±0.62 (n=2) 0.36±0.03 
21.11 (n=1) 0.14 
46.07±3.30 (n=3) 0.07±0.04 
99.19 (n=1) 0.08 





Figure 2.4 Temporal Mn2+ washout curve. The x-axis shows experimental time course 
post- MnCl2 infusion, in hours. The y-axis shows the difference of relaxation rate, ∆R1, 
pre- vs. post- MnCl2 infusion. The insert plot shows the complete washout curve over an 




The form of the Mn2+ washout curve is still uncertain and numerical modeling of 
Mn transport may provide additional insight. The complicated form of this curve could 
contain information about the Mn2+ efflux mechanisms within the myocardium. 
Accumulation of Mn2+ in various compartments within the myocytes could explain the 
variations between the initially rapid washout and the sustained signal enhancement over 
a few days. Differences in individual compartment efflux rates would contribute to the 
washout curve. One potential efflux mechanism for Mn2+ is via the sodium-calcium 
exchanger (NCX). The NCX is an important transporter for the regulation of intracellular 
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Ca2+ concentration (207). By altering the characteristics of different efflux mechanisms, 
such as the NCX channel, it might be possible to further interrogate the form of the curve 
and the underlying physiology. This information, along with the use of physiological 
modulators such as pharmaceutical agents, could be critical for examining potential Mn2+ 
extrudability pathways. This technique could also provide a means of identifying Mn2+ 
efflux modulation due to myocardial injury. 
 
2.1.4 Manganese Influx in a Myocardial Infarction Model 
It has previously been shown (137) that T1-weighted MEMRI in a murine MI 
model provides clear delineation of the myocardial infarction site. The final background 
study for this dissertation was designed to characterize the efficacy of applying a 
quantitative MEMRI T1-mapping technique to assess the dynamic features of calcium 
response due to myocardial injury in a murine model. Results from this study could then 
be used to further address Mn2+ handling dynamics, including alterations following MI, 
which could ultimately lead to a better understanding of the relationship between Mn2+ 
and Ca2+.  
For this study mice were divided into three experimental groups: control (n = 6, 
average weight = 22.57±3.24 g), sham-operated (n = 21, 23.06±2.48 g) and myocardial 
infarction (MI) (n = 6, 23.24±1.02 g). The control group underwent no surgical 
procedures, while the sham-operated and MI groups both underwent thoracotomy with 
the MI group receiving permanent MI via left anterior descending coronary artery (LAD) 
ligation. The aim of this study was to characterize the efficacy of MEMRI T1-mapping 
for assessing alterations in calcium homeostasis. To accomplish this aim, cardiac images 
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were acquired both pre- and post-MI, in a murine model. The post-MI time point was 
chosen to emphasize calcium alteration after MI, while avoiding the pathological 
complexity of heart failure at later times. Imaging was therefore performed 13±4 days 
and 12±6 days post-surgery for the MI and sham-operated groups, respectively. 
For Mn2+ administration, a tail-vein infusion line was placed and all three groups 
of mice were infused with 282.5±4.0 nmoles g−1 BW at a constant rate of 0.6 ml h−1. 
Short axis images were acquired for the control and sham-operated mice midway through 
the left ventricle and perpendicular to the long axis of the heart. In the myocardial 
infarction group the short axis was again defined perpendicular to the long axis of the 
heart, but located at the area with the greatest LV wall-thinning due to the injury, 
typically within 1 mm of the center of the ventricle. In the case of the control and sham-
operated mice, ROI tools were used to select a region of interest within the left 
ventricular free wall (LV Wall). To quantitatively assess the dynamic features of the 
calcium response due to the myocardial injury additional regions of interest were defined 
for the MI group. The peri-infarcted zone ROIs were defined in the regions of the LV 
Wall immediately surrounding the injury site, starting at the outer boundary of the left 
ventricular thinning and extending approximately 1.5mm into the viable tissue. An 
additional ROI, the necrosed tissue ROI, was created within the injury site of the left 
ventricular free wall. In vivo ∆R1 values were calculated as before, with post-MnCl2 T1-
maps being acquired 0.25±0.05 h after the initial MnCl2 infusion. 
Figure 2.5 shows sample post-Mn2+ infusion T1-maps for (a) sham-operated and 
(b) MI mice. The sham-operated mouse shows a well defined LV Wall and 
interventricular septum with relatively uniform Mn2+ uptake throughout. In the MI model 
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there is substantial LV Wall thinning at the injury site, accompanied by higher T1 values 
due to reduced uptake of Mn2+. 
The results of this study are shown in Figure 2.6, where the data is presented as 
the average ROI ∆R1 (solid horizontal line) ± SD (shaded box), with the data range (solid 
vertical line). Table 2.3 also shows theses results, along with the statistical test results. 
Twenty-one sham-operated surgeries were performed to ensure consistency in the 
surgical technique before performing MI surgery in the MI group. Imaging results for all 
of the sham operations were found to be self-consistent (i.e., there was no image-based 





Figure 2.5 Example short-axis post- MnCl2 infusion T1-map cardiac images for; (a) a 
sham-operated mouse, and (b) a myocardial infarction mouse. Significant LV Wall 
thinning can be seen for the MI mouse with a longer T1 relaxation time relative to healthy 
myocardial tissue. (b) shows the interventricular septum (S), myocardial infarction peri-





Figure 2.6 The effect of myocardial injury on the uptake of Mn2+. Regions of interest 
were defined for the LV Wall in the control and sham-operated groups. ROIs for the MI 
model were also defined at the injury site contained within the LV Wall and in the peri-
infarcted zone, immediately surrounding the injury site. Data is presented as the average 
ROI ∆R1 (solid horizontal line, s





There is no statistically significant difference between the LV Wall ∆R1 values of the 
control (4.49±1.63 s−1) and sham-operated (4.62±2.34 s−1) mice (p = 0.91) suggesting 
that the procedure of opening the chest does not affect Mn2+ uptake within the heart. 
Comparing the control and sham-operated LV Wall ∆R1 values with the MI group peri-
infarcted zone ∆R1 values using ANOVA, however, shows that there is a significant 
difference in relaxivity between the groups (p = 0.03). Cross-comparison of all of the 
groups individually with t-tests demonstrates that the MI group peri-infarcted zone ∆R1 
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(2.00±0.49 s−1) is significantly less than the control and sham-operated groups (p < 0.05), 
with the MI injury site ∆R1 (0.97±0.39 s





Table 2.3 Average ∆R1 signal enhancement post-Mn
2+ infusion for control, sham-
operated and myocardial infarction groups. For the myocardial infarction group ROIs 
were defined both for the myocardial infarction peri-infarcted zone, surrounding the 
infarction site, and the infarcted site (MI). 
Group - Region of Interest (ROI) ROI ∆R1 (s
−1) 
Control – LV Wall 4.49±1.63 (n=6)†*‡ 
Sham-Operated – LV Wall 4.62±2.34 (n=21) 
Myocardial Infarction – Peri-infarcted Zone 2.00±0.49 (n=6) 
Myocardial Infarction – MI Site 0.97±0.39 (n=6) 
Values are expressed as mean ± SD, with sample size in parentheses 
†p = 0.03 between all LV Wall groups (ANOVA, single factor) 
*p = 0.91 between control and sham-operated LV Wall groups (unpaired two-tailed t-
test) 
‡p < 0.05 between every two group combination except the control and sham-operated 




This final background study has demonstrated the quantitative ability of MEMRI 
T1-mapping in the murine heart to determine cellular viability in the vicinity of the 
myocardial infarction site. This could ultimately lead to an early in vivo indicator of 
viable treatment options depending on the state of the myocytes and their potential 
salvageability. 
The myocardial infarction study utilized the optimal dose and timing properties 
acquired from the previous sections of this background study. Statistically significant 
differences between healthy myocardial tissue, in the control and sham-operated groups, 
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and the MI peri-infarcted zone in the MI group were demonstrated. Mn2+ had previously 
been shown to provide functional, pathological and viability data in myocardial tissue 
using T1-weighted imaging techniques in mice (137) and dogs (10). Manganese-
dipyridoxyl diphosphate (MnDPDP), a Mn2+ releasing contrast agent (172), is currently 
approved for clinical liver imaging. MnDPDP-enhanced images have demonstrated 
manganese retention in viable pig myocardium (208) with clearance of manganese from 
infarcted myocytes in a rat model (136). This behavior is consistent with MEMRI 
contrast. Recently, MnDPDP has been used as a viability marker in patients with 
myocardial infarction (11). However, more quantitative information was required to be 
able to assess the extent of damage to the myocardium, which has been demonstrated 
here through the T1-mapping protocol. 
Myocardial infarction causes physiological remodeling leading to potential Ca2+ 
handling alterations. This remodeling process can potentially be observed and monitored 
using MEMRI T1-mapping as shown by the sensitivity of our data. The injury site of the 
LV Wall showed a ∆R1 almost 5 times less than the healthy LV Wall of the control 
mouse. More interestingly, with respect to recovery of the injured tissue, this technique is 
sensitive to the reduced uptake of Mn2+ in the peri-infarcted zone. During myocardial 
ischemia intracellular calcium concentrations increase due to increased Ca2+ influx and 
reduced efflux (2). However, our results show reduced Mn2+ uptake in both the MI site 
and peri-infarcted zone. 
The phenomena of reduced Mn2+ uptake in both the MI region and the peri-infarcted 
zone are complex to address. To date, conflicting results have also been reported in other 
studies. In vivo manganese-enhanced MRI has observed signal attenuations in mice 
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(137), rat (138) and larger mammalian species (139). However, in vitro studies have 
shown enhanced Ca2+ influx as a compensatory process (140). 
Camelliti, et al. (141) have shown ex vivo results which demonstrate small islands of 
viable myocytes in ischemic regions. These islands could potentially explain the non-zero 
Mn2+ uptake in the ischemic regions. In the peri-infarcted area this background study 
suggests that the volume of viable tissue is still reduced as compared to healthy LV Wall 
tissue of the control and sham operated mice. This could potentially explain the reduction 
of Mn2+ uptake in this area. Temporal responses to myocardial infarction could now be 
predicted in mice using this preclinical model, looking at the alterations in calcium 
handing with recovery. 
These results demonstrate the sensitivity of this technique to determine altered 
manganese uptake, not only at the necrotic site but also within the peri-infarcted zone. 
Calculating the in vivo Mn content map could allow for potentially salvageable 




These background studies have demonstrated that T1-mapping of cardiac MEMRI 
can be used to quantify Mn concentrations in vivo and to define regions of potentially 
altered Ca2+ homeostasis in a myocardial infarction model. The effect of the manganese 
infusion dose has been studied up to approximately 297 nmoles g−1 BW, with an initial 
slow uptake occurring below 61 nmoles g−1 BW, and a more rapid uptake until 197 
nmoles g−1 BW. At this dose the physiological steady state was achieved. 
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Mn2+ washout has also been investigated in the LV Wall. The ∆R1 signal has 
attenuated to 50% of the steady state signal by approximately 2.5 hours post-infusion. 
There is still a ∆R1 effect remaining after a few days suggesting potential Mn
2+ retention 
at the site. The overall washout progression warrants further investigation, but this 
technique could provide a potential way to examine the extrudability of Mn2+ from the 
myocardium. 
One motivation for these background studies was that myocardial infarction 
causes physiological remodeling leading to potential Ca2+ handling alteration. With the 
potential of using T1-mapping and ICP-MS analysis to quantify the in vivo concentration 
of Mn, more insight into myocardial infarction peri-infarcted zones may be provided. 
This technique could provide additional information such as: (1) optimization of the Mn2+ 
dose to minimize the study dose; (2) quantification of Mn content in vivo; (3) temporal 
response of myocardial infarction or ischemic-reperfusion model(s); (4) pharmacological 
efficacy; and (5) potential preclinical and translational models to monitor disease 
treatment. 
Overall, these background studies have demonstrated the quantitative potential of 
MEMRI studies to study Mn2+ fluxes in healthy and diseased myocardium. This 
dissertation builds upon these preliminary findings in an attempt to further understand 
Mn2+ handling dynamics and the relationship between Mn2+ and Ca2+ handling in the 
mouse myocardium. The following three sections, §2.2, 2.3 and 2.4, outline the goals of 





2.2 Part I – Mn2+ Dose Dependent Cardiac Efflux 
 
The first section of this dissertation attempts to determine the feasibility of 
monitoring Mn2+ efflux in vivo using T1-mapping MEMRI. It has been shown (§2.1.3) 
that MEMRI T1-mapping protocols are sensitive enough to detect alterations in ∆R1 in 
the mouse myocardium post-MnCl2 infusion. However, the relationship between ∆R1 and 
the absolute Mn content has not been determined, and may be variable with increasing 
time post-MnCl2 infusion. Here, a MnCl2 dose dependent study was used to observe the 
effect of altered MnCl2 infusion doses on the temporal rate of change of ∆R1 in the left 
ventricular free wall (LV Wall). To ascertain whether the temporal changes in ∆R1 were 
caused by true Mn2+ efflux from the myocardium, in vivo data was then correlated to the 
acquired absolute Mn content, obtained ex vivo via elemental analysis results from 
sample mice hearts. Results from this study could be used to determine whether ∆R1 
washout curves can predict changes in Mn2+ content, and also to determine the effect of 
altered Mn2+ concentrations on Mn2+ efflux in the healthy myocardium, providing early 
information regarding Mn2+ efflux under healthy conditions. 
 
 
2.3 Part II – Pharmacologically and MI altered Mn2+ Efflux 
 
In order to further probe potential Mn2+ efflux mechanisms, ∆R1 washout curves 
were produced following pharmaceutical alterations of the known Ca2+ efflux 
mechanisms, either by inhibiting the NCX with varying doses of SEA0400, or by using 
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inotropic agent dobutamine, known to increase calcium influx and assumedly calcium 
efflux. The form of these efflux curves could indirectly contain information concerning 
the relative contribution of the Ca2+ transport mechanism. 
Having previously studied Mn2+ dynamics in the unaltered healthy myocardium in 
§2.2, the MEMRI T1-mapping efflux technique was then applied to a myocardial 
infarction model to detect potential regional variations in the Mn2+ efflux properties. 
Alterations in Ca2+ handling following MI can exacerbate myocardial injury. Of 
particular interest is the peri-infarcted zone, which could potentially undergo therapeutic 
intervention to aid remodeling of the myocardium post-infarction. By studying Mn2+ 
efflux as a function of position in the myocardium, it could be possible to determine 
alterations in Mn2+ flux owing to the injury. In order to provide this dynamic, position-
dependent data, novel in-house software was devised and written in order to 
automatically isolate myocardial tissue from the T1 maps with minimal user input and 
bias. The isolated myocardium was then radially segmented, allowing for position-
dependent Mn2+ efflux curves to be produced. Observed dynamic variations in Mn2+ 




2.4 Part III – Pharmacokinetic Modeling of Mn2+ Fluxes 
 
In the final part of this dissertation, data from both previous studies (§2.2 and 
§2.3) were applied to a series of pharmacokinetic models to estimate the various Mn2+ 
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flux rate parameters (including myocardial Mn2+ influx and efflux), studying Mn2+ in the 
blood and heart systems. With knowledge of the Mn2+ infusion rate and dose, as well as 
absolute Mn content in the blood and heart at various time-points post-MnCl2 infusion, in 
vivo ∆R1 values could potentially be used to model the temporal Mn
2+ content in the 
blood and heart as a function of time. Additionally, it should be possible to predict the 
transfer rates of Mn2+ from initial infusion into the blood stream, to myocardial uptake, 
efflux and the potential compartmentalization within the myocytes. This dissertation 
attempts to model both control (healthy myocardium) and MI transfer rates in an attempt 
to further understand the Mn2+ dynamics post-infusion and also the dynamic alterations 










Calcium (Ca2+) is a major regulator of cardiac contractility (202). When a 
myocyte is depolarized by an action potential, Ca2+ enters the cell primarily via L-type 
voltage-gated Ca2+ channels with a smaller contribution occurring via the reverse mode 
of the sodium-calcium exchanger (NCX) (4). This Ca2+ influx in the cytosol acts to 
trigger a subsequent release of Ca2+ stored in the sarcoplasmic reticulum through Ca2+-
release channels ultimately leading to myocardial contraction. 
The efflux of Ca2+ occurs via the forward mode of the NCX and via the plasma 
membrane Ca2+-ATPase mechanism (22). The net Ca2+ flux through the NCX occurs in 
the outward direction. Previous studies estimating the relative contributions to Ca2+ efflux 
showed that the NCX is the dominant mechanism with 9–32% of the efflux occurring 
from non-NCX mechanisms in rats (23,24) and 19% in mice (25). 
Alterations in myocyte Ca2+ handling are essential to the dysfunctional 
characteristics of the failing heart (46). Although research has established that diminished 
cardiac performance in heart failure is due to abnormal intracellular Ca2+ handling, to the 
best of the author’s knowledge no technique exists to directly observe in vivo intracellular 
Ca2+ flux fluctuations across the plasma membrane (47,48).  
As demonstrated in §2, one potential technique for indirectly assessing 
intracellular Ca2+ movement in vivo is to use a surrogate marker such as manganese 
(Mn2+) as a molecular contrast agent. The hypothesis is that the ability to measure Mn2+ 
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efflux in vivo using MEMRI as a quantitative imaging approach should reflect 
information concerning myocardial Ca2+ efflux, if retention of Mn2+ due to 
compartmentalization is relatively small compared to the total intracellular Mn2+ 
concentration.  
The application of a T1-mapping technique during MEMRI provides valuable 
quantitative information, while minimizing the effects of repositioning the animal 
between MEMRI sessions. The background study (§2.1.2) demonstrated that a MEMRI 
T1-mapping protocol in a murine model exhibited a linear relationship between the 
amount of Mn2+ infused (in the range 25 – 197 nmoles g−1 body weight (BW) MnCl2 
infusion) and change in absolute 1H2O relaxation rates (∆R1) in heart tissue (204). This 
linear relationship suggested that the initial Mn2+ compartmentalization, such as in the 
mitochondria, is either linear and/or small compared to changes in the cystolic free Mn2+ 
concentration. Furthermore, §2.1.3 demonstrated that in vivo ∆R1 washout curves could 




The purpose of this study was to use MEMRI in a murine heart model with a T1-
mapping technique to assess the dependence on MnCl2 infusion doses on Mn
2+ washout. 
In order to achieve this goal, it is necessary not only to produce dose dependent efflux 
curves, but also to ascertain the relationship between ∆R1 efflux and Mn
2+ content efflux 
post-MnCl2 infusion. Therefore, this study was designed to 1) determine whether it was 
possible to monitor Mn2+ efflux in the heart using a T1-mapping pulse sequence in order 
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to estimate the absolute Mn2+ content in vivo and 2) to study the dependence on MnCl2 
infusion, and therefore myocyte Mn2+ content, on the efflux properties of Mn2+. 
 
 
3.2 Materials and Methods 
 
3.2.1 Experimental Protocol  
MEMRI experiments were performed in a total of 62 healthy adult male C57Bl/6 
mice (6-14 weeks old, 24.0±1.9 g) following the guidelines of the Institutional Animal 
Care and Use Committee at the Medical College of Georgia, Augusta, GA, USA. For all 
experimental procedures, the animals were anesthetized with a mixture of medical air, 
oxygen (1:1) and 2.5-3.0% isoflurane. The heart rate (HR) was maintained at 444±8 beats 
per minute (bpm) throughout the experiment by carefully adjusting the level of 
isoflurane. A custom-made water bed set at 38°C maintained a constant animal body 
temperature in the cradle throughout the MEMRI procedure. 
Of the 62 mice, 40 were randomized into four MnCl2 dose dependent 
experimental groups to, receiving single MnCl2 infusion of: 
1) 283±6 nmoles g−1 BW (number of mice, nmice = 15; total number of T1-maps post-
MnCl2 infusion, nmaps = 41); 
2) 190±2 nmoles g−1 (Control, nmice = 14, nmaps = 36) 
3) 119±3 nmoles g−1 (nmice = 7, nmaps = 21); 
4) 65±0.2 nmoles g−1 (nmice = 4, nmaps = 14) 
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All of the MnCl2 doses were previously shown not to cause measurable 
cardiotoxic effects (99), with the Control, 190 nmoles g−1 MnCl2 dose, found to lie at the 
high dose end of the linear Mn2+ uptake region, §2.1.2 (204). After the proper level of 
anesthesia was achieved in each animal, MnCl2 infusions (prepared from a 60 mM stock 
solution; Sigma-Aldrich, St. Louis, MO) were administered intravenously via the tail 
vein. All MnCl2 infusions were completed at a constant rate of 0.6 ml h
−1 with the aid of 
a syringe pump (KD Scientific Inc., Holliston, MA, USA).  
For the remaining mice not selected for one of the four dose-dependent efflux 
groups, as well as for select mice included in the efflux study (n = 33), T1-maps were 
acquired prior to MnCl2 infusion to determine the baseline (pre-MnCl2 infusion) R1 
values required for calculation of ∆R1. T1-maps were then acquired for the four efflux 
groups at various post-infusion time points, ranging from 0.2 hrs to 12 hrs. T1 mapping 
was not performed during the first 0.2 hrs following MnCl2 infusion, to allow for 
assumed blood pool clearance (10).  
As previously stated, all mice were anesthetized during the experimental 
procedures (contrast agent infusion, drug administration, and imaging sessions). The 
mice were allowed to recover between procedures so that the maximum time under 
anesthesia was 2.5 hrs for each mouse, followed by a recovery period of at least 2.5 hrs. 
These timeframes reduced the NCX inhibitory effect known to be caused by isoflurane 
(209); imaging time points selected for each mouse therefore followed these guidelines. 
In addition, efforts were made to vary the time interval between successive data points so 
as not to bias the results with potential anesthesia effects. The ∆R1 washout curves were 
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produced for each group by calculating T1 values in the left ventricular free wall from T1-
maps acquired at the various time points post-MnCl2 infusion. 
A subgroup of randomly selected animals (n = 14) was sacrificed immediately 
after imaging to measure the absolute Mn content in the heart tissue (n = 12) and/or blood 
samples (n = 11) by inductively coupled plasma-mass spectrometry (ICP-MS) analysis 
(CANTEST Ltd., North Vancouver, BC, Canada). To maintain a consistent harvest time, 
the tissue and blood samples were obtained approximately one hour after initiation of the 
final T1-map to allow sufficient time to acquire the T1-map (~43 minutes) and to harvest 
the individual samples. 
 
3.2.2 Manganese-Enhanced Magnetic Resonance Imaging 
MEMRI data for this, and subsequent studies, were acquired on a 7.0-T 20-cm 
horizontal bore Bruker BioSpec MRI spectrometer (Bruker Instruments, Billerica, MA, 
USA) equipped with a micro-imaging gradient insert (950 mT m−1). Animal setup 
procedures followed those previously described (99). A standard Bruker volume coil (35 
mm inner diameter) was used to transmit and receive at 1H frequency (300 MHz). 
Electrocardiographic (ECG) and respiratory signals were monitored by a physiological 
monitoring system (SA Instruments, INC., Stony Brook, NY) with the ECG signal used 
to gate the images. All images were gated using the R wave of the ECG. Short axis 
images were acquired midway through the left ventricle and perpendicular to the long 
axis of the heart. A T1-weighted MRI Gradient Echo Flow Compensation (GEFC) pulse 
sequence (210) was used for slice localization and to visualize Mn2+ uptake in the 
myocardium with the imaging parameters as follows: 
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Matrix = 128 x 128; TE/TR = 3.5/35 ms; slice thickness = 1.0 mm; FOV = 3.0 x 
3.0 cm; flip angle = 60° and NA = 6. 
TR was purposely set at a shorter time than the average R-R period detected on the ECG 
(138±1.5 ms) to ensure the true repetition time for the imaging sequence was the R-R 
period. 
Both pre- and post-MnCl2 infusion T1-maps were acquired with an ECG-gated, 
flow-compensated Look-Locker MRI pulse sequence (§1.7.1) as previously described 
(145), using the following parameters: 
Matrix = 128 x 128; TE/TR = 2.5 ms/10 s; slice thickness = 1.0 mm; FOV = 3.0 x 
3.0 cm; NA = 2; inversion time = 9 ms; average echo interval = 138 ms 
(determined by the average R-R period before acquisition); number of echo 
images = 50; average flip angle = 11±1° 
The echo interval was set as the approximate mean R-R period observed prior to the 
execution of each T1-map sequence. The initial inversion pulse per repetition was gated, 
with the subsequent echo pulses separated by the constant echo interval. The T1 value 
estimation was therefore not affected by R-R period fluctuations occurring during TR. 
The total imaging time per T1-map was approximately 43 minutes. 
 
3.2.3 Data Analysis 
 
T1-mapping 
The T1 value of each pixel was calculated using a custom-written C
++ program 
(145). The signal recovery of each pixel was fit from the 50 echo images by the three-
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parameter Levenburg-Marquardt non-linear curve-fitting algorithm. Region-of-interest 
(ROI) analysis was performed on the 2D T1-maps using AMIDE (205) to calculate the 
average regional T1 value. ROIs were selected within the left ventricular free wall (LV 
Wall) area. As previously stated, in vivo ∆R1 values were calculated as (post-MnCl2 
infusion 1/T1) – (pre-MnCl2 infusion 1/T1). The ∆R1 values were stated as a mean ± 
standard deviation in units of [s-1]. 
 
Statistics 
Individual ∆R1 data points for all of the MnCl2 dose dependent groups were fit 
with a least-square first-order exponential decay using GraphPad Prism statistics software 
(GraphPad, San Diego, CA, USA). The 95% confidence intervals (CI) for the 
extrapolated ∆R1 at the time of infusion, t = 0, (∆R1,0 ) and half-life values were 
calculated from the exponential fit. The ∆R1,0 and half-life values were compared 
between groups using an extra sum-of-squares F test, comparing the ratio of the 
difference between the least-square fit from the washout curves to the residual sum of 
squares within each curve. Comparisons between the four experimental groups were 
assessed using ANOVA with a Tukey post hoc test to determine differences between sub-










Figure 3.1 shows sample cardiac short axis T1-maps; pre-MnCl2 infusion (Figure 
3.1a), 0.2 hrs (Figure 3.1b), and 5 hrs (Figure 3.1c) post-MnCl2 infusion. The average LV 
Wall ROI size was 22±5 voxels (Figure 3.1b). 
 
3.3.1 Dose Dependent Efflux 
For all of the dose dependent groups, ∆R1 values were calculated by subtracting 
the average baseline R1 value (0.78±0.04 s
−1) from the post-MnCl2 infusion ROI R1 
values. Figure 3.2a shows the LV Wall ∆R1 washout curves for the four MnCl2 infusion 





Figure 3.1 Example short-axis mouse heart T1-maps (a) pre-MnCl2 infusion (b) 0.2 hrs 
and (c) 5 hrs post-MnCl2 infusion. Left and right ventricles are labeled as LV and RV 




Figure 3.2 Dependence of the temporal changes in LV Wall ∆R1 on the MnCl2 infusion 
dose. (a) Binned data ± 1 standard deviation and first-order exponential fits using 
individual data points with 95% confidence intervals. (b) Corresponding dependence of 
the temporal LV Wall ∆R1 washout half-life on the dose of MnCl2. A first-order 
exponential was used to fit the half-life data. Sample sizes are shown for the mice (nmice) 




As shown in Figure 3.2a, the first-order exponential decay curves provided a good 
fit for the in vivo efflux data (r2 = 0.86±0.08). As the MnCl2 infusion dose increased, 
uptake of Mn2+ in the heart also increased, as did the rate of Mn2+ efflux. 
Figure 3.2b shows the specific correlation between the infusion dose and the 
exponential efflux properties. Mathematical equations describing the total dependence of 
the efflux half-life and ∆R1,0 values on the MnCl2 infusion dose are shown in Equation 
3.1 and Equation 3.2, respectively. The curve associated with Equation 3.1 is shown in 
Figure 3.2b, which illustrates that the Mn2+ efflux half life is exponentially dependent on 
the dose (r2 = 0.70) whereas Mn2+ uptake (proportional to ∆R1,0) is linearly correlated to 
the dose (r2 = 0.99). 
     0.3316.3ehrst nmoles/gDose0.0821/2    Equation 3.1
     0.21nmoles/gDose0.019sΔR 11,0   Equation 3.2
Using the 190 nmoles g−1 MnCl2 group as the control, all other MnCl2 dose 
groups were found to have significantly different half-life and ∆R1,0 values (p < 0.05). 
 
3.3.2 Absolute Manganese Content Efflux 
Figure 3.3 shows the temporal response of the absolute cardiac Mn content post-
infusion for the Control group (n = 12). A first-order exponential curve was fit to the 
absolute Mn content data, as shown. The Control group yielded an absolute Mn content 
efflux half-life of 4.5±3.4 hrs (r2 = 0.58) with a corresponding extrapolated Mn content at 
time zero of 22.2±6.5 µg g−1 wet weight. There was no significant difference between the 
in vivo LV Wall ∆R1 half-life and the absolute cardiac Mn content half-life obtained via 




Figure 3.3 Elemental analysis data showing the temporal changes in Mn content for the 
control, 190 nmoles g−1 group, along with the first order exponential fit. Sample size (n) 






The T1-mapping MEMRI technique used in this study demonstrated its sensitivity 
to detect temporal changes in 1H2O relaxation rates in the LV Wall following infusion of 
MnCl2 in healthy adult male mice. No significant difference was found between the in 
vivo LV Wall ∆R1 half-life and the absolute cardiac Mn content half-life obtained via 
elemental analysis. This correlation between in vivo ∆R1 efflux and the efflux of absolute 
cardiac Mn content post-MnCl2 infusion suggested that the observed ∆R1 changes reflect 
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changes in Mn2+ content, making this technique appropriate for the evaluation of Mn2+ 
efflux in vivo. 
Additionally, this study found that increased MnCl2 infusion doses lead to an 
increase in ∆R1,0 and the ∆R1 efflux rate in the healthy mouse myocardium. The finding 
of a linear dose dependent increase of ∆R1,0 is in agreement with previous Mn
2+ influx 
studies, §2.1.2 (99,204). Within the MnCl2 dose-dependent groups, Mn
2+ efflux occurred 
with a half-life dependent on the initial Mn2+ content such that an increase in the Mn2+ 
uptake caused an increase in the Mn2+ efflux rate. 
This study demonstrated that cardiac MEMRI T1-mapping in mice provided a 
non-invasive technique to monitor changes in ∆R1 from which Mn
2+ efflux could be 
inferred. The temporal change in LV Wall ∆R1 after a 190 nmoles g
−1 BW MnCl2 
infusion followed an exponential decay, thus allowing for inferred determinations of 
Mn2+ efflux half-lives. The half-life for the control curve was 3.4 hrs. The relatively rapid 
blood pool clearance, with a half-life of approximately 12 minutes, compared to the 
cardiac Mn2+ clearance (10), suggested that during the imaging time course there was 
negligible Mn2+ influx, allowing for Mn2+ efflux to be approximated with first-order 
exponential curves. Nevertheless, this first-order exponential fit is not without 
drawbacks. If Mn2+ efflux is multi-compartmental and occurs via multiple mechanisms, a 
more complicated washout form would be warranted with multiple exponential 
parameters.  
Elemental analysis of heart tissue samples collected over the first 8 hrs post-
MnCl2 infusion demonstrated that the reduction in LV Wall ∆R1 was linearly 
proportional to the myocardial Mn content (Figure 3.2). The linearity of the temporal 
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data, suggest that 1) observed temporal changes in ∆R1 are linearly proportional to 
changes in Mn content and 2) Mn2+ efflux could be estimated from the ∆R1 washout 
curves. If significant changes in the amount of intracellular versus extracellular Mn2+ 
occurred during the experimental timeframe, the observed Mn2+ longitudinal relaxivity 
would not be constant, since intracellular and extracellular Mn2+ have different 
relaxivities (211). In addition, the longitudinal relaxivity of intracellular Mn2+ would be 
expected to be much higher due to protein binding. However, the finding of a linear 
correlation between in vivo ∆R1 and absolute heart Mn content over several hours 
suggests that the longitudinal relaxivity does not change over time. Similar to results 
shown by Waghorn et al. (204), this linear relationship suggests that the initial Mn2+ 
compartmentalization, such as in the mitochondria, is either linear and/or small compared 
to changes in the cystolic free Mn2+ concentration. If the latter were true, the degree of 
compartmentalization would have a relatively minor impact on Mn2+ fluxes compared to 
the effect of the NCX efflux mechanism during the current experimental protocol. 
Indeed, Figures 3.2a and 3.3 display non-zero exponential plateaus of ∆R1 and heart Mn 
content respectively for times much longer than the efflux half-life. This residual increase 
above the baseline is relatively small and could be due to Mn compartmentalization. 
 
3.4.1 Study Limitations 
There are a number of factors that could potentially complicate the relationship 
between Mn2+ and Ca2+ transport. Differences between the binding constants of Mn2+ and 
Ca2+ may alter the relative contributions of the NCX as an efflux mechanism. Similarly, 
low extracellular Mn2+ concentrations create a concentration gradient potentially 
 
94 
allowing Mn2+ extrusion to occur via the Ca2+ channels. Compartmentalization of Mn2+ 
and the effect of mitochondrial Mn2+ on the MEMRI signal could also affect the 
interpretation of Mn2+ washout measurements. The compartmentalization effect involves 
compartments that are both extracellular (vascular and interstitial) and intracellular 






The MEMRI T1-mapping protocol provides a quantitative means of measuring 
temporal changes in LV Wall 1H2O longitudinal relaxation rates, allowing for the 
inferred, non-invasive investigation of Mn2+ efflux mechanisms. The findings from this 
study suggest that the half-life of Mn2+ efflux is approximately 3.4 hrs following an 
infusion dose of 190 nmoles g−1 MnCl2. Using in vivo T1-mapping data, myocardial Mn
2+ 
content could be estimated using the correlation between in vivo ∆R1 and elemental 
analysis of Mn content.  
These findings, along with the biochemical similarities between Ca2+ and Mn2+, 
strongly suggest that under appropriate conditions changes in Mn2+ efflux may reflect 
changes in Ca2+ efflux, such that MEMRI T1 mapping could be an innovative and 





CHAPTER 4: PART II – PHARMACOLOGICALLY AND MYOCARDIAL 






Myocardial infarction (MI) is defined as the presence of necrosis (cell death of 
cardiac myocytes) resulting from prolonged ischemia due to a coronary perfusion 
imbalance between blood supply and demand (40). Along with the rise and fall of cardiac 
serum biomarkers, the clinical criteria for diagnosing a MI includes images showing 
acute loss of viable myocardium. Imaging methods such as nuclear medicine (58), 
computerized tomography (59) and magnetic resonance imaging (MRI) (61) are useful 
for detecting the location and size of newly infarcted tissue. Kim et al. (62) demonstrated 
that MRI delayed enhancement methods using gadolinium (Gd) contrast could delineate 
regions of irreversible injury and viable tissue after a myocardial injury. Mechanisms 
underlying Gd concentration in the necrotic myocardium are most likely due to abnormal 
coronary perfusion and increased tissue edema (63). However, use of an intracellular 
viability tracer would allow for improved identification, quantification and evaluation of 
the potentially salvageable peri-infarcted tissue. Such an improved imaging technique 
may assist in developing new therapies for treating damaged tissue in the heart and 
ultimately enhance clinical outcomes for the post-MI patient (56). 
During myocardial ischemia, a reduced calcium (Ca2+) efflux and/or an increased 
Ca2+ influx via the sodium-calcium exchanger (NCX) results in an elevated Ca2+ 
concentration in the myocytes (4). This intracellular Ca2+ overload causes cellular 
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necrosis via protease activation, membrane rupture, cell contracture, and/or gap junction 
dysfunction (5). 
The final background study, §2.1.4 (204) demonstrated that T1-mapping MEMRI 
was able to detect and quantify regional variations of Mn2+ uptake in the infarcted mouse 
heart, which indirectly reflected altered intracellular Ca2+ fluctuations in the necrosed 
versus ischemic myocardium. Thus, the T1-mapping MEMRI technique has the potential 
for improving the evaluation of necrosed and peri-infarcted tissue zones in a post-MI 
model. 
Biochemical similarities and indirect correlations between Mn2+ and Ca2+ 
dynamics suggest that Mn2+ influx, §2.1.2 (99), and efflux, §2.1.3 (212), data could be 
used to predict altered Ca2+ handling. While differences in Mn2+ influx have previously 
been used to delineate MI regions (11,137), complexities of these approaches (e.g., 
myocardial perfusion, Mn2+ dissociation from the chelating agents) limit the 
interpretability of study results. The kinetics underlying Mn2+ efflux are not well 
understood, particularly since Ca2+ efflux (and presumably Mn2+ efflux) occurs via both 
the NCX and the plasma membrane calcium pump ATPase (PMCA).  
Pharmacologic agents that selectively inhibit the NCX mechanism should be 
useful for investigating how the NCX influences cardiac function, particularly since these 
drugs exhibit potential therapeutic effects after myocardial injury (190). During the early 
phase of reperfusion following myocardial ischemia, the trans-sarcolemmal ion gradients 
driving flux via the NCX cause Ca2+ to enter the cell producing intracellular Ca2+ 
overload (213,214). NCX inhibitors reduce intracellular Ca2+ concentration in these 
situations, which minimizes the amount of myocardial injury and lessens the detrimental 
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remodeling effects promoting heart failure (215). SEA0400, the most selective and potent 
NCX inhibitor to date (190,195), has been shown to protect against cardiac ischemia-
reperfusion injury, digitalis-induced arrhythmias, and myocardial stunning. 
 
4.1.1 Purpose 
The first part of this study was designed to test the sensitivity of the T1-mapping 
MEMRI technique in a murine heart model to detect changes in ∆R1 following treatment 
with NCX inhibitor SEA0400. The goal was to determine whether changes in ∆R1 were 
correlated to changes in the absolute Mn2+ content in the myocardium. The hypothesis 
was that Mn2+ will be extruded from cells via the NCX, with changes in Mn2+ efflux 
reflecting changes in Ca2+ efflux. 
Furthermore, this study examined the potential of implementing T1-mapping 
MEMRI to monitor potential changes in Mn2+ efflux rates following inhibition of the 
NCX with various doses of SEA0400 as well as with the inotropic agent dobutamine and 
post-MI. Observed temporal changes could potentially be used for inferring Mn2+ efflux 
as a tool for monitoring changes in Ca2+ efflux, a technique which could be used to 
monitor cardiac disease progression. 
Therefore, the purpose of this study was to characterize myocardial Mn2+ efflux 
properties in both healthy male adult mice and ones experiencing surgically induced MI. 
The goals for this section of the dissertation were therefore: 
1. To determine whether the MEMRI T1 mapping technique was sensitive to 
changes in Mn2+ efflux following SEA0400 administration, and whether 




2. To study and quantify the changes in Mn2+ efflux in healthy male mice, using T1-
mapping MEMRI, for different conditions (various NCX antagonist 
pharmacologic agent doses and a β-adrenergic agonist pharmacologic agent) 
3. To quantitatively define the peri-infarcted zone in post-MI male adult mice 
4. To study difference in Mn2+ efflux properties between healthy and MI murine 






4.2.1 Experimental Protocol  
MEMRI experiments were performed on adult male C57Bl/6 mice (6-14 weeks 
old, 23.9±2.3 g) following the guidelines of the Institutional Animal Care and Use 
Committee at the Medical College of Georgia, Augusta, GA. MEMRI efflux studies were 
conducted in n = 60 mice, as described in §3.2.1. The mice were randomized into four 
groups: 
1. SEA0400 (10 – 50 mg kg−1 SEA0400 following 190 nmoles g−1 MnCl2; n = 30); 
2. Dobutamine (15 µg g−1 dobutamine following 190 nmoles g−1 MnCl2; n = 6); 
3. Sham (sham-operation / thoracotomy only with 190 nmoles g−1 MnCl2; n = 7); 
4. MI (surgically induced MI with either 190 or 280 nmoles g−1 MnCl2; n = 17) 
Table 4.1 shows the number of mice in, and total number of T1 maps generated 
for, each of these groups (as well as the dose dependent groups from §3) and their 
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associated pharmacologic dose/procedure subgroups. Both MnCl2 doses used in this 
study (i.e. 190 and 280 nmoles g−1) have been shown not to cause cardiotoxic effects in 
rodents (99,204). The reference MnCl2 dose of 190 nmoles g
−1 was found to lie at the 
high level end of the linear Mn2+ uptake region, §2.1.2 (204). The pharmacologic agents 
SEA0400 (Taisho Pharmaceutical, Tokyo, Japan) and dobutamine (MP Biomedicals, 
Irvine, CA) were used to manipulate Mn2+ efflux via alteration of intracellular Ca2+ 
concentration. A selective NCX inhibitor, SEA0400, was given to a group of healthy 
mice in order to attenuate Ca2+ efflux in the myocardium and thereby reduce Mn2+ efflux 
(190,198,212). A β-adrenergic agonist, dobutamine, was given to a separate group of 
healthy mice to increase contractility while minimally affecting heart rate (216). This 
positive inotropic effect was expected to increase Ca2+ efflux and thereby increase Mn2+ 
efflux in the healthy murine myocardium. Both SEA0400 and dobutamine were 
administered as a bolus intraperitoneal injection one hour after the MnCl2 infusion. 
 
4.2.2 Myocardial Infarction Model 
Mice randomized into both the Sham and MI groups underwent a thoracotomy to 
expose the heart. As previously described (204), the Sham mice then had their chests 
immediately sutured closed and the MI mice had their left anterior descending coronary 
artery permanently ligated to produce an acute infarction in the left ventricular (LV) 
myocardium. These mice were then allowed to recover from the surgery for 8±1 days 
before beginning the MEMRI sessions. Previous research demonstrated that the mice 
recovered from surgery without complications during this time period, providing an 
observable differentiation between the infarcted and remote viable tissue during imaging 
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(204). Additionally, waiting for 8-days minimized any potential complications that would 
confound the data results owing to the early inflammatory processes occurring after 
surgery since inflammatory cells such as macrophages are known to uptake Mn2+ (149). 
 
4.2.3 Manganese-Enhanced Magnetic Resonance Imaging  
MEMRI data were again acquired on a 7.0-T 20-cm horizontal bore Bruker 
BioSpec MRI spectrometer (Bruker Instruments, Billerica, MA) equipped with a micro-
imaging gradient insert (950 mT/m) (204), as described in §3.2.2. Short-axis images were 
acquired midway through the LV and perpendicular to the long axis of the heart for the 
healthy and sham-operated mice. For the MI group, the short-axis slice contained the area 
with the thinnest portion of the LV wall (typically located within 1 mm of the LV center). 
  
4.2.4 Data Analysis 
 
T1 Mapping 
Mn2+ efflux properties were characterized via T1 maps generated from pre-
contrast MRI as well as MEMRI, as described in §3.2.3. T1 values were estimated by 
fitting the signal recovery of each pixel with a three-parameter Levenburg-Marquardt 
non-linear curve-fitting algorithm using the 50 echo images acquired via the Look-
Locker sequence (145). Region-of-interest (ROI) analysis was performed on the 2D T1 
maps for the SEA0400, and Dobutamine groups using the AMIDE (205) software to 
calculate the mean T1 value in the LV free wall area.  
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T1 maps were generated from MRI performed prior to MnCl2 infusion for the 
non-surgical SEA0400 and Dobutamine (n = 33), Sham (n = 21) and MI (n = 9) groups, 
and at various times post-MnCl2 infusion. These T1 maps assessed residual Mn
2+ 
retention and changes in absolute 1H2O relaxation rate, ∆R1, in the LV free wall. In vivo 
∆R1 values were again calculated as (post-MnCl2 infusion 1/T1) – (pre-MnCl2 infusion 
1/T1), whereby the relaxation rate (R1) equaled 1/T1 in units of [s
−1] (212). T1 mapping 
was not performed during the first 0.2 hours following MnCl2 infusion to allow for an 
assumed blood pool clearance (10). 
 
Myocardial Isolation and Segmentation Software 
Using the created T1 maps, a custom Matlab® (Math Works, Natick, MA) 
program was run to automatically and objectively isolate the myocardium area for the 
Control (190 nmoles g−1 MnCl2 dose, §4), Sham and MI groups (see Appendix A, Figure 
A.1 and Figure A.2). T1 map data for the myocardium were segmented automatically 
using a program developed in our lab by Dr. Nathan Yanasak, and adapted for use within 
this study. The program required a T1-weighted (T1W) image and a T1 map as input, 
using the high contrast difference between tissue and blood on the T1W image to define 
the interior wall of the LV via segmentation of blood using a histogram of image 
intensities. The program user was also required to provide a point graphically to represent 
the approximate center of the heart and another to locate the approximate center of the 
necrosed tissue within the MI site, or the center of the RV for the healthy or sham-
operated mice. The line subtended between these two points allows the angular segments 
from each myocardium to be aligned for statistical comparison (using a line between the 
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LV center and the right ventricle as a reference for 0o, the line between LV center and MI 
is approximately 135o). 
Isolation of the myocardium proceeds by determining an initial guess for the 
middle position of myocardium tissue and corresponding T1 at this position as a function 
of angle of rotation around the LV. At each angular position around the myocardium, 
final isolation used the guessed mean value of T1 to define a range of T1 values around 
that mean, within which pixels are included in the myocardium. The function that defined 
this range varies inversely with mean T1, to prevent contamination of the MI tissue with 
adjacent chest wall of similar T1 value. Isolated pixels were organized into 360 regions, 
or “sectors”, by angular position (i.e. 360 × 1° radial segments, with approximately 4 
voxels per sector), and the mean and standard deviation of T1 and R1 values were 
calculated in each sector. 
To determine the initial guess for the middle myocardial position and T1 value, 
blood was segmented using the T1W image and a mask was created. Blood in the LV 
defined the approximate inner boundary of the search volume containing the 
myocardium. Blood from the RV was used to define the approximate outer boundary of 
the search volume containing the myocardium, which included a region slightly larger 
than the RV location. Next, the approximate position of middle of the myocardial wall at 
a given angle of rotation around the LV was determined. Within the search volume, the 
pixel with the minimum T1 value in the myocardium at a particular angle was considered 
to be located at the middle of the myocardial wall. These locations over all angles formed 
a distorted ellipse. As the myocardium can be considered to be well-approximated by an 
elliptical shape, the function defining the middle position of the myocardium at a given 
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angle was smoothed spatially. Smoothing occurred in three stages: an initial boxcar 
smoothing procedure, followed by convolution of the function with a gaussian kernel. A 
final stage involving frequency-domain filtering eliminated components with a spatial 
periodicity < 60o. Using this smoothed function, the T1 value in the middle of the 
myocardium was determined as a function of angle, and this was smoothed as well using 
the same frequency-domain filtering process. 
 
Region Defining MI Curve Fitting Algorithm 
From the 360 one-degree sectors calculated for the isolated myocardium, radial 
position-dependent ∆R1 values were calculated for each sector. For the Control and Sham 
groups, the ∆R1 values were calculated from the average T1 value across the isolated 
myocardium. For the MI mice, an algorithm was applied to the radial data to delineate 
between the 1) viable [healthy, unaffected remote tissue; Region A], 2) necrosed 
[infarcted tissue; Region B] and 3) peri-infarcted [ischemic with an admixture of viable 
and necrotic tissue] zones. Regions A and B were defined as constant ∆R1 values with 
∆R1(A) > ∆R1(B). The peri-infarcted zone was defined as the region between the viable 
and necrosed zones such that ∆R1 varied linearly with the specific radial position. Using 
these definitions, an algorithm using a non-linear least-square fitting technique produced 
a curve locating the viable, necrosed, and peri-infarcted regions. The 180° location 
defined the middle of the necrosed zone.  
Using these average ∆R1 values, efflux curves were produced for the Control, 
Sham and MI (Regions A and B) groups. Then individual ∆R1 values from each radial 
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With the exception of the Dobutamine group, the ∆R1 efflux data were fitted to a 
least-square first-order exponential decay curve using GraphPad Prism statistics software 
(GraphPad, San Diego, CA). The Dobutamine group ∆R1 efflux data were fitted to a 
second-order exponential decay curve along with the 190 nmoles g−1 MnCl2 (Control 
dose, §3) and 50 mg kg−1 SEA0400 data. The second-order exponential decay curves 
were generated to account for the relatively short elimination half-life of dobutamine in 
the myocardium. The extrapolated ∆R1 at the time of infusion (t = 0; ∆R1,0 ) and half-life 
values were calculated from these exponential decay curves. The ∆R1,0 and half-life 
values were compared between groups using an extra sum-of-squares F test (0.05 level of 
significance), which compared the ratio of the difference between the least-square fit 
from the washout curves to the residual sum of squares within each decay curve. 
 
Histology 
Three post-MI mice were randomly selected for histological analysis following 
MEMRI to provide preliminary data for correlating the in vivo segmented region-defining 
MI curve locating the viable, necrosed and peri-infarcted regions to histological evidence. 
While heavily anesthetized with isoflurane, the animals were sacrificed by 
exsanguination when the hearts were excised from the chest. The hearts were then sliced 
along the short-axis for hematoxylin and eosin (H&E) staining. Histologic sections 
 
105 
corresponding to individual MEMRI images of each animal were qualitatively compared 





4.3.1 Detecting Pharmacologically Altered Mn2+ Efflux Rates in vivo 
Figure 4.1 shows an example of four cardiac short-axis T1 maps generated over 
time from mice in the Control group. Following infusion of 190 nmoles g−1 MnCl2, the 
myocardial tissue becomes darker in the T1 maps, representing a reduction in the T1 
values due to an increase in Mn2+ content. The T1 values gradually return to the pre-
infusion T1 values with increasing time, shown as a yellow color. 
Absolute Mn content was measured from the heart tissue and blood samples of 
randomly selected mice to establish the relationship between temporal changes in the LV 
Wall ∆R1 and absolute cardiac Mn content, following SEA0400 administration. Figure 
4.2 shows the elemental analysis results for the heart tissue samples obtained from the 
control, 20 mg kg−1 and 50 mg kg−1 SEA0400 experimental groups, with Figure 4.2a 
showing the relationship between the LV Wall ∆R1 and absolute heart Mn content, 
including data from §2.1.2. No statistically significant differences were found between 
the groups following linear least-square fitting to the data. A common fit with a slope of 
0.10 (p = 0.38) and y-intercept of 0.48 (p = 0.08) was found. The absence of statistically 
significant differences in the slopes of the ∆R1 / Mn content curves between the control 
and SEA0400 groups suggests that myocardial 1H2O relaxivities were not influenced by 
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administration of SEA0400. A linear fit to all of the data groups was demonstrated with 
the 95% confidence band in Figure 4.2a. This corresponding relaxivity in the 






Figure 4.1 Sample short-axis mouse heart T1 maps from a healthy myocardium, acquired 
(a) pre-MnCl2 infusion, (b) 1.3 h, (c) 4.1 h, and (d) 11.4 h post-190 nmoles g−1 MnCl2 
infusion. Left and right ventricles are labeled as LV and RV, respectively. A sample LV 





Figure 4.2 Elemental analysis data showing; (a) the effect of the absolute heart Mn 
content on the in vivo LV Wall ∆R1 for three experimental groups; control (square), 20 
mg kg−1 (triangle) and 50mg kg−1 (open circle) SEA0400. A linear fit to all of the data, 
along with the 95% confidence band, is shown. Also shown is dose dependent data (x) 
from Waghorn et al, 2008, §2.1.2. Temporal changes in Mn content for each group are 
shown in (b), along with first order exponential fits for the control and 50 mg kg−1 
SEA0400. Sample size (n) is also shown. 
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Figure 4.2b shows the temporal response of the absolute cardiac Mn content post-
infusion. First-order exponential curves were fit to both the control (n = 12, squares) and 
50 mg kg−1 SEA0400 groups (n = 9, open circles), as shown. The control group yielded a 
half-life of 4.5±3.4 hrs (r2 = 0.58, as shown in §3.3.2) while the half-life for the 50 mg 
kg−1 SEA0400 was 6.87±5.2 hrs (r2 = 0.63). The corresponding extrapolated Mn contents 
at time zero were 22.2±6.5 and 29.3±7.1 µg g−1 wet weight for the control and 50 mg kg−1 
SEA0440 groups respectively. Exponential curves for the control and 50 mg kg−1 
SEA0400 groups were significantly different (p < 0.05). At 6 hrs post-MnCl2, the 50 mg 
kg−1 SEA0400 group exhibited a Mn content of 16.0 μg g−1 that was approximately twice 
the content of the control group for the same time point. 
T1 values were acquired from blood samples taken from 16 mice (n = 3, pre-
MnCl2 (baseline); n = 6, control; n = 4, SEA0400 20 mg kg
−1; n = 3, SEA0400 50 mg 
kg−1). ∆R1,blood values were calculated by subtracting the average baseline (pre-MnCl2) R1 
value (R1,blood,baseline = 1.28±0.17 s
-1) from the individual R1 values post-MnCl2 infusion. 
The average ∆R1,blood for the control, 20 mg kg
−1 and 50 mg kg−1 SEA0400 experimental 
groups over the time range of 1.5 – 12.4 hrs post-infusion was 0.17±0.48 s-1 (∆R1,blood = 
0.13±0.20, 0.20±0.17 and 0.23±0.35 for the control, 20 mg kg−1 and 50 mg kg−1 
SEA0400 groups respectively). 
In addition to the ∆R1,blood calculations, elemental analysis was performed on the 
blood samples from 18 mice (n = 2, baseline; n = 8, control; n = 8, SEA0400 50mg kg−1). 
The average baseline Mn content was 0.09±0.01 µg ml−1 with the corresponding contents 
for the control and SEA0400 groups being 0.16±0.04 and 0.19±0.05 µg ml−1, 
respectively, both in the time range of 1.5 to 12.4 hrs post-infusion. The increase in blood 
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Mn content for both groups, although non-zero, was minute compared to the infused 
content and could not be detected as an increase in ∆R1,blood. Using a linear least-square 
best fit, no temporal trend for the blood Mn content was observed for either the control 
(slope = −0.01±0.01 µg ml−1 hour−1, r2= 0.55), or 50 mg kg−1 SEA0400 (slope = 
−0.01±0.01 µg ml−1 hour−1, r2= 0.20) groups over the time range of sample acquisition (t 
= 1.5 – 12.4 hrs). 
For the in vivo data, values of ∆R1 for the healthy mice were calculated by 
subtracting the average baseline ROI R1 (R1,baseline,LVWall = 0.78±0.04 s
-1 from 33 mice) 
from the post-MnCl2 infusion ROI R1 value. Infusion of 190 nmoles g
−1 BW MnCl2 
solution into the control group produced a LV Wall ∆R1 washout curve as shown in 
Figure 4.3 (squares, also shown in §3). Fitting a least-square first-order exponential to the 
individual, unbinned data points (r2 = 0.83) gave ∆R1 (at zero time post-infusion), ∆R1,0 = 
3.4±0.3 s-1. The T1 shortening effect was rapidly attenuated, with a ∆R1 half-life of 
3.4±0.6 hrs (n = 14; total number of T1-maps = 36). There was no significant difference 
between the in vivo LV Wall ∆R1 half-life and the absolute cardiac Mn content half-life 




Figure 4.3 The effect of the NCX channel inhibitor SEA0400 on the temporal changes in 
∆R1, measured in the LV Wall. First order exponential fits using individual data points 





The effects of the NCX inhibitor SEA0400 on the temporal changes in LV Wall 
∆R1 are also shown in Figure 4.3. The washout curves displayed in Figure 4.3 were 
obtained following a single intraperitoneal injection of either 20 mg kg−1 or 50 mg kg−1 
SEA0400 one hour post-MnCl2 infusion. Least-square first-order exponential curves were 
fit to the temporal LV Wall ∆R1 data beginning at one hour post-MnCl2 infusion (t = 1 
hour). For the 50 mg kg−1 SEA0400 group (open circles) (n = 7, total number of T1-maps 
= 29), the exponential curve was extended, with a ∆R1 reduction half-life of 5.6±1.1 hrs 
and a ∆R1,0 = 4.3±0.4 s
-1 (r2 = 0.87). The 20 mg kg−1 SEA0400 group (triangles) 
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displayed a half-life of 3.6±0.5 hrs and a ∆R1,0 = 4.8±0.2 s
-1 (n = 8, total number of T1-
maps = 33, r2 = 0.91). For comparison, the control group was also fit to a least-square 
first-order exponential curve excluding data for t < 1 hour. This fit yielded a half-life of 
3.2±0.5 hrs and a ∆R1,0 = 3.5±0.8 s
-1 (r2 = 0.77). All three washout curves in Figure 4.3 
include the 95% CI envelopes, where regions with no overlap between groups 
demonstrated significance at that particular time. 
In the time range of 4.9 – 5.9 hrs post-MnCl2 infusion, the average ∆R1 values for 
the SEA0400 groups were 2.46±0.29 s-1 (n = 4) and 1.72±0.24 s-1 (n = 5) for 50 mg kg−1 
and 20 mg kg−1 doses respectively, as compared to the control group of 1.27±0.28 s-1 (n = 
4). This range was selected to ensure that sufficient time had elapsed after SEA0400 
administration, to allow for the observation of any potential drug effects. An ANOVA 
test comparing the LV Wall ∆R1 values for the three groups within this time interval 
showed a significant difference in LV Wall ∆R1 between the groups (p < 0.05). Further 
Tukey post hoc comparisons revealed significant differences between all group 
combinations (p < 0.05). 
Figure 4.4 illustrates the dependence of the exponential temporal response of the 
LV Wall ∆R1 washout curves on the SEA0400 dose. Figure 4.4a shows the dependence 
of half-life on the dose; Figure 4.4b shows the dependence of ∆R1,0. For both curves, 
SEA0400 dose was plotted against the relevant exponential fit parameters of the washout 
data (t ≥ 1 hour) with the 95% CI shown. An extra sum-of-squares F test showed that the 
washout half-life was significantly different between these three groups (p < 0.01). The 
50 mg kg−1 group had a half-life significantly different from the control group (p < 0.01), 
although the half-life for the 20 mg kg−1 group was not statistically different from the 
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control group (p = 0.54). No statistical difference was found between ∆R1,0 measured in 
the two SEA0400 groups (p = 0.12), although a statistical difference existed between 
∆R1,0 when comparing all three groups (p < 0.01). These findings suggest that SEA0400 
caused an initial increase in ∆R1 that was independent of dose, while a higher dose of 




Figure 4.4 The dependence of the temporal LV Wall ∆R1 washout half-life (a) and 
extrapolated ∆R1 at the time of MnCl2 infusion (∆R1,0) (b) on the dose of NCX inhibitor 
SEA0400. Both values result from a first order exponential fit to the temporal ∆R1 
washout, starting at one hour post-Mn2+ infusion. Shown are the 95% CI values and 





4.3.2 The Effect of SEA0400 and Dobutamine on Mn2+ Efflux 
Having demonstrated the ability of MEMRI T1-mapping to detect 
pharmacologically altered Mn2+ efflux rates (§4.3.1), additional studies were performed 
to further assess the Mn2+ efflux mechanisms. Combining data from Part I (§3) and Part 
II (§4), Figure 3.2, Table 4.1, Figure 4.1, and Figure 4.3 all provide evidence that T1-
mapping MEMRI detected and quantified Mn2+ efflux in healthy male mice under 
different conditions. Table 4.1 summarizes the heart rate, half-life and ∆R1,0 values for 
the different group conditions and their associated pharmacologic/procedural subgroups. 
A one-way ANOVA test showed a significant difference in heart rate among the groups 
(p = 0.028); the Tukey post-hoc test found that heart rate was only significantly different 
between the 35 mg kg−1 SEA0400 and Dobutamine groups (p = 0.02). The 34 and 50 mg 
kg−1 SEA0400 dose group half-life values were significantly different from the MnCl2 
Control (190 nmoles g−1) group, as were the Dobutamine and Region B (Necrosed) 
groups (p < 0.05). Half-life values normalized to the Control group are shown in the final 
column of Table 4.1. Normalized values < 1 represent an increase in the efflux rate 
relative to the control group and values > 1 an increase in Mn2+ efflux rate. 
For the healthy mice not undergoing surgery (SEA0400, and Dobutamine groups), 
∆R1 values were calculated by subtracting the average baseline R1 value (0.78±0.04 s
−1) 
from the post-MnCl2 infusion ROI R1 values. Figure 4.5a shows the LV Wall ∆R1 
washout curves for the four SEA0400 doses; Figure 4.5b shows the corresponding half-
life and ∆R1,0 values. A small increase in ∆R1 was observed after SEA0400 
administration relative to the control group. The first-order exponential curves provided a 
reasonable fit to the SEA0400 efflux data (r2 = 0.91±0.05) with increasing doses of 
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SEA0400 reducing the efflux rate following longer retention of Mn2+. In Figure 4.5b, a 
significant increase in the efflux half-life was observed for the 35 and 50 mg kg−1 
SEA0400 groups (p = 0.04 and 0.02, respectively) compared to the MnCl2 Control group. 
While a significant increase in ∆R1,0 was observed for all SEA0400 groups compared to 
the MnCl2 Control group (p < 0.05), the ∆R1,0 values among the SEA0400 groups were 
not significantly different (p = 0.30). 
Figure 4.6a shows the second-order exponential decay curves for the Dobutamine 
group in comparison to the MnCl2 Control and 50 mg kg
−1 SEA0400 groups; Figure 4.6b 
shows the corresponding exponential half-life values. The Dobutamine efflux curve was 
found to be significantly different from the Control and SEA0400 curves (p < 0.001). 
Figure 4.6b shows how the Dobutamine group’s Initial (fast efflux rate) and Delayed 
(slow efflux rate) half-life values compared to the other two groups. The Dobutamine 
group had an initial efflux rate significantly faster than the Control and 50 mg kg−1 
SEA0400 groups with a slower associated delayed rate. This finding suggests an apparent 
increase in Mn2+ efflux following increases in the inotropic rate, which decreased with a 
reduced drug effect. 
Figures 4.7 and 4.8 both provide evidence that T1-mapping MEMRI quantitatively 
defined the peri-infarcted zone. Figure 4.7 shows examples of the segmentation output 
for post-MnCl2 infusion T1 maps in post-MI mice; the radial orientation is shown in 
Figure 4.7b. Figures 4.7c, 4.7d, and 4.7e illustrate the temporal changes in T1 values due 




Figure 4.5 Effect of altering the SEA0400 dose (sodium calcium exchanger inhibitor) on 
the temporal changes in LV Wall ∆R1. (a) Binned data ± 1standard deviation and first-
order exponential fits using individual data points with 95% confidence intervals. (b) 
Corresponding dependence of the temporal LV Wall ∆R1 washout half-life (solid 




Figure 4.6 The effect of dobutamine on the temporal changes in LV Wall ∆R1 compared 
to the Control (190 nmoles g−1) and 50 mg kg−1 SEA0400 groups. (a) Binned data ± 
1standard deviation and first-order exponential fits using individual data points with 95% 
confidence intervals. (b) A comparison between the second-order fast (open circle) and 
slow (solid square) half-lives for the 190 nmoles g−1, 50 mg kg−1 SEA0400 and 




Figure 4.7 (a) Sample cardiac short-axis T1 map for a myocardial infarction mouse after infusion of the manganese contrast agent 
(MnCl2). The segmented myocardium is shown with the remaining tissue illustrated with increased opacity. (b) Demonstration of the 
sectoring orientation on the isolated myocardium. Temporal manganese ion efflux is demonstrated at (c) 1.6 h (d) 3.6 h and (e) 6.3 h 




Figure 4.8 Sample radial fitting for an infarcted myocardium at 1.6 h after infusion of the manganese contrast agent. The fitting 
algorithm optimizes average ∆R1 values for the viable zone (A), and the necrosed zone (B), with the peri-infarcted zone linearly 
connecting these two regions. Also shown is a comparison of the in vivo ∆R1 radial profile to histological staining, along with the 
correlating histological slice locations. 
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Figure 4.8 illustrates how the sectored ∆R1 values fitted to a region-defining MI 
curve to delineate Region A (viable zone), Region B (necrosed zone) and the peri-
infarcted zone boundaries (radial positions a, b, c and d). Three histological H&E stained 
images are also shown that correspond to the defined viable (Figure 4.8a), peri-infarcted 
(Figure 4.8b), and necrosed (Figure 4.8c) zones on the curve. 
Figure 4.9 and Figure 4.10 both showed that Mn2+ efflux properties differed 
between healthy and MI murine hearts, as well as between the necrosed and peri-infarct 
regions. For the Sham group, Figure 4.9a illustrates the dependence of ∆R1 on position in 
the segmented myocardium (allowing for calculation of the average ∆R1 value) as well as 
on time. A similar trend was observed for the Control group (data not shown). As MnCl2 
post-infusion time increased, the average ∆R1 values were reduced due to Mn
2+ efflux 
from the myocardium. Figure 4.9b shows a similar temporal trend for the MI group data 
with the segmented region-defining MI curves overlaid on the regional ∆R1 data. As 
before, the ∆R1 values decreased as time post-infusion increased, with the rate dependent 




Figure 4.9 Sample temporal radial fitting of the segmented myocardium for the (a) Sham 




Figure 4.10 (a) First-order exponential efflux curves for the Control (no surgery; 190 
nmoles g−1 MnCl2), Sham (thoracotomy only) and MI (thoracotomy and coronary artery 
occlusion) groups. Sample sizes are shown with corresponding 95% confidence intervals. 
(b) Radial Mn2+ efflux half-life data points calculated from first-order exponential curves 
on each sector of the myocardium. A radial fit is overlaid of the calculated average half-
life values for the viable and necrosed zones. A line depicting the peri-infarcted zone 
linearly connects these two regions. A = Region A; B = Region B. 
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Efflux curves for the Control and Sham groups, as well as MI Regions A and B 
(with the 190 nmoles g−1 MnCl2 infusion), are shown in Figure 4.10a. For the Control 
group, no significant difference was found when comparing the efflux half-life obtained 
using the isolation/segmentation software versus the ROI technique (p = 0.19). No 
significant difference was found between the first-order exponential fits of the Control, 
Sham and MI Region A groups (p = 0.39). However, a significant difference was found 
in both the half-life and ∆R1,0 for MI Region B (p < 0.05). Additionally, the MI Region B 
group with the 280 nmoles g−1 MnCl2 infusion was initially significantly different than 
MI Region B group with 190 nmoles g−1 MnCl2 (t = 0.3±0.1 h), but no significant 
difference was observed by t = 1.6±0.1 h. Finally, efflux curves were produced for the MI 
group by calculating ∆R1 for each radial sector. These values were then fitted to a first-
order exponential curve, with the position-dependent half-life results shown in Figure 
4.10b. Furthermore, Figure 4.10b shows that the regional rate of Mn2+ efflux exhibited a 
position-dependent pattern similar to the ∆R1 region-defining MI curve shown in Figure 





Results from this study demonstrated the sensitivity of the T1-mapping MEMRI 
technique for detecting and measuring Mn2+ efflux in the myocardium of both healthy 
and post-MI mice under various conditions. Changes in ∆R1 over time may be used to 
quantify changes in Mn2+ content in vivo under control conditions (§3) and/or when 
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modulating NCX kinetics with the NCX inhibitor SEA0400. This information could be 
useful for indirectly assessing and understanding Ca2+ efflux properties as Mn2+ is 
considered its biochemical analogue. Most importantly, however, this study demonstrated 
a novel technique for identifying and quantifying specific regional differences in tissue 
characteristics that occur after a MI in the murine model. The region-defining MI curve 
not only eliminates user bias in determining the location of the infarcted, peri-infarcted, 
and viable myocardium, but also indirectly allows for the assessment of Ca2+ handling 
alterations in the salvageable peri-infarcted zone. Using the segmentation and curve 
fitting methodology derived from T1-mapping MEMRI, the salvageable peri-infarcted 
tissue adjacent to the necrosed area can be specifically located, the extent of which is 
known to be a predictor of post-MI mortality (56). Thus, this innovative imaging 
technique could ultimately enhance clinical outcomes for post-MI patients. 
 
4.4.1 Pharmacologically Altered Mn2+ Efflux 
This study found that varying doses of SEA0400 and a single dose of dobutamine 
affected Mn2+ efflux in the healthy murine heart. Inhibition of the NCX with SEA0400 
extended the ∆R1 washout curve due to an assumed inhibition of the Mn
2+ efflux. 
Treating mice with 50 mg kg−1 SEA0400 extended the ∆R1 half-life from 3.4 to 5.6 hrs. 
Several hours after inhibition of the NCX with 50 mg kg−1 SEA0400, the absolute cardiac 
Mn content was greater in the treatment group mice than in the control mice (Figure 
4.2b). These results suggest that a greater retention of Mn2+ occurred following MnCl2 
infusion. This effect was also observed with in vivo T1-mapping (Figure 4.3 and Figure 
4.5). Therefore, the inhibition of Mn2+ efflux using a known NCX inhibitor, in 
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conjunction with the previous establishment of Mn2+ as a Ca2+ analogue during influx 
(99), indicated that changes in Mn2+ efflux most likely reflected changes in Ca2+ efflux. 
The 34 and 50 mg kg−1 SEA0400 doses increased ∆R1,0 following NCX inhibition, which 
reduced net Mn2+ efflux without affecting Mn2+ influx via the L-type Ca2+ channels. 
Altered Mn2+ efflux rates were not seen with the lower SEA0400 doses, probably because 
SEA0400 has a biological half-life shorter than the current imaging temporal resolution. 
The positive inotropic state following administration of dobutamine caused a 
biphasic Mn2+ efflux curve in the healthy myocardium. This finding was exhibited by an 
initial rapid increase in the Mn2+ efflux rate followed by a gradual decrease as a slower 
Mn2+efflux rate reduced the Mn2+ content. These results suggest that alterations in Ca2+ 
handling caused by changes in the inotropic state of the heart are also observed for Mn2+, 
and that the T1 mapping MEMRI efflux technique is sensitive enough to detect these 
effects. 
The 50 mg kg−1 SEA0400 efflux curve in Figure 4.3 and Figure 4.5 suggested that 
a gradual de-inhibition of the NCX occurred over time. At approximately 6 hrs post-
MnCl2 infusion, the temporal rate of change of ∆R1 appeared to increase, suggesting a 
reduction in the inhibitory effects of the NCX inhibitor. This study demonstrated that a 
first-order exponential fit provided a relatively good approximation for detecting Mn2+ 
efflux rates and modulations. A thorough modeling of the washout data is essential to 
fully understand the inhibitory effects of SEA0400 and Mn2+ efflux rates, and such 
modeling is studied in §5. 
The SEA0400 doses used in the current study were selected based on previous 
studies conducted in vivo in cerebral models, due to a lack of in vivo cardiac studies using 
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SEA0400. Previously, SEA0400 was found to be an extremely potent and selective 
inhibitor of the NCX in neurons, astrocytes, and microglia, with IC50 values of 5 to 33 
nM when 1 and 3 mg kg−1 doses were administered intravenously, respectively (195). 
The precise mechanism of SEA0400 in NCX inhibition remains to be determined. 
Nevertheless, significant interactions are seen between SEA0400 and the intrinsic ionic 
regulatory mechanisms of NCX1.1 (218). For example, in this study Lee et al. suggested 
that SEA0400 acted to inhibit the reverse mode of the NCX more effectively than the 
forward mode (~90% vs. ~30% following application of 300 nm SEA0400). These 
investigators concluded that the potency of SEA0400 depended on the experimental 
conditions, with the greatest potency observed for the conditions approaching 
unidirectional transport in the Ca2+ entry mode. 
An increase in ∆R1,0 relative to the control group was observed following 
SEA0400 administration, independent of the dose (Figure 4.5). There are two potential 
explanations for this phenomenon. Firstly, when net Mn2+ efflux is inhibited by SEA0400 
and the influx of Mn2+ via Ca2+ channels is unchanged, a resultant increase in Mn2+ 
accumulation could occur. The net Mn2+ efflux is defined as the unidirectional efflux – 
unidirectional influx, where the unidirectional influx approaches zero for a majority of 
the experiment conditions as extracellular Mn2+ is shown to be near zero. Ultimately, this 
effect would be expected to increase the Mn2+ content in the LV wall of a treated mouse 
heart compared to an untreated one. The results of the current study showed a small 
increase in blood Mn content above the baseline level between 1.5 and 12.4 hrs post-
MnCl2 infusion. Therefore, one can assume that the blood Mn
 content was also above the 
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pre-MnCl2 infusion baseline level at one hour post-MnCl2 infusion when SEA0400 was 
administered. 
Also, increased ∆R1,0 may be due to an increase in the longitudinal relaxivity 
following binding of Mn2+ with larger molecules within the cell. This effect could 
potentially be caused by the introduction of SEA0400 to the system. These potential 
mechanisms warrant further study. 
One concern with using SEA0400 was the potential positive inotropic effect in the 
mouse myocardium, which was previously reported in rats but not rabbits (219). As 
demonstrated by Hu et al. (99), positive inotropic and chronotropic effects altered Mn2+ 
influx. While the current study found no chronotropic changes (i.e., no change in heart 
rate) associated with administration of SEA0400, this pharmacologic agent may still 
cause an increase in inotropy (i.e., contractility measured via left ventricular pressure) of 
the mouse heart. The apparent independence of ∆R1,0 on the SEA0400 dose found in this 
study suggests that SEA0400 doses between 20 and 50 mg kg−1 may not considerably 
alter the myocardial inotropic state. However, further research is required to fully 
understand these changes in Mn2+ uptake following treatment with SEA0400. 
 
Overall, this aspect of the study using a healthy murine myocardium found that 
the T1-mapping MEMRI technique detected and quantified: 
1) increased Mn2+ uptake associated with an increased Mn2+ efflux rate due to 
increased Mn2+ infusion doses 
2) decreased Mn2+ efflux rates following NCX inhibition with SEA0400 
3) increased Mn2+ efflux rates due to the positive inotropic effect of dobutamine 
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This information concerning Mn2+ efflux dynamics could potentially enhance 
understanding of Ca2+ dynamics, particularly when investigating pathophysiological 
phenomena and/or developing new therapeutic pharmaceutical agents. 
 
4.4.2 MI Altered Mn2+ Efflux 
As previously mentioned, this study introduced a novel quantitative method for 
objectively identifying the locations of necrosed, peri-infarcted and viable tissue in the 
post-MI myocardium. This innovative methodology isolates and segments the MEMRI 
T1 maps and then fits the calculated ∆R1 values into a region-defining MI curve that 
shows the location (in radial degrees) of the infarcted (necrosed), peri-infarcted 
(ischemic) and viable remote tissue.  
This information would be clinically useful not only for treating the precise areas 
of salvageable tissue, but also for monitoring progression of the remodeling process 
during healing. Thus, patient outcomes would be enhanced as improved treatment 
modalities target specific tissue areas and ultimately prevent the adverse remodeling that 
promotes heart failure development in post-MI patients.  
Results from this study further showed Mn2+ handling within the viable region of 
the MI group and the Sham group were unaltered after surgery. However, decreases in 
both ∆R1,0 and efflux half-life were observed in both the necrosed and peri-infarcted 
zones of the MI group.  
Within the MnCl2 dose-dependent groups, Mn
2+ efflux occurred with a half-life 
dependent on the initial Mn2+ content such that an increasing Mn2+ uptake caused an 
increase in the Mn2+ efflux rate. Therefore, the regional Mn2+ uptake in viable cells 
 
129 
within the peri-infarcted zones could potentially be estimated by examining the Mn2+ 
efflux properties. Mn2+ efflux from the necrosed region (MI Region B) occurred with a 
significantly faster half-life than in the Control group with the same MnCl2 infusion dose. 
Using Equation 3.1, the inferred equivalent infusion dose for the infarcted (necrosed) and 
peri-infarcted regions was found to be larger than the 280 nmoles g−1 MnCl2 infusion 
dose. This finding suggests that both the necrosed and peri-infarcted regions experience 
increased Mn2+ uptake, and therefore potentially Ca2+ uptake. 
A limitation of this assumption is that the rapid ∆R1 efflux rate from the necrosed 
and/or peri-infarcted tissue could be caused in part by the dissociation of Mn2+ from 
larger molecules and proteins, reducing T1 values independent of intracellular Mn
2+ 
content handling. However, the initial efflux rate in the necrosed region was shown to be 
dose-dependent, which is an effect that would likely be caused by altered intracellular 
Mn2+ concentration rather than molecular dissociation. Although Mn2+ has potential 
cardiotoxic effects, the subtoxic MnCl2 doses used in this study provided sufficient signal 
enhancement and contrast. Additionally, Mn-based contrast agent MnDPDP has been 
successfully used in a number of cardiac human studies (11). 
Although Mn2+ handling data may mimic alterations in Ca2+ handling, the precise 
relationship between these two ions is still unknown. Ca2+ and Mn2+ extrusion rates are 
not equal due to their different binding constants and maximal rates for efflux 
transporters (NCX and PMCA). Furthermore, Mn2+ can be extruded via the reverse mode 
of Ca2+ channels due to low extracellular Mn2+ concentration. These conditions make the 
precise relationship between Mn2+ and Ca2+ transport complicated, and studies to address 




In summary, this study showed that T1-mapping MEMRI quantified Mn
2+ 
dynamics in both healthy and post-MI mice under various conditions. A novel technique 
was also introduced for identifying and quantifying specific regional differences of tissue 
characteristics in the post-MI mouse heart that could potentially be translated into the 
clinical environment. This information from healthy and post-MI mice may be used to 
evaluate Mn2+ efflux dynamics, which would broaden the understanding of Ca2+ 




Table 4.1 Group Characteristics 
Types 
Size* Heart Rate Exponential Fit† Normalized
nmice nmaps (bpm) t1/2 (h) ∆R1,0 (s
−1) t1/2 ‡ 
MnCl2 Dose (nmoles g
−1)   
283±6 15 41 444±21 2.0±0.6§ 5.0±0.6§ 0.6 
190±2 (Control) 14 36 456±30 3.4±0.6 3.4±0.3 1.0 
119±3 7 21 438±54 6.8±3.3§ 2.0±0.3§ 2.0 
65±0.2 4 14 438±32 9.5±2.2§ 0.96±0.1§ 2.8 
SEA0400 Dose (mg kg−1) 
10±0.2 11 35 455±27 3.1±0.7 4.3±0.6§ 0.9 
20±0.2 8 33 449±30 3.6±0.5 4.8±0.2§ 1.0 
34±0.8 4 17 427±24# 4.7±0.7§ 4.2±0.3§ 1.4 
50±0.2 7 29 439±32 5.6±1.1§ 4.3±0.4§ 1.6 
Dobutamine Dose (µg g−1)ǁ 
15.0±0.3 6 17 478±37#    
Initial    0.29±0.14§ − 0.1 
Delayed    17.9±2.6§ − 5.3 
Sham 
190±1 nmoles g−1 7 25 447±31 2.5±2.0 2.0±0.4  
MI  
190±1 nmoles g−1 9 30 444±35    
Region A (Viable)  3.8±2.7 2.2±0.3  
Region B (Necrosed)  0.49±0.2§ 0.54±0.3§  
282±2 nmoles g−1 8 8 430±33 − −  
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Table 4.1 (continued). 
* nmice is the number of mice in each group; nmaps is the number of T1 maps generated for 
each group. 
† Exponential half-life and ∆R1,0 values (mean ± standard deviation) for each group. 
‡ Half-life value of MnCl2, SEA0400 and Dobutamine groups normalized to MnCl2 
Control group. 
§ Significantly different from MnCl2 Control group (p < 0.05). 
ǁ Second-order exponential data. 











A majority of Ca2+ ions entering cardiac cells via L-type calcium channels induce 
calcium release from the sarcoplasmic reticulum (SR) (3). The resultant increase in 
intracellular free calcium, [Ca2+]i, boosts the amount of Ca
2+ binding to the thin-filament 
protein troponin C, ultimately resulting in contraction. During relaxation, Ca2+ is 
removed from the cytosol via one of four transporters: two extracellular transporters (the 
sodium-calcium exchanger, NCX, and plasma membrane Ca2+-ATPase, PMCA), and two 
intracellular transporters (SR Ca2+-ATPase and mitochondrial Ca2+ uniporter). Previous 
attempts to estimate the relative contributions to Ca2+ efflux have shown that the NCX is 
the dominant efflux mechanism, with non-NCX mechanisms contributing between 9 and 
32% (23,24) of the efflux in rats and 19% in mice (25). 
In addition to the important role of Ca2+ in the function of viable myocytes, 
alterations in Ca2+ handling, primarily via increases in [Ca2+]i (2), provide a major 
contribution to irreversible ischemic damage (46-48). Cell death can result from one of 
several mechanisms following elevations in [Ca2+]i. Protocols that selectively inhibit the 
NCX are useful for investigating the roles of the NCX and PMCA, and have been shown 
to have potential therapeutic effects during myocardial ischemic-reperfusion injuries 
(190). When the NCX works as a pathway for Ca2+ entry, as it does during 
ischemia/reperfusion injury, the NCX inhibitor is expected to guard against Ca2+ 
 
134 
overloading. SEA0400, a selective and potent NCX inhibitor, has been shown to provide 
protection from cardiac ischemia/reperfusion injury (190,198,199) and from myocardial 
stunning (200). 
Despite the established importance of Ca2+ for myocardial viability, no in vivo 
imaging technique exists to assess the Ca2+ content or changes in Ca2+ handling post-MI 
in the heart. As shown in §3 and §4, MEMRI studies have demonstrated the ability to 
detect Mn2+ efflux in vivo (212), with Mn2+ efflux occurring, at least in part, via the 
NCX. It has also been shown that T1-weighted MEMRI provides clear delineation of the 
myocardial infarction site in both murine (137,204) and canine (10) MI models, with 
similar application in humans (11). 
Application of pharmacokinetic models to biological data can provide an insight 
into physiologic processes, allowing for the determination of pharmaceutical efficacy and 
handling properties. One commonly employed approach to characterize the 
pharmacokinetic properties of external agents (such as pharmaceuticals and contrast 
agents) is to represent the body as a system of homogeneous compartments (220). 
Transfer rates between compartments, as well as elimination rates of the agent from the 
system, are assumed to follow first-order linear kinetics. Agents that are introduced into 
the body require a finite amount of time to distribute throughout the system of available 
compartments. Therefore, following intravenous administration of a given contrast agent 
or pharmaceutical, such as I.V. MnCl2 infusions, at least two compartments are required 
to model the disposition of the agent, transported from the blood compartment to other 





This final part of the dissertation aims to model the cardiac transport properties of 
Mn2+, using in vivo cardiac MEMRI efflux data collected in §3 and §4 in combination 
with a number of pharmacokinetic models. Such a model would allow future predictions 
of functional cardiac behavior in the laboratory, in preparation for future translational 
studies. Complimentary to data describing ordinary efflux (§3), additional data from in 
vivo MEMRI efflux studies was acquired using mice following inhibition of the NCX 
with SEA0400 (§4), with the pharmacokinetic properties of SEA0400 as well as the 
efflux properties of Mn2+ serving as the processes under investigation. Knowledge of the 
properties of SEA0400, such as the rates of drug absorption from the peritoneum and 
clearance (likely by the liver) are important to fully understand the Mn2+ and Ca2+ 
transport alterations. Finally, alterations in Ca2+ transport mechanisms following 
myocardial infarction (MI) were addressed by performing in vivo cardiac MEMRI efflux 
studies in mice following MI (§4). This data was then compared to the healthy transport 
data for assessment of Mn2+ handling alterations.  
Ultimately, this study attempts to characterize Mn2+ transport mechanisms in the 
mouse heart using pharmacokinetic models, and by inference, to derive a descriptive 
framework for understanding cardiac Ca2+ flux data. This could provide useful 
information regarding pharmaceutical properties as well as allowing for better estimates 






5.2 Methods and Materials 
 
In vivo MEMRI T1-mapping efflux studies were previously conducted (§3 and §4) 
in adult male C57Bl/6 mice (6-14 weeks old, 23.9±2.3 g) (212). All experiments 
followed the guidelines of the Institutional Animal Care and Use Committee at the 
Medical College of Georgia, Augusta, GA, USA, as previously described (204).  
MnCl2 infusions (prepared from a 60 mM stock solution) were administered 
intravenously via the tail vein, at a constant rate (k0) of 0.6 ml h
−1 (= 3.6×104 nmoles h−1) 
with the aid of a syringe pump (KD Scientific Inc., Holliston, MA, USA). The total 
infusion time, T (h), was therefore dependent on the infusion dose and mouse body 









   T        0
T0    0
0 t
tk
tk  Equation 5.1
The mice, as previously described, were randomized into three groups for efflux studies: 
1) MnCl2 dose dependent (65±0.2, 119±2, 190±3 (Control) and 283±6 nmoles g
−1 
body weight MnCl2, n = 40 mice) 
2) SEA0400 dose dependent (190±1 nmoles g−1 BW MnCl2 infusion, followed 1 hour 
later with an i.p. injection of 10±0.2, 20±0.2, 34±0.8 and 50±0.2 mg kg−1 
SEA0400, n = 30) 
3) Myocardial infarction (MI, 190±0.1 nmoles g−1 BW MnCl2, n = 9) 
Table 5.1 shows the total study sizes (number of mice and total number of T1-
maps post-MnCl2 infusion), MnCl2 infusion doses (nmoles g
−1 BW), and pharmaceutical 




Table 5.1 Summarized raw input data 
Study Group 
Infusion 










Control (nmoles g−1 MnCl2) 
283±6 0.18 14 41 3 
190±2 0.12 14 36 9 
119±3 0.08 7 21 1 
65±0.2 0.05 4 14 1 
SEA0400 (mg kg−1) (1 h post-190 nmoles g−1 BW MnCl2) 
10±0.2 0.13 11 35 1 
20±0.2 0.13 8 33 1 
34±0.8 0.14 4 17 1 
50±0.2 0.13 7 29 9 
Myocardial Infarction (nmoles g−1 MnCl2) 




As previously presented, washout curves were obtained for each group, showing 
changes in left ventricular free wall (LV Wall) relaxation rate, ∆R1 = 1/T1(post-) – 
1/T1(pre-MnCl2 infusion). From the duration of the T1 map acquisition (~43 min), 
individual data points were defined to have been acquired at the center of k-space, 
approximately 21.5 min after initiation of the imaging sequence. Elemental analysis data, 
using inductively coupled plasma-mass spectrometry (ICP-MS) analysis (CANTEST 
Ltd., North Vancouver, BC, Canada), were acquired from select heart (n = 29) and blood 
(n = 26) samples to obtain the absolute sample Mn content. A correlational analysis was 
performed between the ex vivo data to in vivo ∆R1 data, to obtain a relationship between 
the increase in Mn content and ∆R1. 
 
Pharmacokinetic Models 
The MnCl2 pharmacokinetic properties, with and without use of SEA0400, were 
modeled using three models: Model 1 (Figure 5.1a) was a two-compartment model, 
representing the blood and heart; Model 2 (Figure 5.1b) was a three-compartment model, 
consisting of blood, cytosolic free Mn2+ and cytosolic compartmentalized Mn2+; Model 3 
(Figure 5.1c) contained four compartments for the blood, cytosolic free Mn2+, 
sarcoplasmic reticulum and mitochondria compartments. Appendix A, Figures A.3 and 
A.4 represent the modeling process in the form of a flow chart. 
For each of the models, MnCl2 was infused into the blood compartment at a rate 
of k0(t), as given in Equation 5.1, with the infusion duration, T, dependent on the mouse 
BW. First order rate parameters, kab [h
-1] (Figure 5.1), were used to describe the rate of 




efflux from the blood to organs other than the heart (e.g. liver, kidney and other major 
organs). 
For the SEA0400 group, the NCX inhibitor was administered one hour post-
MnCl2 infusion with the expected effect of reducing the cardiac efflux transfer rates, 
dependent on the drug’s absorption and elimination rates. In order to model the drug 
pharmacokinetics of SEA0400, and therefore the Mn2+ transport mechanisms, an 
equation for the drug plasma concentration (Cp) was used (Equation 5.2), commonly 
applied to pharmaceutical modeling (221): 
 














In Equation 5.2, F is the fraction of drug absorbed, Vp is the apparent volume of 
distribution of the drug and D is the drug dose administered. The rate parameters, kel and 
kabs represent the drug elimination and absorption rates respectively. 
The form for the Mn2+ transfer rate parameter k21 was given by Equation 5.3, 
under the assumption that k21 decreases linearly with increasing SEA0400 plasma 
concentration, Cp, as in Equation 5.2: 
 













ktk  Equation 5.3
Parameter k21,intial is defined as the pre-pharmaceutical administration transfer 
parameter, k21(t < 1 h). Due the relatively fast blood pool clearance, on order to 12 
minutes (212), and the fact that SEA0400 was administered one hours post-MnCl2 
infusion, k12 is not expected to change appreciably following SEA0400 administration. 
All the transfer rate and pharmaceutical parameters were therefore time-independent with 




Figure 5.1 Schematic representations of pharmacokinetic Models 1 (a), 2 (b) and 3 (c). 
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The pharmaceutical absorption and elimination half-live (t1/2abs and t1/2el 












2/1   Equation 5.5
For all of the models, a system of ordinary differential equations (ODEs) was 
obtained, dependent on the number of compartments and transfer rate parameters. The 
individual models and ODEs are described in more detail in the following subsections, 
and are summarized in Table 5.2. 
Solutions to the ODEs were acquired using simultaneous 4th Order Runge-Kutta 
numerical methods in Matlab (Nantick, MA). Temporal in vivo cardiac Mn2+ content data 
and ex vivo blood Mn2+ content data were fit simultaneously to acquire least square fits 
for the first order rate parameters, kab. Least square fits of the pharmaceutical parameters, 
kabs and kel were also obtained using the SEA0400 groups, assuming that kab was 
unchanged from the control 190 nmoles g−1 group. Parameter k21,intial (Equation 5.3) was 
defined as the best fit k21 parameter using the control 190 nmoles g
−1 BW group. The only 
constraint made by the least square fitting technique was that the transfer rate parameters 




Table 5.2 Summary of the pharmacokinetic models 
Model 
Compartment Model Fit Parameters 










MnCl2 k10, k12, k21 
5 
SEA0400 kabs, kel 




MnCl2 k10, k12, k21, k23, k32 
7 
SEA0400 kabs, kel 






k10, k12, k21a,21b (NCX, 
PMCA), k23,24 k32, k42, a, 






Least square curve fitting techniques are inherently sensitive to the initial 
estimates of kab. For a given initial estimate of kab the fit may converge on solutions at 
local minima, which may not be the global minimum. In order to minimize potential 
errors caused by this effect, all the models employed a global search over a wide range in 
parameter space to find the initial estimates of kab corresponding to lowest fit residuals. 
To use the most realistic initial estimates for the fitting function, simultaneous solutions 
were obtained for the control 190 nmoles g−1 heart and 50 mg kg−1 SEA0400 heart efflux 
data, as well as the corresponding blood efflux data. All models assume that the two 
efflux groups share the same transfer rate parameters, with only k21(t), characterized by 
kabs and kel, being affected by administration of SEA0400. 
 
Model 1 – Two-Compartment Model 
Model 1 contains components representing the blood and myocardium (Figure 
5.1a) with the absolute Mn content for each given by X1(t) and X2(t) [nmoles] 
respectively.  
A system of ordinary differential equations (ODEs) was setup with dependent 

















For the SEA0400 groups, a similar set of simultaneous ODEs was used, with k21 
modeled as a function of time (Equation 5.3). This function was also applied to the 




Model 2 – Three-Compartment Model 
In order to address the kinetics of Mn2+ compartmentalization within the 
myocardium, a third compartment was added (Figure 5.1b). Free Mn2+ was assumed to 
reside in compartment 2, but a third compartment representing the compartments within 
the myocyte (e.g. mitochondria and SR) was assumed. Rate parameters k23 and k32 define 
the uptake and release rates respectively for the third compartment. 
A system of ordinary differential equations (ODEs) was setup for this model as 

























Least square best fit values for the rate parameters (kab) were acquired following 
simultaneous least square fitting for both the blood (X1) and heart (X2 + X3) 
compartments. 
 
Model 3 – Four-Compartment Model 
The four-compartment model was designed for the most physiological and 
anatomical specificity. The model contains two cytosolic compartments, representing the 
SR (compartment 3) and mitochondria (compartment 4), in addition to the free cytosolic 
Mn2+ (compartment 2). Additionally, efflux from the myocardium was modeled using 
two efflux rates, k21a and k21b, representing the NCX and PMCA efflux mechanisms 
respectively. The ODEs for this model are shown in Equation 5.8. 
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It is possible that differences exist in the longitudinal relaxivity, r1, between 
cytosolic Mn in compartment 2 and the compartmentalized Mn in compartments 3 and 4, 
possibly due to the binding of Mn2+ to larger molecules within the compartments or to 
potential chelation of the free Mn2+ ions. To model this phenomenon, an additional 
function was added. Equation 5.9 demonstrates the relationship between the changes in 




















From Equation 5.9, r1,T, is defined as the ratio between in the in vivo cardiac ∆R1 
values and the increase in Mn content. ∆R1,T, ∆R1,cytosolic and ∆R1,comp represent the 
change in relaxation rates for the total heart (combined compartments 2, 3 and 4), 
cytosolic Mn (compartment 2) and compartmentalized Mn (compartments 3 and 4) 
respectively, with weighting constants a and b proportional to the relaxivities of 
compartment 2 and 3 respectively. The total cytosolic and compartmentalized Mn content 
was therefore a/r1,T ·Xcytosolic and b/r1,T ·Xcomp respectively, using solutions to Equation 5.8, 
Xcytosolic (= X2) and Xcomp (= X3 + X4). 
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To reduce the number of variables in Model 4 for better model behavior while 
maintaining realistic physiological constraints, the following relationships were used for 
the rate parameters (Equation 5.10 and Equation 5.11), all derived from literature 
regarding Ca2+ transfer rates (25,222-225): 
 
totalbtotala kkkk 21212121 0.2   ,0.8   Equation 5.10
 
compcomp kkkk 224223 0.1   ,0.9   Equation 5.11
k21total and k2comp are the total transfer rates from compartment 2 to the blood, and 
from compartment 2 to compartments 3 and 4, respectively. These two parameters were 
estimated via the modeling technique. SEA0400 was assumed only to reduce the rate of 
Mn2+ efflux via the NCX (k21a), with k21a therefore being modeled as a function of time 
using Equation 5.3. 
 
Statistics 
For all the models, the residuals and coefficient of determination, R2, were 
calculated. The models were then compared to each other using an F test, both for 
individual efflux study groups as well as an overall model comparison for all of the efflux 
groups combined. These tests were used to ascertain whether potential decreases in sum-
of-squares for the more complicated models outweighed the loss of degrees of freedom 
following increased numbers of fit parameters. The level of significance was set at 0.05. 
For comparison, a first-order exponential fit was also made for the efflux data, 






For each T1 map in the MI group, in house software was used to isolate the 
myocardium from the remaining tissue. The isolated myocardium was then segmented 
into 360 × 1° radial segments, where each sector contained approximately 4 voxels. 
Within each segment (with the center of the necrotic region shifted to 180°), the average 
T1 values were determined, and the associated regional ∆R1 values calculated. Average 
∆R1 values were calculated for the observed plateaus of the remote viable tissue (Region 
A) and the necrotic tissue (region B). Temporal average ∆R1 values for regions A and B 
were fit with first-order exponentials. The exponential efflux properties of these regions 





The average pre-infusion Mn content in the heart and blood was found to be 
1.13±0.01 and 2.02±0.37 nmoles respectively, assuming a total heart weight of 0.1g, and 
a total blood volume of 2.17 ml/ 25 g BW (226,227). Correlating the ex vivo elemental 
analysis data to in vivo ∆R1 data allowed for a relationship between the increase in Mn 
content (above the pre-infusion baseline) and ∆R1 to be obtained (Equation 5.12, r
2 = 
0.91). Using this equation, estimates for the increase in absolute Mn content were made 
from in vivo ∆R1 values. 
    11 sec56.11nmolescontent Mn in  Increase  R  Equation 5.12





Figure 5.2 Cardiac Mn2+ efflux data for the MnCl2 dose dependent infusion groups (a), and the SEA0400 dose dependent groups (c). 
Overlaid are the least square best fit total heart model results from Model 2. Mn2+ content in the heart (compartments 2 + 3, solid line), 
compartment 2 (dashed line) and compartment 3 (dotted line) for the 190 nmoles g−1 MnCl2 and 35 mg kg−1 SEA0400 groups are 




Figure 5.3 Temporal Mn2+ efflux transfer rate, k21(t), predicted by Model 2 following inhibition of the NCX with varying does of 




Figure 5.4 Model 2 total heart compartment (compartments 2 and 3) residuals for the control (a) and SEA0400 (b) dose dependent 
groups c) Model comparisons of the combined blood and heart sum of residuals squared for all the study groups, normalized to Model 
1. * represents significance (p < 0.05) 
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Figure 5.2 shows the raw LV Wall Mn efflux data for the dose dependent (Figure 
5.2a) and SEA0400 (Figure 5.2c) groups, along with the best fit solutions to Model 2 
(solid lines). The total Mn2+ content in the heart (compartments 2 + 3, solid line), 
compartment 2 (dashed line) and compartment 3 (dotted line) for the 190 nmoles g−1 
MnCl2 and 35 mg kg
−1 SEA0400 groups are shown in Figures 5.2b and 5.2d respectively. 
The SEA0400 dose dependent temporal fits for k21 are shown in Figure 5.3, with the 
temporal residuals for Model 2 displayed in Figures 5.4a and 5.4b. Output figures 
showing the least square best fits for all the three models for each efflux group are shown 
in Appendix B, Figure B.1. 
 
Model Comparison 
The least-square best-fit parameters from all three models are summarized in 
Table 5.3. By definition the SEA0400 groups have the same transfer rate parameters as 
the 190 nmoles g−1 MnCl2 group, with the additional pharmaceutical parameters kabs and 
kel also shown in Table 5.3. Individual coefficients of determination, R
2, are shown in the 
lower right region of Table 5.3. For comparison between the three models, Figure 5.4c 
displays the sum of square residuals for the combined blood and heart data, normalized to 
Model 1, for each of the groups. Using an F test, there was no statistically significant 
benefit in increasing the number of model variables for each individual efflux group (p > 
0.05), with the exception of the 50 mg kg−1 SEA0400 group where Model 2 provided a 
significant improvement over Model 1 (p = 0.02). Comparison of the three models for all 
of the efflux groups combined, demonstrated that no significant improvement was gained 
(p = 0.62) by adding additional compartments to Model 1. Considering this, Model 1 
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provided an adequate fit for all of the dose dependent efflux groups, as well as the 10, 20 
and 35 mg kg−1 SEA0400 groups. The addition of a third compartment in Model 2 
created a statistically significant improvement over the two-compartment model for the 
50 mg kg−1 SEA0400 group. It is possible however that models with multi-cardiac 
compartments could provide more utility and realism in other pathological circumstances. 
Indeed, since the three-compartment model provided a better description for the 50 mg 
kg−1 SEA0400 group, and since there is virtually no difference between the models under 
other circumstances, use of a three-compartment model provides the most useful 
description. 
 
Transfer Rate Parameters 
The robustness of the different models can also be demonstrated from Table 5.3. 
The transfer rate parameters from the smaller, less complicated, models have 
demonstrated stability following addition of more compartments. Figure 5.5 displays the 
transfer rate parameters and pharmaceutical absorption and elimination half lives for the 
statistically best models. Applying a linear least square best-fit to the dose dependent 
transfer rate parameters yielded:  
      0.78R      0.35.8Dose101.43.9 2310  k  Equation 5.13 
      0.90R      0.010.04Dose100.31.2 2412  k  Equation 5.14 
      0.97R      0.030.04Dose100.21.4 2321  k  Equation 5.15 
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Table 5.3 Best fit parameters calculated by the three models 
Dose 
Model Fit Parameters (Model 1/ Model 2/ Model 3) 
Model 3 
(s−1nmoles−1) 
Transfer rate parameters (h-1)  
k10 k12 k21(a,) k23 k32 k24 k42 a/b (× 11.56) 
Control (nmoles g−1)        
280 6.9/6.9/6.9 0.07/0.07/0.07 0.37/0.91/0.79 −/5.9/0.41 −/4.5/0.57 −/−/0.05 −/−/0.87 1.1/2.3 
190 6.4/6.7/6.6 0.06/0.06/0.06 0.22/0.62/0.71 −/7.4/0.48 −/4.3/0.37 −/−/0.05 −/−/0.75 1.1/2.4 
119 6.5/6.1/6.5 0.06/0.05/0.05 0.11/0.54/0.58 −/11.8/0.61 −/3.1/0.28 −/−/0.07 −/−/0.37 1.0/2.5 
65 5.9/6.0/6.0 0.04/0.04/0.04 0.08/0.51/0.60 −/12.4/0.60 −/2.4/0.19 −/−/0.07 −/−/0.31 0.9/2.3 
 Drug Parameters (h−1)  Coefficient of Determination, R2 
 kabs kel  Control (nmoles g
−1) SEA0400 (mg kg−1) 
SEA0400 (mg kg−1) 
  
   
10  671/68/85 1.7/1.6/1.1  280 0.83/0.83/0.83 10 0.86/0.86/0.86 
20  672/149/118 0.51/0.47/0.44  190 0.83/0.83/0.83 20 0.86/0.86/0.87 
34  680/115/9.4 0.49/0.41/0.33  119 0.80/0.81/0.81 34 0.87/0.87/0.87 





Figure 5.5 Dose dependent trends for the transfer rate parameters (a) and pharmaceutical 
absorption and efflux half-lives (b) predicted by the best model (Model 1 for all groups 
except the 50 mg kg−1 SEA0400 group, which is improved with Model 2). Also shown 
are linear least square and exponential best fits for the transfer rate parameters (a) and 
half-lives (b) respectively.  
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Similarly, first order exponential fits to the SEA0400 half lives yield: 
         0.92R    Dose103.08.5exp107.24.9min 2232/1  abst  Equation 5.16 
         0.94R    Dose101.25.2exp17.00.30hrs 222/1  elt  Equation 5.17 




Results from the MI study are displayed in Figure 5.6. Figure 5.6a represents, for 
one mouse, a sample regional plot of the remote (∆R1 = A) and necrosed (∆R1 = B) 
tissue, as well as the boundaries of the peri-infarcted zone. The range of peri-infarcted 
zone values is shaded in all the subplots of Figure 5.6. Figure 5.6b displays the temporal 
response of Mn2+ efflux in regions A and B, with first order exponential fits overlaid. In 
order to compare the infarcted efflux data to the control dose dependent data, a third plot, 
Figure 5.6c, is shown. This figure displays the efflux half lives of the dose dependent 
groups, as well as those for regions A and B. Following extrapolation of the exponential 
fit to the dose dependent half lives, the infarcted region is shown to correspond to a 
MnCl2 infusion dose of approximately 400 nmoles g
−1. Using the linear fit for the 
predicted efflux transfer rate, k21 (Equation 5.15), shown in Figure 5.5a, the approximate 
efflux transfer rate for the infarcted region is 0.52 h−1, an increase from 0.22 h−1 for the 
viable region of the same infusion dose. Thee efflux transfer rates for the peri-infarcted 




Figure 5.6 Comparison of the MI efflux data to the modeled healthy efflux data. (a) shows an example output from the radial MI 
fitting algorithm, fitting constant ∆R1 values for the remote (A) and necrosed (B) tissue, and linearly changing ∆R1 in peri-infarcted 
zone between. The temporal efflux of regions A and B are illustrated in (b). The exponential efflux half-lives for these regions are 






The goals of this portion of the dissertation were to characterize the Mn2+ 
transport properties using pharmacokinetic modeling to gain an insight into the 
relationship between Mn2+ and Ca2+ transport in the healthy heart as well as alteration in 
Mn2+ handling following MI. The groups used to study the Mn2+ handling properties in 
the healthy heart were designed to test both the infusion dose dependence on Mn2+ influx 
and efflux, as well as to probe the efflux mechanisms by inhibiting the NCX with varying 
doses of SEA0400. It was found that, given the current sensitivity of the MEMRI 
technique, a two-compartment model incorporating compartments for the blood and heart 
(Model 1), was sufficient to describe the systems of Mn2+ transport. Only modeling of the 
50 mg kg−1 SEA0400 group (Figure 5.4c), the most extreme case of NCX inhibition, 
gained a significant improvement with the addition of a third compartment representing 
cytosolic compartmentalization. These findings suggest that compartmentalization is not 
negligible; however, prolonged retention of Mn2+ is required in order for the models to be 
able to quantify this with certainty. Indeed, over the experimental timeframe Model 2 
predicts that over half of the Mn2+ contained within the cytosol is retained within 
intracellular compartments (Figure 5.2). 
Within this study, the transfer rate parameters k10, k12 and k21, were all shown to 
increase linearly with increasing MnCl2 infusion doses (Figure 5.5a). The dose 
dependence of the linear uptake parameter, k12, is in agreement with work previously 
conducted by Waghorn et al. (204), studying the relationship between Mn2+ infusion dose 
and myocardial Mn2+ uptake. While Mn2+ is known to act as a surrogate marker for Ca2+ 
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with respect to ionic uptake and efflux from the cytosol, the relationship between Ca2+ 
transport and Mn2+ transport is not well known. The relative contributions of the NCX 
and PMCA are likely to be different for Mn2+ and Ca2+ due to differences between their 
binding constants. Similarly, low extracellular Mn2+ concentrations create a concentration 
gradient potentially allowing Mn2+ extrusion to occur via the Ca2+ channels, while 
intracellular compartmentalization may also differ between the ions.  
For Ca2+, the NCX is known to account for approximately 80% of the total efflux 
in mice (25). Model 2 predicts that following inhibition of the NCX, the Mn2+ efflux rate 
is reduced to just 8.2, 1.8, 1.6 and 1.0 % of the initial, pre-SEA0400 administration, rate 
for the 10, 20, 35 and 50 mg kg−1 SEA0400 groups respectively. This maximum 
inhibition occurred on average 3 minutes post-SEA0400 administration. A possible cause 
of the difference between Ca2+ and Mn2+ efflux is due to the aforementioned differences 
in the extracellular concentrations of the respective ions. The relative contribution from 
the passive NCX is expected to increase with decreasing ion concentration gradients, 
with a consequent reduction in the contributions from the active PMCA. This effect is 
observed following inhibition of the NCX, where for the highest dose of SEA0400 the 
models predict that approximately 99% of Mn2+ efflux occurs via the NCX. 
With respect to compartmentalization, it has been shown that Ca2+ uptake into the 
SR and mitochondria occurs at rates of 6.1×10-3 and 1.0×10-6 M s−1, respectively 
(222,223), compared to an efflux rate of 3.0×10-2 M s−1 across the NCX. The efflux rate 
for Ca2+ is therefore approximately 5 times greater than for compartmentalization. In 
contrast, Model 2 predicts that the uptake of Mn2+ into the intracellular compartments 
occurs at a rate approximately 12 times greater than the efflux rate. Although further 
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studies are required to fully address this potential effect, if found to be significant, 
differences in Mn2+ and Ca2+ handling could potentially be explained by differences in 
the binding constants of the ions. 
Model 3 attempts to address differences in relaxivity between free cytosolic Mn2+ 
and compartmentalized Mn2+. For the dose dependent groups, the relaxivity of the 
compartments (SR and mitochondria) was found to be 2.3±0.1 times larger than for free 
cytosolic Mn2+. This is most likely caused by the binding of Mn2+ to larger molecules 
within the compartments. An alternative hypothesis would be that, once 
compartmentalized, Mn2+ becomes chelated, thus reducing the relaxivity; however this 
effect was not predicted by the models. When considering the contribution of multiple 
compartments on the overall relaxation rate, a more thorough representation of the 
effective relaxation rate would be to consider the be the weighted average of the 
relaxation in the two compartments (228). If compartment i has a volume fraction fi, an 
initial T1 given by T1i and a contrast agent concentration Ci, then the effective relaxation 

















Model 3 incorporates a simplification of this equation (Equation 5.9), assuming 
that the volume fractions, fi, for the free Mn
2+ and compartmentalized Mn2+ are equal to 
each other. While a reasonable approximation for this study, the cytosol only constitutes 
approximately 11.5% of the myocardial cell volume, with the SR and mitochondria 
accounting for 36 % and 3.5% respectively (4,229). 
The pharmacokinetic properties of SEA0400 were also addresses in this study, 
assuming that the plasma concentration was inversely proportional to the efflux rate, k21 
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(Equation 5.3). The models all predict that the drug uptake occurs rapidly, with the 
maximum inhibition of the NCX occurring approximately 3 minutes post-administration. 
With respect to drug elimination, the predicted SEA0400 elimination half-lives are 
predicted to be of the same order of magnitude as unpublished SEA0400 data in rats. 
Although there is no published data for the kinetic properties of SEA0400, the 
assumptions and models presented in this current study appear to provide a good first 
order approximation for the pharmacokinetic transport properties of SEA0400, although 
further work is warranted to fully understand this. 
It has previously been demonstrated that T1-mapping MEMRI can be used to 
delineate different regions of the infarcted myocardium (204). This current study 
provides additional information with regards Mn2+ handling within different regions of 
the infarcted myocardium. Figure 5.6c demonstrates that the Mn2+ efflux half-life of the 
necrotic tissue within the MI site, as well as the peri-infarcted zone tissue, corresponds to 
efflux half-lives observed following increased Mn2+ infusion doses in healthy mice. The 
affected tissue also has Mn2+ handling properties associated with increased Mn2+ efflux 
rates. Application of MEMRI techniques to detect increases in [Ca2+]i in ischemic tissue 
are currently limited, in part due to reduced perfusion in the ischemic tissue. However, by 
modeling Mn2+ efflux data, this study has demonstrated the ability of MEMRI T1-
mapping to minimize the uncertainties caused by perfusion limitations. The technique has 
also indirectly predicted an increase in Mn2+ content and Mn2+ efflux rates in the viable 
cells within ischemic regions. This increase is consistent with ex vivo Ca2+ studies, with 
the MEMRI T1-mapping efflux technique having the potential to be used to indirectly 





Implementation of three multi-compartment pharmacokinetic models to Mn2+ 
efflux data in healthy and infarcted mice hearts has been demonstrated to effectively 
model Mn2+ transport mechanisms. In order to address the difference in Mn2+ and Ca2+ 
handling in the myocardium, the model predicted that Mn2+ is more dependent on the 
NCX for ionic efflux than is Ca2+. This is likely due to the difference in the concentration 
gradients between the ions, driving the passive NCX pump. Within the cytosol the model 
predicts that Mn2+ uptake into compartments occurs at a faster rate than for efflux, 
contrary to the effect observed for Ca2+. This can potentially be explained by considering 
differences in the binding constants for Mn2+ and Ca2+. Additionally, Mn2+ stored within 
intracellular compartments, for example the SR and mitochondria, exhibits an apparent 
increase in relaxivity, r1, relative to free cytosolic Mn
2+, possibly due to Mn2+ binding 
with larger molecules. 
Finally, there is an apparent increase in the Mn2+ efflux rate from ischemic tissue, 
commensurate with increased Mn2+ content in viable cells within these regions. This 
effect has been widely observed for ex vivo Ca2+ transport, but has thus far proved elusive 
for in vivo MEMRI studies. The predictions made by this modeling technique allow for a 
more thorough understanding of the relationship between Mn2+ and Ca2+ handling in the 
heart. This approach therefore has the potential to be applied as a diagnostic tool in the 











Quantitative T1-mapping MEMRI techniques were applied within this dissertation 
to study the handling properties of Mn2+ in the myocardium under healthy control, 
pharmaceutically altered and post-MI conditions. The technique demonstrated its 
sensitivity to detect temporal changes in the absolute Mn content in the myocardium for 
both healthy mice, and mice undergoing alterations in Mn2+ handling due to inhibition of 
the NCX with SEA0400. These changes in Mn content were calculated using the 
correlation between in vivo ∆R1 efflux and the efflux of absolute cardiac Mn
 content post-
MnCl2 infusion. Elemental analysis of heart tissue samples collected at various time 
points post-MnCl2 infusion demonstrated that the reduction in LV Wall ∆R1 was linearly 
proportional to the myocardial Mn content. The linearity of the temporal data, suggest 
that 1) observed temporal changes in ∆R1 are linearly proportional to changes in Mn 
content and 2) Mn2+ efflux could be estimated from the ∆R1 washout curves. This 
technique is therefore appropriate for the evaluation of Mn2+ efflux in vivo. 
For healthy mice not undergoing any pharmaceutical intervention, the temporal 
change in LV Wall ∆R1, and therefore Mn content, followed an exponential decay. This 
allowed for inferred determinations of Mn2+ efflux half-lives. For example, the half-life 
for the control, 190 nmoles g−1 BW MnCl2, curve was 3.4 hrs. Increasing the absolute Mn 
content in the myocardium by infusing the mouse with increasing MnCl2 infusion doses 
lead to an increase in the ∆R1 efflux rate. Mn
2+ efflux occurred with a half-life dependent 
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on the initial Mn2+ content such that an increase in the Mn2+ uptake caused an increase in 
the Mn2+ efflux rate.  
It was also shown in this dissertation that changes in ∆R1 over time may be used 
to quantify changes in Mn2+ content in vivo when modulating NCX kinetics with the 
NCX inhibitor SEA0400. This information could be useful for indirectly assessing and 
understanding Ca2+ efflux as Mn2+ is considered its biochemical analogue. By varying the 
intraperitoneal doses of SEA0400, as well as by using a single dose of dobutamine, Mn2+ 
efflux in the healthy murine heart was affected. Inhibition of the NCX with SEA0400 
extended the ∆R1 washout curve due to an assumed inhibition of the Mn
2+ efflux. The 
inhibition of Mn2+ efflux using a known NCX inhibitor, in conjunction with the previous 
establishment of Mn2+ as a Ca2+ analogue during influx (99), indicates that changes in 
Mn2+ efflux most likely reflect changes in Ca2+ efflux.  
The positive inotropic state following administration of dobutamine caused a 
biphasic Mn2+ efflux curve in the healthy myocardium. This finding was exhibited by an 
initial rapid increase in the Mn2+ efflux rate followed by a gradual decrease as a slower 
Mn2+efflux rate reduced the Mn2+ content. These results suggest that alterations in Ca2+ 
handling caused by changes in the inotropic state of the heart are also observed for Mn2+, 
and that the T1 mapping MEMRI efflux technique is sensitive enough to detect these 
effects. 
Overall, this study of Mn2+ efflux in the healthy murine myocardium found that 
the T1-mapping MEMRI technique detected and quantified: 
1) increased Mn2+ uptake associated with an increased Mn2+ efflux rate due to 
increased Mn2+ infusion doses 
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2) decreased Mn2+ efflux rates following NCX inhibition with SEA0400 
3) increased Mn2+ efflux rates due to the positive inotropic effect of dobutamine 
This information concerning Mn2+ efflux dynamics could potentially enhance 
understanding of Ca2+ dynamics, particularly when investigating pathophysiological 
phenomena and/or developing new therapeutic pharmaceutical agents. 
 
One of the primary goals of this dissertation was to study alterations in Mn2+ 
handling in the post-MI murine heart. This dissertation has demonstrated a novel 
technique for identifying and quantifying specific regional differences in tissue 
characteristics that occur after a MI in the murine model. This innovative methodology 
isolates and segments the MEMRI T1 maps and then fits the calculated ∆R1 values into a 
region-defining MI curve that determines the location (in radial degrees) of the infarcted 
(necrosed), peri-infarcted (ischemic) and viable remote tissue. The region-defining MI 
curve introduced in this dissertation not only eliminates user bias in determining the 
location of the infarcted, peri-infarcted, and viable myocardium, but also has potential as 
a clinical tool to assist clinicians in diagnosing and treating post-MI patients. 
Results from this study further showed that Mn2+ handling within the viable 
region of the MI group and the Sham group were unaltered after surgery. However, 
decreases in both the initial uptake of Mn2+ (represented by ∆R1,0) and efflux half-life 
were observed in both the necrosed and peri-infarcted zones of the MI group. As shown 
above, Mn2+ efflux occurred with a half-life dependent on the initial Mn2+ content such 
that an increasing Mn2+ uptake caused an increase in the Mn2+ efflux rate. Therefore, the 
regional Mn2+ uptake in viable cells within the peri-infarcted zones could potentially be 
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estimated by examining the Mn2+ efflux properties. Mn2+ efflux from the necrosed region 
(MI Region B) occurred with a significantly faster half-life than in the Control group with 
the same MnCl2 infusion dose. The inferred equivalent infusion dose for the infarcted 
(necrosed) and peri-infarcted (ischemic) regions was found to be larger than the 280 
nmoles g−1 MnCl2 infusion dose. This finding suggests that both the necrosed and peri-
infarcted regions experience increased Mn2+ uptake, and therefore potentially Ca2+ 
uptake. 
 
The final section of the dissertation demonstrated the ability to characterize the 
Mn2+ transport properties using pharmacokinetic modeling. Implementation of three 
multi-compartment pharmacokinetic models to Mn2+ efflux data in healthy and infarcted 
mice hearts has been demonstrated to effectively model Mn2+ transport mechanisms. In 
order to address the difference in Mn2+ and Ca2+ handling in the myocardium, the model 
predicted that Mn2+ is more dependent on the NCX for ionic efflux than is Ca2+. This is 
likely due to the difference in the concentration gradients between the ions, driving the 
passive NCX pump. Within the cytosol the model predicts that Mn2+ uptake into 
compartments occurs at a faster rate than for efflux, contrary to the effect observed for 
Ca2+. This can potentially be explained by considering differences in the binding 
constants for Mn2+ and Ca2+. Additionally, Mn2+ stored within intracellular 
compartments, for example the SR and mitochondria, exhibits an apparent increase in 
relaxivity, r1, relative to free cytosolic Mn




Within this study, the transfer rate parameters k10, k12 and k21, were all shown to 
increase linearly with increasing MnCl2 infusion. The dose dependence of the linear 
uptake parameter, k12, is in agreement with the background work presented in §2.1 (204). 
While Mn2+ is known to act as a surrogate marker for Ca2+ with respect to ionic uptake 
and efflux from the cytosol, the relationship between Ca2+ transport and Mn2+ transport is 
not well known. The relative contributions of the NCX and PMCA are likely to be 
different for Mn2+ and Ca2+ due to differences between their binding constants. Similarly, 
low extracellular Mn2+ concentrations create a concentration gradient potentially 
allowing Mn2+ extrusion to occur via the Ca2+ channels, while intracellular 
compartmentalization may also differ between the ions.  
For Ca2+, the NCX is known to account for approximately 80% of the total efflux 
in mice (25). The relative contribution from the passive NCX is expected to increase with 
decreasing ion concentration gradients, with a consequent reduction in the contributions 
from the active PMCA. This effect is observed following inhibition of the NCX, where 
for the highest dose of SEA0400 the models predict that approximately 99% of Mn2+ 
efflux occurs via the NCX. 
Model 3 attempts to address differences in relaxivity between free cytosolic Mn2+ 
and compartmentalized Mn2+. For the dose dependent groups, the relaxivity of the 
compartments (SR and mitochondria) was found to be 2.3±0.1 times larger than for free 
cytosolic Mn2+. This is most likely caused by the binding of Mn2+ to larger molecules 
within the compartments. 
It has previously been demonstrated (§2.1 and §3) that T1-mapping MEMRI can 
be used to delineate different regions of the infarcted myocardium (204). This current 
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study provides additional information with regards Mn2+ handling within different 
regions of the infarcted myocardium. Modeling conducted within this dissertation 
suggested that there is an apparent increase in the Mn2+ efflux rate from ischemic tissue, 
commensurate with increased Mn2+ content in viable cells within these regions. This 
effect has been widely observed for ex vivo Ca2+ transport, but has thus far proved elusive 
for in vivo MEMRI studies. The predictions made by this modeling technique allow for a 
more thorough understanding of the relationship between Mn2+ and Ca2+ handling in the 
heart. This approach therefore has the potential to be applied as a diagnostic tool in the 




In summary, the findings presented in this dissertation, along with the 
biochemical similarities between Ca2+ and Mn2+, strongly suggest that under appropriate 
conditions changes in Mn2+ efflux may reflect changes in Ca2+ efflux. As such, MEMRI 
T1 mapping could be an innovative and effective technique to monitor an important factor 
associated with the progression of heart disease. 
This study showed that T1-mapping MEMRI quantified Mn
2+ dynamics in both 
healthy and post-MI mice under various conditions. A novel technique was also 
introduced for identifying and quantifying specific regional differences of tissue 
characteristics in the post-MI mouse heart that could potentially be translated into the 
clinical environment. Using the segmentation and curve fitting methodology derived 
from T1-mapping MEMRI, the salvageable ischemic tissue adjacent to the necrosed area 
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can be pinpointed for direct application of pharmacologic therapies. This information 
would be clinically useful not only for treating the precise areas of salvageable tissue, but 
also for monitoring progression of the remodeling process during healing. Thus, patient 
outcomes would be enhanced as improved treatment modalities target specific tissue 
areas and ultimately prevent the adverse remodeling that promotes heart failure 
development in post-MI patients. 
 
 
6.2 Long-Term Goals 
 
Although this dissertation suggests that Mn2+ handling data may mimic alterations 
in Ca2+ handling, the precise relationship between these two ions is still unknown. Ca2+ 
and Mn2+ extrusion rates are not equal due to their different binding constants and 
maximal rates for efflux transporters (NCX and PMCA). Furthermore, Mn2+ can be 
extruded via the reverse mode of Ca2+ channels due to low extracellular Mn2+ 
concentration. These conditions, although studied via pharmacokinetic modeling, make 
the precise relationship between Mn2+ and Ca2+ transport complicated, and studies to 
address this are required to address these long term goals. 
In the study by Medina et al., 2007, (203), the authors speculate in their 
conclusions that knowledge of the relationship between Mn2+ and Ca2+ transport could 
allow for widespread repercussions in disciplines such as pharmacology and pathology. 
The current dissertation has attempted to answer many questions about the relationship 
between the flux of Mn2+, as seen via in vivo MEMRI studies, and the true Ca2+ transport 
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properties. By using a known NCX inhibitor, SEA0400, alterations in Ca2+ flux can be 
estimated from the observed Mn2+ flux. However, the relationship between the two 
quantities will need to be further explored in order to fully determine Ca2+ fluxes in vivo. 
One potential way of achieving this goal is by using diffuse reflectance and 
fluorescence techniques, as have been demonstrated by Du et al., 2005, (230). This study 
was shown to detect intracellular calcium changes during cerebral ischemia in a rat 
model. Despite the fact that calibrations between the Ca2+ fluxes detected using 
fluorescent and MEMRI techniques are potentially complicated, additional future studies 
applying this fluorescence technique to cardiac studies could add additional information 
to the in vivo MEMRI data that is presented in this dissertation. 
Ultimately, this pre-clinical work has goals to be translated into the clinic, with 
the potential of being able to provide early diagnosis of cardiac disease, while offering in 
vivo insight into the dynamic Ca2+ alterations on a microscopic level. Such knowledge 
could be advantageous not only diagnostically, but also could help determine patient-
specific treatment plans. 
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Figure A.1 Automated myocardial isolation flow chart. Representation of the short axis 
cardiac slice orientation (top left) used to acquire a short axis T1-map of a MI mouse 
post-MnCl2 infusion (top right). Input of this T1 map with an associated T1-weighted 
image (not shown), an unbiased isolation program was used to isolate the myocardial 





Figure A.2 Myocardium segmentation flow chart. The orientation definition (defined in 
the top image) is used to create a position dependent T1 profile (top graph). Data from 
both pre- and post-MnCl2 infusion T1 maps are input into the shown equation, with a 





Figure A.3 Flow chart of the process of data acquisition and absolute Mn content 
calculation for the efflux studies, leading to the modeling of Mn transport with either 2- 






Figure A.4 Flow chart of the procedures involved with estimating the transfer rate and 








The following figures (Figure B.1) show the least square best fits for the three 
models described in §5. The model number and best fit parameters are shown in the top 
left panel of each figure, with the efflux group labeled above the plot in the top right 
panel. 
For the control dose dependent figures there are a total of four panels. The raw 
cardiac Mn content data is shown in the top right panel along with the best fit to the 
model. The sum of residuals squared for each model fit are shown inside the axis. The 
same information for the blood is displayed in the bottom left panel, with the temporal 
heart residuals illustrated in the bottom right. For Model 2, the best fit Mn content for 
compartment 2 is illustrated by a dashed line, with compartment 3 shown as a dotted line. 
The fourth compartment in Model 3 is also shown with a dotted line; by definition at any 
given time the Mn content in compartment 4 is less than in compartment 3. 
Due to the fact that the SEA0400 groups possess the same time independent 
transfer rate parameters as the Control 190 nmoles g−1 group for t < 1hr, the Control 190 
nmoles g−1 and SEA0400 data is shown within the same figure for each SEA0400 model. 
For these SEA0400 groups the best fits cardiac data are shown for the control (top center; 
blue) and SEA0400 (top right, red) groups, with the corresponding blood data both 
shown in the bottom left panel. For reference, the total heart Mn content fit for the control 
group is overlaid on the SEA0400 plot as a dashed blue line. The cardiac residuals for the 
control and SEA0400 fits are displayed in the bottom center panel, with the temporal k21 
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